Original Article
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
N Engl J Med 2004; 351:1502-1512October 7, 2004
- Abstract
Background
Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease.
Methods
From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned to receive 12 mg of mitoxantrone per square meter of body-surface area every three weeks, 75 mg of docetaxel per square meter every three weeks, or 30 mg of docetaxel per square meter weekly for five of every six weeks. The primary end point was overall survival. Secondary end points were pain, prostate-specific antigen (PSA) levels, and the quality of life. All statistical comparisons were against mitoxantrone.
Results
As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence interval, 0.62 to 0.94; P=0.009 by the stratified log-rank test) and those given weekly docetaxel had a hazard ratio for death of 0.91 (95 percent confidence interval, 0.75 to 1.11; P=0.36). The median survival was 16.5 months in the mitoxantrone group, 18.9 months in the group given docetaxel every 3 weeks, and 17.4 months in the group given weekly docetaxel. Among these three groups, 32 percent, 45 percent, and 48 percent of men, respectively, had at least a 50 percent decrease in the serum PSA level (P<0.001 for both comparisons with mitoxantrone); 22 percent, 35 percent (P=0.01), and 31 percent (P=0.08) had predefined reductions in pain; and 13 percent, 22 percent (P=0.009), and 23 percent (P=0.005) had improvements in the quality of life. Adverse events were also more common in the groups that received docetaxel.
Conclusions
When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plus prednisone.
Media in This Article
Figure 1
Kaplan–Meier Estimates of the Probability of Overall Survival in the Three Groups.Figure 2
Greatest Change and Median Change from Baseline in Normalized Scores on the Functional Assessment of Cancer Therapy–Prostate Questionnaire for Individual Domains of the Quality of Life during Treatment.Article Activity
- Article
Prostate cancer is the most common cancer among men, with approximately 220,000 cases and 29,000 deaths annually in the United States.1 About 10 to 20 percent of men with prostate cancer present with metastatic disease, and in many others, metastases develop despite treatment with surgery or radiotherapy.
Treatment of metastatic prostate cancer is palliative. In about 80 percent of men, primary androgen ablation leads to symptomatic improvement and a reduction in serum levels of prostate-specific antigen (PSA), but in all patients the disease eventually becomes refractory to hormone treatment. The options then include symptomatic care with narcotic analgesics, radiotherapy to dominant sites of bone pain, treatment with bone-seeking isotopes such as strontium-89, and cytotoxic chemotherapy. Bisphosphonates may reduce skeletal complications,2-4 and low-dose prednisone or hydrocortisone may be palliative in some patients.5,6
Chemotherapy can reduce serum PSA levels in patients with hormone-refractory prostate cancer and relieves pain in some patients, but tolerability is of concern, particularly since most patients are elderly and many have other medical problems.7 A randomized trial showed that mitoxantrone plus low-dose prednisone relieved pain and improved the quality of life more frequently than did prednisone alone.8,9 Consistent benefits of mitoxantrone plus a corticosteroid were observed in other randomized trials, but none found that this approach improved survival.10-12 These trials established mitoxantrone plus a corticosteroid as the treatment of reference for hormone-refractory prostate cancer.
Phase 2 studies of the taxane docetaxel have reported PSA responses (defined as a reduction in serum PSA levels of at least 50 percent) in up to 50 percent of patients.13-16 Studies of docetaxel plus either estramustine or calcitriol have shown PSA responses in up to 80 percent of patients.17-19 However, outcomes of single-group studies are subject to bias.20
We conducted a phase 3 study, the TAX 327 Study, comparing docetaxel (given either every three weeks or weekly) plus daily prednisone with mitoxantrone plus prednisone. The docetaxel regimens were selected on the basis of their dose equivalence (a dose intensity of 25 mg per square meter of body-surface area per week and a maximal cumulative dose of 750 mg per square meter) and their activity and tolerability in phase 2 studies. The primary hypothesis was that treatment with docetaxel plus prednisone would improve overall survival as compared with mitoxantrone plus prednisone.
Methods
Patients
This randomized, nonblinded, phase 3 study involved centers in 24 countries. Eligible patients had histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiologic evidence of metastatic disease, had had disease progression during hormonal therapy, and were receiving primary androgen-ablation therapy as maintenance therapy. At least four weeks had to have elapsed between the withdrawal of antiandrogens (six weeks in the case of bicalutamide) and enrollment, so as to avoid the possibility of confounding as a result of the response to antiandrogen withdrawal.21,22 Another requirement was disease progression, as indicated by increasing serum levels of PSA on three consecutive measurements obtained at least one week apart or findings on physical examination or imaging studies.
Eligible patients had a Karnofsky performance-status score of at least 60 percent, no prior treatment with cytotoxic agents (except estramustine) or radioisotopes, no history of another cancer within the preceding five years (except basal or squamous-cell skin cancer), no brain or leptomeningeal metastases, no symptomatic peripheral neuropathy of grade 2 or higher, and no other serious medical condition. At least four weeks had to have elapsed between prior surgery or radiotherapy (limited to no more than 25 percent of the bone marrow) and enrollment. Prior treatment with corticosteroids was allowed. Normal cardiac function was required. Laboratory criteria for eligibility included a neutrophil count of at least 1500 per cubic millimeter, a hemoglobin level of at least 10.0 g per deciliter, a platelet count of at least 100,000 per cubic millimeter, a total bilirubin level below the upper limit of the normal range for each institution, and serum alanine aminotransferase, aspartate aminotransferase, and creatinine levels that were no more than 1.5 times the upper limit of the normal range.
A clinical history was obtained, and a physical examination, with radiographic imaging, computed tomography, and bone scanning, was performed within 14 days before randomization. Blood tests including measurement of serum PSA, electrocardiography, and an evaluation of the left ventricular ejection fraction by means of a multiple gated acquisition scan or echocardiography were performed. Pain, analgesic intake, and the quality of life were assessed at baseline. Pain was assessed by means of the Present Pain Intensity (PPI) scale from the McGill–Melzack questionnaire, which uses verbal descriptors; scores can range from 0 to 5, with higher scores indicating greater pain.23 Patients recorded their daily PPI score and analgesic use in a diary. A daily analgesic score was calculated by assigning a score of 4 for a standard dose of a narcotic analgesic (e.g., 10 mg of morphine) and a score of 1 for a standard dose of a nonnarcotic analgesic. Patients were required to have stable levels of pain for at least seven days before randomization, defined by a daily variation of no more than 1 in the PPI score or of no more than 25 percent in the analgesic score. The quality of life was assessed with the Functional Assessment of Cancer Therapy–Prostate (FACT-P) questionnaire; scores on this self-administered questionnaire can range from 0 to 156, with higher scores indicating a better quality of life.24,25
All patients provided written informed consent, and the study was approved by all institutional review boards in accordance with the international standards of good clinical practice. An independent data and safety monitoring committee was established.
Randomization and Treatment
Randomization was centralized with the use of a stratified, permuted-block allocation scheme according to the baseline pain level (pain was classified as present, as defined by a median PPI score of at least 2 or a mean analgesic score of at least 10, or as absent, as defined by a median PPI score of less than 2 and a mean analgesic score of less than 10) and the baseline Karnofsky performance-status score (70 percent or less vs. 80 percent or more). Patients who were randomly assigned to the docetaxel groups received either 75 mg of docetaxel (Taxotere, Aventis) per square meter as a 1-hour intravenous infusion on day 1 every 21 days or 30 mg of docetaxel per square meter as a 30-minute intravenous infusion on days 1, 8, 15, 22, and 29 of a 6-week cycle. Patients who were randomly assigned to the standard-therapy group received 12 mg of mitoxantrone (Novantrone, Immunex and Wyeth–Ayerst) per square meter as a 30-minute infusion on day 1 every 21 days. All patients received 5 mg of prednisone (or prednisolone, if prednisone was not available) orally twice daily starting on day 1. Premedication with dexamethasone was required in the docetaxel groups (8 mg given 12 hours, 3 hours, and 1 hour before the docetaxel infusion in the group treated every three weeks and 8 mg given 1 hour before docetaxel in the group treated weekly). Antiemetic medication was prescribed according to local practice.
Up to 10 cycles of treatment were planned for the group given docetaxel every three weeks and the mitoxantrone group and up to 5 cycles (of six weeks each) in the weekly-docetaxel group. Treatment delays of up to two weeks and up to two dose reductions were allowed. Dose reductions were specified for patients who had had grade 4 neutropenia for at least seven days, an infection, or grade 3 or 4 neutropenia with an oral temperature of at least 38.5°C. A dose reduction or treatment delay was also stipulated for patients who had an absolute neutrophil count of less than 1500 per cubic millimeter (for those on three-week schedules) or less than 1000 per cubic millimeter (for those receiving weekly docetaxel) on a treatment day and for those with grade 3 or 4 thrombocytopenia. Treatment with granulocyte colony-stimulating factor was allowed for patients with febrile neutropenia. Systemic corticosteroids (other than dexamethasone and prednisone) and bisphosphonates were not permitted.
Follow-up and Outcomes
Physical examinations and baseline blood tests were repeated at three-week intervals. Imaging studies to determine the extent of disease were performed at intervals of six to nine weeks and repeated after four weeks to identify those with a response.
The primary end point was overall survival. Secondary end points were predefined reductions in pain, an improvement in the quality of life, a reduction in serum PSA levels of at least 50 percent, and objective tumor responses.
Patients with a PPI score of at least 2, an analgesic score of at least 10, or both (averaged over the previous week) at baseline were assessed for the pain response at three-week intervals. A pain response was defined as a two-point reduction in the PPI score from baseline without an increase in the analgesic score or as a reduction of at least 50 percent in the analgesic score without an increase in the PPI score, either of which was maintained for at least three weeks. Pain progression was defined as an increase in the PPI score of at least one point from the nadir, an increase from baseline of at least 25 percent in the analgesic score, or a requirement for palliative radiotherapy.
Serum PSA was measured every three weeks, and a response (for patients with a baseline PSA level of at least 20 ng per milliliter) was defined as a reduction from baseline of at least 50 percent that was maintained for at least three weeks, whereas PSA progression was defined as an increase from the nadir of either at least 25 percent for men with no PSA response or at least 50 percent for all others. The duration of the PSA response and the pain response was defined as the time between the first and last evaluations at which the response criteria were met. For patients with at least one bidimensionally measurable lesion, tumor response was evaluated with the use of World Health Organization criteria.26
The quality of life was assessed with the FACT-P questionnaire at baseline, every three weeks during therapy, and every month after the completion of therapy. All patients who answered the questionnaire at baseline were included in the evaluation, and the FACT-P score was compared with the baseline value for each of these patients. Patients were defined as having a quality-of-life response if they had a 16-point improvement in their FACT-P score, as compared with baseline, on two measurements obtained at least three weeks apart.
Adverse events were classified according to the Common Toxicity Criteria of the National Cancer Institute (version 2). Serious adverse events were fatal or life-threatening, required or prolonged hospitalization, resulted in persistent or substantial disability or incapacity, or were considered important medical events. Treatment was stopped for any of the following reasons: completion of planned treatment, progression of disease, severe adverse events, or withdrawal of consent.
Statistical Analysis
There were three comparisons of interest between the docetaxel and mitoxantrone groups: docetaxel given every three weeks was compared with mitoxantrone, weekly docetaxel was compared with mitoxantrone, and the combined docetaxel groups were compared with mitoxantrone. The study was designed to detect with 90 percent power a hazard ratio of 0.75 for death in the docetaxel groups as compared with the mitoxantrone group, with a two-sided type I error of 0.05 and with the data analyzed according to the intention to treat. The sample size was established as 1002 patients, and analysis was planned after 535 deaths had occurred. To allow for multiple comparisons, a P value of 0.04 was considered to indicate statistical significance for the comparison of the combined docetaxel groups with the mitoxantrone group, and a P value of 0.0175 was considered to indicate statistical significance for the comparison of each docetaxel group with the mitoxantrone group (all P values were two-sided), thus ensuring an overall significance level of 0.05.
In the primary analysis, overall survival was analyzed by means of the Kaplan–Meier method, with log-rank comparisons stratified according to the level of pain and the Karnofsky performance-status score. Pain, PSA, tumor, and quality-of-life responses were compared by means of the Cochran–Mantel–Haenszel test. All randomized patients were included in the analysis of survival, and all treated patients were included in the evaluation of adverse effects.
Hazard ratios for death were calculated after adjustment for any chance imbalance in potential prognostic factors between the groups. The following factors were entered into a full stratified Cox proportional-hazards model and a backward selection model in which nonsignificant factors were eliminated sequentially at a P level of 0.10: age (less than 65 years vs. 65 years or older); visceral involvement (yes vs. no); liver involvement (yes vs. no); number of prior hormonal therapies (two or fewer vs. more than two); prior estramustine (yes vs. no); presence of rising serum PSA levels alone, as compared with the presence of other indications of progression; baseline hemoglobin level; and baseline serum level of alkaline phosphatase. One planned interim analysis of safety was conducted after the recruitment of 120 patients. No interim analysis for efficacy was performed.
The study was designed by Dr. Tannock in collaboration with Aventis personnel, and the protocol was finalized after being reviewed by the other study cochairs, Drs. de Wit and Eisenberger. The data were collected and maintained by Aventis, but the cochairs handled all questions regarding the management of the study. Only the data and safety monitoring committee saw the results of the interim safety analysis; no analysis was undertaken nor were the results seen by Aventis, the study cochairs, or any other investigator until the predefined number of events had occurred. The protocol contained a plan for analysis and publication at that time. All data were provided to the cochairs at the completion of the study. Aventis personnel undertook the statistical analysis. The article was drafted by Dr. Tannock and modified after being reviewed by the cochairs and other coauthors. Aventis reviewed the manuscript, but its final content was entirely determined by the investigators.
Results
Characteristics of the Patients and Treatment
A total of 1006 patients underwent randomization from March 2000 through June 2002. The database was locked on August 6, 2003, after the requisite number of deaths, specified in the statistical plan, had occurred.
The baseline characteristics of the patients were well balanced among the three treatment groups (Table 1Table 1
Baseline Characteristics of the Patients.). The median age was 68 years; about 20 percent of the patients were at least 75 years old. About 45 percent had pain, and about 40 percent had measurable soft-tissue lesions. The most common indicators of disease progression before study entry were an increasing serum PSA level and evidence of an increase in bone metastases on bone scanning.Only nine patients (1 percent) did not receive chemotherapy and prednisone (Table 2Table 2
Treatment.). Patients tended to receive more cycles of the regimen in which docetaxel was given every three weeks than of the regimen in which mitoxantrone was given every three weeks. Most patients received the prescribed doses on schedule, with 8 to 12 percent requiring a dose reduction and 21 to 34 percent requiring at least one chemotherapy infusion to be delayed. Twenty percent of the patients who were randomly assigned to receive mitoxantrone subsequently received docetaxel, and 27 percent of those in the group given docetaxel every three weeks received subsequent mitoxantrone, as did 24 percent of those in the weekly-docetaxel group.Efficacy
The median duration of follow-up was similar among the three groups: 20.8 months in the group given docetaxel every 3 weeks and 20.7 months in the other two groups. There were 166 deaths (50 percent; hazard ratio for death, 0.76; 95 percent confidence interval, 0.62 to 0.94) in the group given docetaxel every three weeks and 190 deaths (57 percent; hazard ratio, 0.91; 95 percent confidence interval, 0.75 to 1.11) in the group given weekly docetaxel, as compared with 201 deaths (60 percent) in the mitoxantrone group. When the two docetaxel groups were combined and compared with the mitoxantrone group, the hazard ratio for death was 0.83 (95 percent confidence interval, 0.70 to 0.99; P=0.04). As compared with the survival rate in the mitoxantrone group, the survival rate was significantly higher (P=0.009) in the group given docetaxel every three weeks but not in the group given weekly docetaxel (P=0.36). The median duration of survival was 18.9 months (95 percent confidence interval, 17.0 to 21.2) in the group given docetaxel every 3 weeks, 17.4 months (95 percent confidence interval, 15.7 to 19.0) in the group given weekly docetaxel, and 16.5 months (95 percent confidence interval, 14.4 to 18.6) in the mitoxantrone group. Kaplan–Meier survival curves for the three groups are shown in Figure 1Figure 1
Kaplan–Meier Estimates of the Probability of Overall Survival in the Three Groups..The result of the sensitivity analysis, in which survival was adjusted for possible imbalances in potential prognostic factors, was consistent with the primary result. The hazard ratio for death in the group given docetaxel every three weeks, as compared with the mitoxantrone group, was 0.76 without adjustment and 0.74 and 0.75 after adjustment in the full stratified and backward Cox proportional-hazards models, respectively. As expected, visceral involvement, a high baseline alkaline phosphatase level, and a low hemoglobin level were negative prognostic factors in the multivariate models, whereas a rising serum PSA as the sole indicator of progression was a favorable factor. Post hoc analysis indicated that a high Gleason score (8, 9, or 10) was an adverse prognostic factor for survival. The survival benefit of docetaxel given every three weeks was consistent across subgroups defined according to the presence or absence of pain at baseline, the Karnofsky performance-status score (70 percent or less vs. 80 percent or more), and age (younger than 65 years vs. 65 years or older) (data not shown).
A reduction in pain was more frequent among patients receiving docetaxel every three weeks than among those treated with mitoxantrone (35 percent vs. 22 percent, P=0.01) (Table 3Table 3
Response to Treatment, as Measured by Decreases in Pain, PSA Level, and Tumor Burden and Improvements in the Quality of Life.), but the percentage of patients with reduced pain in the weekly docetaxel group (31 percent) did not differ significantly from that of the mitoxantrone group. The median duration of reduced pain was 3.5 to 5.6 months and did not differ significantly among the groups.Rates of PSA response were significantly higher in the docetaxel groups (45 percent in the group given docetaxel every three weeks and 48 percent in the group given weekly docetaxel, P<0.001 for both comparisons) than in the mitoxantrone group (32 percent) (Table 3). The median duration of the PSA response ranged from 7.7 to 8.2 months and did not differ significantly among the three groups.
Although patients with measurable soft-tissue lesions who received docetaxel every three weeks had a somewhat higher rate of tumor response than such patients who received mitoxantrone every three weeks (12 percent vs. 7 percent, P=0.11), this difference was not significant (Table 3).
Adverse Events
The incidence of grade 3 and 4 neutropenia was relatively low, and febrile neutropenia was rare (Table 4Table 4
Adverse Events of Any Grade, or of Grade 3 or 4, That Occurred or Worsened during Treatment.). Two patients died from sepsis during treatment, one in the docetaxel group and one in the mitoxantrone group. There was a higher incidence of cardiac events among patients who received mitoxantrone (Table 4). Most other types of adverse events were more frequent among patients receiving docetaxel, and there was no trend toward a lower frequency with weekly docetaxel than with docetaxel given every three weeks. Low-grade adverse events that occurred in at least 15 percent of patients in one of the groups included fatigue, nausea or vomiting or both, alopecia, diarrhea, nail changes, sensory neuropathy, anorexia, changes in taste, stomatitis, dyspnea, tearing, peripheral edema, and epistaxis (Table 4). More patients in the docetaxel groups than in the mitoxantrone group had at least one serious adverse event, with rates of 26 percent among those in the group given docetaxel every three weeks, 29 percent among those given weekly docetaxel, and 20 percent among those given mitoxantrone. Five deaths were probably related to treatment, three of them in the mitoxantrone group.More patients in the mitoxantrone group stopped treatment because of disease progression than was the case in the docetaxel groups, and more stopped treatment because of completion of treatment or adverse events in the docetaxel groups (Table 2). Adverse events that led to the discontinuation of treatment included fatigue, musculoskeletal or nail changes, sensory neuropathy, and infection in the docetaxel groups and cardiac dysfunction in the mitoxantrone group.
Quality of Life
The quality of life was evaluated in 815 patients, a group that made up the intention-to-treat population from countries in which a local translation of the FACT-P was available (Table 3). The percentage of patients who had an improvement in the quality of life was similar in the two docetaxel groups (22 percent in the group given docetaxel every three weeks and 23 percent in the group given weekly docetaxel) and significantly higher than that in the mitoxantrone group (13 percent; P=0.009 and P=0.005, respectively). Figure 2Figure 2
Greatest Change and Median Change from Baseline in Normalized Scores on the Functional Assessment of Cancer Therapy–Prostate Questionnaire for Individual Domains of the Quality of Life during Treatment. shows the greatest changes in the scores and the median changes in the scores for individual domains of the FACT-P during treatment. The greatest benefit in the docetaxel groups was in the subscale representing prostate-specific concerns (including weight loss, appetite, pain, physical comfort, and bowel and genitourinary function).Discussion
In this phase 3 study, two schedules of docetaxel administered with prednisone were compared with mitoxantrone plus prednisone, the standard chemotherapy for hormone-refractory prostate cancer. The median overall survival was higher for the group that received docetaxel every three weeks than for the mitoxantrone group, but not for the group that received weekly docetaxel. These differences were not influenced by adjustment for potential prognostic factors, and there were consistent trends in survival in the intention-to-treat population and in various subgroups. Overall, as compared with the mitoxantrone group, the docetaxel groups had better pain control and quality of life and more frequent PSA responses, but at the cost of a higher incidence of adverse effects.
The characteristics of the patients in this study are typical of those seen in oncology practices. Most patients were elderly and had received at least two types of hormonal manipulation. Most had bone metastases and a high serum PSA level, and about half had substantial pain. All these patients had a short life expectancy. Four published phase 3 studies have evaluated mitoxantrone plus prednisone for hormone-refractory prostate cancer.9-12 In our study, patients in the mitoxantrone group had a PSA response rate of 32 percent and a rate of predefined reduction in pain of 22 percent. In prior studies of symptomatic patients alone, mitoxantrone plus prednisone resulted in PSA response rates of 34 percent9 and 29 percent,12 whereas one study of asymptomatic patients reported a 48 percent response rate.10 Rates of reduction in pain of 38 percent9 and 39 percent12 have been reported, but these studies used less strict response criteria than we did. The median survival among patients in the mitoxantrone group in our study was 16.5 months, as compared with 10 to 12.5 months in the Canadian and Cancer and Leukemia Group B studies9,11,12 and 21 months in a study of asymptomatic patients.10 Mitoxantrone plus prednisone remains an appropriate treatment for patients with hormone-refractory prostate cancer who might be susceptible to the toxic effects of docetaxel. However, treatment with mitoxantrone plus a corticosteroid has not improved survival over that afforded by a corticosteroid alone.9-11
Previous experience with docetaxel in the treatment of hormone-refractory prostate cancer is limited to phase 2 studies. The PSA response ranged from 38 to 46 percent for docetaxel alone13-16 and up to 80 percent for docetaxel combined with estramustine or calcitriol.17-19 The rate of objective reduction in pain after treatment with docetaxel alone was 48 percent in the only study that evaluated pain.13 In our study, the rates of PSA response were 45 percent in the group given docetaxel every three weeks and 48 percent in the group given weekly docetaxel, and the respective rates of predefined (and stringent) reductions in pain were 35 percent and 31 percent, all of which, except for the response of pain in the weekly-docetaxel group, were significantly higher than the rates in the mitoxantrone group. More important, we found a significant improvement in overall survival for docetaxel as compared with mitoxantrone. A similar improvement in survival for docetaxel plus estramustine in comparison with mitoxantrone plus prednisone was found in a phase 3 study by the Southwest Oncology Group that is reported in this issue of the Journal.27
Safe use of docetaxel requires premedication with dexamethasone. Since the docetaxel group received about twice the dose of corticosteroids that the mitoxantrone group received, the better results in the docetaxel group may have been due in part to the higher dose of corticosteroids.5,6,9-11 This seems unlikely because with prednisone or hydrocortisone alone, the rate of PSA response in large phase 3 studies was in the range of 16 to 24 percent and was generally transient.5,9-11,28 In symptomatic patients, prednisone or hydrocortisone treatment was inferior to chemotherapy plus corticosteroid in reducing pain and other symptoms.9,10,28 Intensive treatment with dexamethasone was reported to have no effect on hormone-refractory prostate cancer in one small study.29
Serious adverse events occurred among 26 percent of patients in the group given docetaxel every three weeks and 29 percent of the group given weekly docetaxel, as compared with 20 percent in the mitoxantrone group. However, hematologic events were rare in all three groups, and most patients received the prescribed doses of the assigned drug on schedule. Although neutropenia was most common in the group given docetaxel every three weeks, infection was rare. There was a higher incidence of cardiotoxicity in the mitoxantrone group, but it was rarely of clinical importance. Most adverse events associated with docetaxel were of low grade and were bothersome rather than life-threatening; loss of sensation in the fingers and toes proved particularly annoying to some patients.
We designed this study to include a schedule with lower doses of docetaxel given weekly to assess whether a weekly regimen was better tolerated than treatment every three weeks. We found no evidence of a lower rate of adverse events or improved outcomes with the weekly schedule. Treatments given at intervals of three weeks are more convenient for most patients and we think should remain the standard with docetaxel.
Significantly more patients satisfied the stringent criterion of a 16-point improvement from baseline in the total FACT-P score in the docetaxel groups (22 percent in the group given docetaxel every three weeks and 23 percent in the weekly docetaxel group) than in the mitoxantrone group (13 percent). This result suggests that docetaxel has superior palliative effects despite the increase in toxicity. It is likely that the improvement in the quality of life would have been greater if our study had been restricted to symptomatic patients. Overall, the aspects of the quality of life that are assessed by the FACT-P questionnaire were maintained or improved during treatment, with the greatest benefit occurring for prostate-cancer–specific concerns.
Our findings provide evidence that cytotoxic chemotherapy can significantly prolong survival among men with hormone-refractory prostate cancer. Our data suggest that docetaxel plus prednisone is the preferred option for most patients with hormone-refractory prostate cancer.
Supported by Aventis.
Dr. Tannock reports having received grant support from Immunex; Drs. De Wit and Rosenthal consulting fees from Aventis; Drs. Berry, Oudard, and Turesson consulting fees and lecture fees from Aventis; and Drs. Chi, James, and Eisenberger consulting fees, lecture fees, and grant support from Aventis.
We are indebted to the men who participated in this study; to the study contributors; to investigators who recruited patients, including D. Campos (Argentina); H. Gurney and M. Stockler (Australia); M. Rauchenwald (Austria); T. Gil, Y. Humblet, and A. van Oosterom (Belgium); D. Herchenhorn (Brazil); S. Ernst, L. Lacombe, M. Moore, F. Saad, D. Soulieres, P. Venner, and E. Winquist (Canada); M. Urban (Czech Republic) P. Kellokumpu-Lehtinen (Finland); G. Deplanque, B. Duclos, I. Krakowski, and L. Mignot (France); J. Breul and R. Paul (Germany); I. Bodrogi (Hungary); S. Bracarda (Italy); G. Chahine (Lebanon); J.L. Bruins and J.A. Witjes (the Netherlands); T. Demkow and K. Bar (Poland); O. Kariakine and M. Matveev (Russia); I. Andrasina (Slovak Republic); D. Vorobiof (South Africa); J. Bellmunt and J.-R. Germa (Spain); A. Widmark (Sweden); A. Horwich, T. Roberts, and J. Wylie (United Kingdom); and L. Baez, W. Dugan, and N. Tirumali (United States); to the members of the Data and Safety Monitoring Committee — D. Osoba (Canada), F. Boccardo (Italy), M. Parmar (United Kingdom), and N. Dawson and E. Klein (United States) — and to C. Beauchard (study manager), N. Yateman and S. Thompson (statisticians), M. Kopreski (safety), and E. Borghi, S. Yao, and A. Yver (clinical directors), who were key Aventis personnel.
Source Information
From the Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto (I.F.T.); the Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, the Netherlands (R.W.); Raleigh Hematology Oncology Associates, Cary, N.C. (W.R.B.); the Department of Chemotherapy and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary (J.H.); the Department of Chemotherapy, Medical University, Lodz, Poland (A.P.); BC Cancer Agency, Vancouver, B.C., Canada (K.N.C.); Hôpital Européen Georges Pompidou, Paris (S.O.); Institut Gustav Roussy, Villejuif, France (C.T.); Cancer Research UK Institute for Cancer Studies, Birmingham, United Kingdom (N.D.J.); the Section of Oncology, Uppsala University Hospital, Uppsala, Sweden (I.T.); Cancer Trials Australia, Victoria, Australia (M.A.R.); and the Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore (M.A.E.).
Address reprint requests to Dr. Tannock at the Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave., Toronto, ON M5G 2M9, Canada, or at ian.tannock@uhn.on.ca.
- References
References
1
American Cancer Society (ACS). Cancer facts & figures 2003. (Accessed September 13, 2004, at http://www.cancer.org/docroot/STT/stt_0_2003.asp?sitearea=STT&level=1.)
2
Oades GM ,Coxon J ,Colston KW . The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis 2002;5:264-272
CrossRef | Web of Science | Medline3
Saad F ,Gleason DM ,Murray R , et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468
CrossRef | Web of Science | Medline4
Dearnaley DP ,Sydes MR ,Mason MD , et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:1300-1311
CrossRef | Web of Science | Medline5
Fossa SD ,Slee PH ,Brausi M , et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer genitourinary group. J Clin Oncol 2001;19:62-71
Web of Science | Medline6
Tannock I ,Gospodarowicz M ,Meakin W ,Panzarella T ,Stewart L ,Rider W . Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7:590-597
Web of Science | Medline7
Martel CL ,Gumerlock PH ,Meyers FJ ,Lara PN Jr . Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev 2003;29:171-187
CrossRef | Web of Science | Medline8
Osoba D ,Tannock IF ,Ernst DS ,Neville AJ . Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999;17:1654-1663
Web of Science | Medline9
Tannock IF ,Osoba D ,Stockler MR , et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764
Web of Science | Medline10
Berry W ,Dakhil S ,Modiano M ,Gregurich M ,Asmar L . Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168:2439-2443
CrossRef | Web of Science | Medline11
Kantoff PW ,Halabi S ,Conaway M , et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506-2513
Web of Science | Medline12
Ernst DS ,Tannock IF ,Winquist EW , et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-3342
CrossRef | Web of Science | Medline13
Beer TM ,Pierce WC ,Lowe BA ,Henner WD . Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12:1273-1279
CrossRef | Web of Science | Medline14
Berry W ,Dakhil S ,Gregurich MA ,Asmar L . Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001;28:Suppl 15:8-15
CrossRef | Web of Science | Medline15
Friedland D ,Cohen J ,Miller R Jr , et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999;26:Suppl 17:19-23
Web of Science | Medline16
Picus J ,Schultz M . Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26:Suppl 17:14-18
Web of Science | Medline17
Savarese DM ,Halabi S ,Hars V , et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 2001;19:2509-2516
Web of Science | Medline18
Petrylak DP . Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002;20:Suppl 1:31-35
CrossRef | Medline19
Beer TM ,Eilers KM ,Garzotto M ,Egorin MJ ,Lowe BA ,Henner WD . Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21:123-128
CrossRef | Web of Science | Medline20
Chen TT ,Chute JP ,Feigal E ,Johnson BE ,Simon R . A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst 2000;92:1601-1607
CrossRef | Web of Science | Medline21
Kelly WK ,Slovin S ,Scher HI . Steroid hormone withdrawal syndromes: pathophysiology and clinical significance. Urol Clin North Am 1997;24:421-431
CrossRef | Web of Science | Medline22
Wirth MP ,Froschermaier SE . The antiandrogen withdrawal syndrome. Urol Res 1997;25:Suppl 2:S67-S71
CrossRef | Web of Science | Medline23
Melzack R . The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277-299
CrossRef | Web of Science | Medline24
Esper P ,Mo F ,Chodak G ,Sinner M ,Cella D ,Pienta KJ . Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument. Urology 1997;50:920-928
CrossRef | Web of Science | Medline25
Kornblith AB ,Herndon JE II ,Zuckerman E ,Godley PA ,Savarese D ,Vogelzang NJ . The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 2001;12:633-641
CrossRef | Web of Science | Medline26
WHO criteria. In: WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979. (Offset publication no. 48.)
27
Petrylak DP ,Tangen CM ,Hussain MHA , et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520
Full Text | Web of Science | Medline28
Small EJ ,Meyer M ,Marshall ME , et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000;18:1440-1450
Web of Science | Medline29
Weitzman AL ,Shelton G ,Zuech N , et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 2000;163:834-837
CrossRef | Web of Science | Medline
- Citing Articles (1071)
Citing Articles
1
Joaquim Bellmunt, Gerhardt Attard, Amit Bahl, Hartwig Huland, Laurence Klotz, Deborah Kuban, Stéphane Oudard, William Watson. (2012) Advances in the management of high-risk localised and metastatic prostate cancer. BJU International 109, 8-13
CrossRef2
Akinori Minato, Naohiro Fujimoto, Tatsuhiko Kubo, Shuji Harada, Soichiro Akasaka, Tetsuro Matsumoto. (2012) Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer. Medical Oncology
CrossRef3
Alexandre Ingels, Alexandre Taille, Guillaume Ploussard. (2012) Radical Prostatectomy as Primary Treatment of High-risk Prostate Cancer. Current Urology Reports
CrossRef4
S. Oudard, P. Combe. (2012) Résistance au docétaxel: mécanismes et applications thérapeutiques. Oncologie
CrossRef5
Chun-Han Chen, Cho-Hwa Liao, Ya-Ling Chang, Jih-Hwa Guh, Shiow-Lin Pan, Che-Ming Teng. (2012) Protopine, a novel microtubule-stabilizing agent, causes mitotic arrest and apoptotic cell death in human hormone-refractory prostate cancer cell lines. Cancer Letters 315:1, 1-11
CrossRef6
Douglas F. Beach, Robert A. Somer, Jean Hoffman-Censits, Jianqing Lin, Yu-Ning Wong, Elizabeth Plimeck, Gary Hudes, David Vaughn, Guy T. Bernstein, Gloria J. Morris. (2012) A Wealth of New Options: A Case Presentation of the Management of Castration-Recurrent Prostate Cancer. Seminars in Oncology 39:1, 1-8
CrossRef7
Jeffrey Peppercorn, Andrew Armstrong, David W. Zaas, Daniel George. (2012) Rationing in urologic oncology: Lessons from sipuleucel-T for advanced prostate cancer
. Urologic Oncology: Seminars and Original Investigations
CrossRef8
Alfons JM van den Eertwegh, Jurjen Versluis, H Pieter van den Berg, Saskia JAM Santegoets, R Jeroen A van Moorselaar, Tim M van der Sluis, Helen E Gall, Thomas C Harding, Karin Jooss, Israel Lowy, Herbert M Pinedo, Rik J Scheper, Anita GM Stam, B Mary E von Blomberg, Tanja D de Gruijl, Kristen Hege, Natalie Sacks, Winald R Gerritsen. (2012) Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. The Lancet Oncology
CrossRef9
Satoshi Yamamoto, Naoki Tomita, Yuri Suzuki, Tomohiko Suzaki, Tomohiro Kaku, Takahito Hara, Masuo Yamaoka, Naoyuki Kanzaki, Atsushi Hasuoka, Atsuo Baba, Mitsuhiro Ito. (2012) Design, Synthesis, and Biological Evaluation of 4-Arylmethyl-1-phenylpyrazole and 4-Aryloxy-1-phenylpyrazole Derivatives as Novel Androgen Receptor Antagonists. Bioorganic & Medicinal Chemistry
CrossRef10
E. Bismarck, B.J. Schmitz-Dräger, O. Schöffski. (2012) Was erwartet die Medizin von der Gesundheitsökonomie?. Der Urologe
CrossRef11
Zhaomei Mu, C-M Ma, Xiaoming Chen, Dusica Cvetkovic, Alan Pollack, Lili Chen. (2012) MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment. Physics in Medicine and Biology 57:2, 535-545
CrossRef12
Y. Loriot, C. Massard, K. Fizazi. (2012) Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Annals of Oncology
CrossRef13
Jihua Liu, Pavla Kopečková, Huaizhong Pan, Monika Sima, Patrick Bühler, Philipp Wolf, Ursula Elsässer-Beile, Jindřich Kopeček. (2012) Prostate-Cancer-Targeted N-(2-Hydroxypropyl)methacrylamide Copolymer/Docetaxel Conjugates. Macromolecular Biosciencen/a-n/a
CrossRef14
Hung-Wei Yang, Mu-Yi Hua, Hao-Li Liu, Rung-Ywan Tsai, Cheng-Keng Chuang, Po-Chun Chu, Pei-Yi Wu, Ying-Hsu Chang, Heng-Chang Chuang, Kai-Jie Yu, See-Tong Pang. (2012) Cooperative Dual-Activity Targeted Nanomedicine for Specific and Effective Prostate Cancer Therapy. ACS Nano120116164607007
CrossRef15
Timothy A. Yap, Charles Swanton, Johann S. Bono. (2012) Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. The EPMA Journal
CrossRef16
Deborah Mukherji, Carmel J Pezaro, Johann S De-Bono. (2012) MDV3100 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs1-7
CrossRef17
M. L. Huber, L. Haynes, C. Parker, P. Iversen. (2012) Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. JNCI Journal of the National Cancer Institute
CrossRef18
Simon Mahoney, Frank Arfuso, Pierra Rogers, Susan Hisheh, David Brown, Michael Millward, Arun Dharmarajan. (2012) Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. Journal of Biosciences
CrossRef19
Naveed H. Akhtar, Orrin Pail, Ankeeta Saran, Lauren Tyrell, Scott T. Tagawa. (2012) Prostate-Specific Membrane Antigen-Based Therapeutics. Advances in Urology 2012, 1-9
CrossRef20
Bin Han, Naohiro Fujimoto, Mizuki Kobayashi, Tetsuro Matsumoto. (2012) Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells. Prostate Cancer 2012, 1-6
CrossRef21
Ariel E. Marciscano, Matthew E. Hardee, Nicholas Sanfilippo. (2012) Management of High-Risk Localized Prostate Cancer. Advances in Urology 2012, 1-11
CrossRef22
Niall M Corcoran, Martin E Gleave. (2012) Targeted therapy in prostate cancer. Histopathology 60:1, 216-231
CrossRef23
Bing Liu, Guoyan Geng, Rongtuan Lin, Cuiyan Ren, Jian Hui Wu. (2012) Learning From Estrogen Receptor Antagonism: Structure-Based Identification of Novel Antiandrogens Effective Against Multiple Clinically Relevant Androgen Receptor Mutants. Chemical Biology & Drug Designno-no
CrossRef24
P Kharaziha, P Rodriguez, Q Li, H Rundqvist, A-C Björklund, M Augsten, A Ullén, L Egevad, P Wiklund, S Nilsson, G Kroemer, D Grander, T Panaretakis. (2012) Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death and Disease 3:1, e262
CrossRef25
Robert W. Ross, Matthew D. Galsky, Phil Febbo, Marc Barry, Jerome P. Richie, Wanling Xie, Fiona M. Fennessy, Rupal S. Bhatt, Julia Hayes, Toni K. Choueiri, Clare M. Tempany, Philip W. Kantoff, Mary E. Taplin, William K. Oh. (2012) Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer. Cancern/a-n/a
CrossRef26
Kanishka Sircar, Heng Huang, Limei Hu, David Cogdell, Jasreman Dhillon, Vassiliki Tzelepi, Eleni Efstathiou, Ismaël H. Koumakpayi, Fred Saad, Dijun Luo, Tarek A. Bismar, Ana Aparicio, Patricia Troncoso, Nora Navone, Wei Zhang. (2012) Integrative Molecular Profiling Reveals Asparagine Synthetase Is a Target in Castration-Resistant Prostate Cancer. The American Journal of Pathology
CrossRef27
Miguel A. Climent, Josep Mª Piulats, Alfredo Sánchez-Hernández, José Ángel Arranz, Javier Cassinello, Jesús García-Donas, Aránzazu González del Alba, Luis León-Mateos, Begoña Mellado, Mª José Méndez-Vidal, Begoña Pérez-Valderrama. (2012) Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Critical Reviews in Oncology/Hematology
CrossRef28
Judd W. Moul, Nancy Dawson. (2012) Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature. Cancer Investigation 30:1, 1-12
CrossRef29
Shintaro Narita, Norihiko Tsuchiya, Teruaki Kumazawa, Shinya Maita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei Horikawa, Shigeru Satoh, Hiroshi Nanjyo, Tomonori Habuchi. (2012) Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World Journal of Surgical Oncology 10:1, 1
CrossRef30
Rauf Taner Divrik, Levent Türkeri, Ali F. Şahin, Bülent Akdoğan, Ferhat Ateş, Çağ Çal, Sümer Baltacı. (2012) Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer. Urologia Internationalis 88:1, 25-33
CrossRef31
Masuo Yamaoka, Takahito Hara, Takenori Hitaka, Tomohiro Kaku, Toshiyuki Takeuchi, Junzo Takahashi, Satoru Asahi, Hiroshi Miki, Akihiro Tasaka, Masami Kusaka. (2012) Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. The Journal of Steroid Biochemistry and Molecular Biology
CrossRef32
Heather Payne, Richard Pearcy. (2012) Symptoms and health-related quality of life in castration-resistant prostate cancer: the patient's perspective. Journal of Men's Health
CrossRef33
M. Spahn, M. Krebs. (2012) Wie soll die Hormontherapie beim kastrationsresistenten Prostatakarzinom fortgeführt werden?. Der Urologe 51:1, 15-19
CrossRef34
M. Santis, M. Bachner. (2012) Rolle der Chemotherapie beim kastrationsresistenten Prostatakarzinom. Der Urologe 51:1, 39-43
CrossRef35
Álvaro Pinto, María Merino, Pilar Zamora, Andrés Redondo, Beatriz Castelo, Enrique Espinosa. (2011) Targeting the endothelin axis in prostate carcinoma. Tumor Biology
CrossRef36
Keiichiro Uemura, Kiyoaki Nishihara, Tokumasa Hayashi, Katsuro Tomiyasu, Kei Matsuoka. (2011) Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide. Journal of Infection and Chemotherapy
CrossRef37
Sriram Yennurajalingam, Bradley Atkinson, Jessica Masterson, David Hui, Diana Urbauer, Shi-Ming Tu, Eduardo Bruera. (2011) The Impact of an Outpatient Palliative Care Consultation on Symptom Burden in Advanced Prostate Cancer Patients. Journal of Palliative Medicine111205073512001
CrossRef38
Li-Juan Meng, Jun Wang, Wei-Fei Fan, Xiao-Lin Pu, Fu-Yin Liu, Min Yang. (2011) Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients. Journal of Cancer Research and Clinical Oncology
CrossRef39
Ary Serpa Neto, Marcos Tobias-Machado, Rafael Kaliks, Marcelo Langer Wroclawski, Antônio Carlos Lima Pompeo, Auro Del Giglio. (2011) Ten Years of Docetaxel-Based Therapies in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis of 2244 Patients in 12 Randomized Clinical Trials. Clinical Genitourinary Cancer 9:2, 115-123
CrossRef40
V. Harris, K. Lloyd, S. Forsey, P. Rogers, M. Roche, C. Parker. (2011) A Population-based Study of Prostate Cancer Chemotherapy. Clinical Oncology 23:10, 706-708
CrossRef41
Igor Tsaur, Jasmina Makarević, Lukasz Hudak, Eva Juengel, Martin Kurosch, Christoph Wiesner, Georg Bartsch, Sebastian Harder, Axel Haferkamp, Roman A. Blaheta. (2011) The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Letters 313:1, 84-90
CrossRef42
Brant A. Inman, Igor Frank, Stephen A. Boorjian, Joseph W. Akornor, R. Jeffrey Karnes, Bradley C. Leibovich, Michael L. Blute, Eric J. Bergstralh. (2011) Dynamic prediction of metastases after radical prostatectomy for prostate cancer. BJU International 108:11, 1762-1768
CrossRef43
Haruki Kume, Motofumi Suzuki, Tetsuya Fujimura, Hiroshi Fukuhara, Yutaka Enomoto, Hiroaki Nishimatsu, Akira Ishikawa, Yukio Homma. (2011) Docetaxel as a vital option for corticosteroid-refractory prostate cancer. International Urology and Nephrology 43:4, 1081-1087
CrossRef44
Robert Dreicer, Jorge Garcia, Maha Hussain, Brian Rini, Nicholas Vogelzang, Sandy Srinivas, Bradley Somer, Yan D. Zhao, Marek Kania, Derek Raghavan. (2011) Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Investigational New Drugs 29:6, 1441-1448
CrossRef45
Andreas Varkaris, Paul G Corn, Sanchaika Gaur, Farshid Dayyani, Christopher J Logothetis, Gary E Gallick. (2011) The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opinion on Investigational Drugs 20:12, 1677-1684
CrossRef46
Orazio Caffo, Teodoro Sava, Evi Comploj, Annamaria Fariello, Fable Zustovich, Romana Segati, Cosimo Sacco, Antonello Veccia, Enzo Galligioni. (2011) Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. BJU International 108:11, 1825-1832
CrossRef47
Vincent Ravery, Karim Fizazi, Stephane Oudard, Ludovic Drouet, Jean-Christophe Eymard, Stephane Culine, Gwenaelle Gravis, Christophe Hennequin, Marc Zerbib. (2011) The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU International 108:11, 1782-1786
CrossRef48
Michael R. Harrison, Noah M. Hahn, Roberto Pili, William K. Oh, Hans Hammers, Christopher Sweeney, KyungMann Kim, Scott Perlman, Jamie Arnott, Carolyn Sidor, George Wilding, Glenn Liu. (2011) A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational New Drugs 29:6, 1465-1474
CrossRef49
Mehmet Asim Bilen, Rosale General, Shi-Ming Tu. (2011) Prolonged Remission of Fulminant Castrate-Resistant Prostate Cancer: A Case Report. Clinical Genitourinary Cancer 9:2, 133-136
CrossRef50
Alice Vajda, Laure Marignol, Ruth Foley, Thomas H. Lynch, Mark Lawler, Donal Hollywood. (2011) Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients. Cancer Treatment Reviews 37:8, 643-654
CrossRef51
Bamidele A Adesunloye, William L Dahut. (2011) Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials. Clinical Investigation 1:12, 1651-1661
CrossRef52
Elizabeth A. Guancial, Mary-Ellen Taplin. (2011) Case Report: Responses to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer After Extensive Docetaxel Treatment. Clinical Genitourinary Cancer 9:2, 130-132
CrossRef53
Wei-Xiang Qi, Zan Shen, Yang Yao. (2011) Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials. Journal of Cancer Research and Clinical Oncology 137:12, 1785-1790
CrossRef54
Catherine Sánchez, Alejandro Mercado, Héctor R. Contreras, Patricia Mendoza, Juan Cabezas, Cristian Acevedo, Christian Huidobro, Enrique A. Castellón. (2011) Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins. The Prostate 71:16, 1810-1817
CrossRef55
Keita Nakane, Yasunori Fujita, Riyako Terazawa, Yuko Atsumi, Taku Kato, Yoshinori Nozawa, Takashi Deguchi, Masafumi Ito. (2011) Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells. International Journal of Urologyno-no
CrossRef56
Neeraj Agarwal, Guru Sonpavde, Cora N. Sternberg. (2011) Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer. European Urology
CrossRef57
Carmel J. Pezaro, Deborah Mukherji, Johann S. De Bono. (2011) Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. Drug Discovery Today
CrossRef58
C.-H. Ohlmann, J. Kamradt, M. Stöckle. (2011) Antihormonelle Therapie des Prostatakarzinoms der 3. Generation. Der Urologe
CrossRef59
B. Molitor, C. Börgermann. (2011) Zweitlinientherapie beim kastrationsresistenten Prostatakarzinom (CRPC). Der Urologe
CrossRef60
Ranbir Chander Sobti, Nega Berhane, Shiferaw Melese, Salih Abdul Mahdi, Libsy Gupta, Hitender Thakur, Neha Singh. (2011) Impact of XPD gene polymorphism on risk of prostate cancer on north Indian population. Molecular and Cellular Biochemistry
CrossRef61
David R. Yates, Morgan Rouprêt. (2011) Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response. World Journal of Urology
CrossRef62
G Bousquet, J Alexandre, C Le Tourneau, F Goldwasser, S Faivre, H de Mont-Serrat, R Kaiser, J L Misset, E Raymond. (2011) Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. British Journal of Cancer 105:11, 1640-1645
CrossRef63
Carsten-H. Ohlmann, Axel S. Merseburger, Henrik Suttmann, David Schilling, Lutz Trojan, Carsten Kempkensteffen, Stefan Corvin, Michael J. Mathers, Patrick J. Bastian. (2011) Novel options for the treatment of castration-resistant prostate cancer. World Journal of Urology
CrossRef64
Ryoichi Yano, Aya Konno, Kyohei Watanabe, Hitoshi Tsukamoto, Yuichiro Kayano, Hiroaki Ohnaka, Nobuyuki Goto, Toshiaki Nakamura, Mikio Masada. (2011) Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. International Journal of Clinical Oncology
CrossRef65
F. Dayyani, G. E. Gallick, C. J. Logothetis, P. G. Corn. (2011) Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. JNCI Journal of the National Cancer Institute 103:22, 1665-1675
CrossRef66
Winald R. Gerritsen, Padmanee Sharma. (2011) Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy. Journal of Clinical Immunology
CrossRef67
Tomoyuki Shimabukuro, Shigeru Sakano, Kenji Matsuda, Yoriaki Kamiryo, Norio Yamamoto, Yoshitaka Kaneda, Takahito Nasu, Yoshikazu Baba, Akinobu Suga, Mitsutaka Yamamoto, Akihiko Aoki, Kimio Takai, Satoru Yoshihiro, Motohiko Konishi, Katsuhiko Imoto, Hideyasu Matsuyama. (2011) Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study. International Journal of Clinical Oncology
CrossRef68
Daniel Castellano, José L González-Larriba, Luis M Antón-Aparicio, Javier Cassinello, Enrique Grande, Emilio Esteban, Juan Sepúlveda. (2011) Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. Expert Opinion on Pharmacotherapy 12:16, 2433-2439
CrossRef69
Jianqing Lin, Victoria J. Sinibaldi, Michael A. Carducci, Samuel Denmeade, Danny Song, Theodore DeWeese, Mario A. Eisenberger. (2011) Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations 29:6, 670-675
CrossRef70
A. Flechon, D. Pouessel, C. Ferlay, D. Perol, P. Beuzeboc, G. Gravis, F. Joly, S. Oudard, G. Deplanque, S. Zanetta, P. Fargeot, F. Priou, J. P. Droz, S. Culine. (2011) Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Annals of Oncology 22:11, 2476-2481
CrossRef71
Francesco Fabbri, Wainer Zoli, Silvia Carloni, Paola Ulivi, Chiara Arienti, Giovanni Brigliadori, Marco Montanari, Anna Tesei, Rosella Silvestrini, Dino Amadori. (2011) Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: Role of golgi apparatus. Journal of Cellular Physiology 226:11, 3035-3042
CrossRef72
Olav Lindqvist. (2011) Living with Bodily Changes in Hormone-Refractory Prostate Cancer. Seminars in Oncology Nursing 27:4, 309-316
CrossRef73
Lakshmi Rajdev, Abdissa Negassa, Qun Dai, Gary Goldberg, Kathy Miller, Joseph A. Sparano. (2011) Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemotherapy and Pharmacology 68:5, 1119-1124
CrossRef74
Stephanie Jeske, Scott T. Tagawa, Olugbenga Olowokure, Jodi Selzer, Paraskevi Giannakakou, David M. Nanus. (2011) Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations 29:6, 676-681
CrossRef75
Joyce M. Dodewaard-de Jong, John M. H. Klerk, Haiko J. Bloemendal, Bart P. J. Bezooijen, Marie J. Haas, Richard H. Wilson, Joe M. O’Sullivan. (2011) A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). European Journal of Nuclear Medicine and Molecular Imaging 38:11, 1990-1998
CrossRef76
Heather Payne, Philip Cornford. (2011) Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urologic Oncology: Seminars and Original Investigations 29:6, 593-601
CrossRef77
Mary Weinstein Dunn, Meredith Wallace Kazer. (2011) Prostate Cancer Overview. Seminars in Oncology Nursing 27:4, 241-250
CrossRef78
Jenny J Kim, Daniel Keizman, Samuel R Denmeade, Emmanuel S Antonarakis. (2011) The unfolding treatment landscape for men with castration-resistant prostate cancer. Clinical Investigation 1:11, 1533-1544
CrossRef79
Masaya Ito, Kazutaka Saito, Yosuke Yasuda, Gen Sukegawa, Yuichi Kubo, Noboru Numao, Shinichi Kitsukawa, Shinji Urakami, Takeshi Yuasa, Shinya Yamamoto, Junji Yonese, Iwao Fukui. (2011) Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel. Urology 78:5, 1131-1135
CrossRef80
Oliver Sartor, William Goeckeler, Oyvind Bruland. (2011) Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. Asian Journal of Andrology 13:6, 783-784
CrossRef81
William Y. Kim, Young E. Whang, Raj S. Pruthi, Maria Q. Baggstrom, W. Kimryn Rathmell, Julian G. Rosenman, Eric M. Wallen, Lav K. Goyal, Gayle Grigson, Catharine Watkins, Paul A. Godley. (2011) Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. Urologic Oncology: Seminars and Original Investigations 29:6, 608-613
CrossRef82
K. Fizazi, J.S. De Bono, A. Flechon, A. Heidenreich, E. Voog, N.B. Davis, Ming Qi, R. Bandekar, J.T. Vermeulen, M. Cornfeld, G.R. Hudes. (2011) Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer
CrossRef83
Bertrand Tombal. (2011) Continuous Improvement Versus Innovation: The Case for Sipuleucel-T. European Urology
CrossRef84
Daniel J. Lee, Eugene K. Cha, Justin M. Dubin, Himisha Beltran, Thomas F. Chromecki, Harun Fajkovic, Douglas S. Scherr, Scott T. Tagawa, Shahrokh F. Shariat. (2011) Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU Internationalno-no
CrossRef85
Celestia S. Higano, E. David Crawford. (2011) New and emerging agents for the treatment of castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations 29:6, 1-8
CrossRef86
Karim Fizazi, Francois Lesaunier, Remy Delva, Gwenaëlle Gravis, Frederic Rolland, Frank Priou, Jean-Marc Ferrero, Nadine Houedé, Loïc Mourey, Christine Theodore, Ivan Krakowski, Jean-François Berdah, Marjorie Baciuchka, Brigitte Laguerre, Aude Fléchon, Alain Ravaud, Isabelle Cojean-Zelek, Stéphane Oudard, Jean-Luc Labourey, Jean-Léon Lagrange, Paule Chinet-Charrot, Claude Linassier, Gaël Deplanque, Philippe Beuzeboc, Jean Geneve, Jean-Louis Davin, Elodie Tournay, Stephane Culine. (2011) A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. European Journal of Cancer
CrossRef87
Roberto Iacovelli, Antonella Palazzo, Giuseppe Procopio, Paola Gazzaniga, Enrico Cortesi. (2011) Abiraterone acetate in castration-resistant prostate cancer. Anti-Cancer Drugs1
CrossRef88
Anthony V D'Amico, Ming-Hui Chen, Mario de Castro, Marian Loffredo, David S Lamb, Allison Steigler, Philip W Kantoff, James W Denham. (2011) Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. The Lancet Oncology
CrossRef89
Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Toshiya Tanaka, Weiguang Zhang, Kotaro Azuma, Kenich Takayama, Daisuke Obinata, Taro Murata, Kuniko Horie-Inoue, Tatsuhiko Kodama, Yasuyoshi Ouchi, Yukio Homma, Satoshi Inoue. (2011) Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer. Cancer Scienceno-no
CrossRef90
M.K. Magnusson, R. Kraaij, R.M. Leadley, C.M.A. De Ridder, W.M. van Weerden, K.A.J. Van Schie, M. Van der Kroeg, R.C. Hoeben, N.J. Maitland, L. Lindholm. (2011) A Transductionally Retargeted Adenoviral Vector for Virotherapy of Her2/neu-Expressing Prostate Cancer. Human Gene Therapy111012121242004
CrossRef91
Orazio Caffo, Angela Gernone, Cinzia Ortega, Teodoro Sava, Giacomo Cartenì, Gaetano Facchini, Giovanni Lo Re, Placido Amadio, Roberto Bortolus, Vincenzo Pagliarulo, Veronica Prati, Antonello Veccia, Enzo Galligioni. (2011) Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. Journal of Neuro-Oncology
CrossRef92
S Miyamoto, K Ito, M Miyakubo, R Suzuki, T Yamamoto, K Suzuki, K Suzuki, H Yamanaka. (2011) Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy. Prostate Cancer and Prostatic Diseases
CrossRef93
Andrew Eichholz, Roberta Ferraldeschi, Gerhardt Attard, Johann S. de Bono. (2011) Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Molecular and Cellular Endocrinology
CrossRef94
Joseph W. Kim, Ravi A. Madan, James L. Gulley. (2011) Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine. Clinical Genitourinary Cancer
CrossRef95
Eric A. Singer, Ramaprasad Srinivasan. (2011) Intravenous therapies for castration-resistant prostate cancer: Toxicities and adverse events. Urologic Oncology: Seminars and Original Investigations
CrossRef96
Alexander Kutikov, Peter Makhov, Konstantin Golovine, Daniel J. Canter, Mohit Sirohi, Ryan Street, Jay Simhan, Robert G. Uzzo, Vladimir M. Kolenko. (2011) Interleukin-6: A Potential Biomarker of Resistance to Multitargeted Receptor Tyrosine Kinase Inhibitors in Castration-resistant Prostate Cancer. Urology 78:4, 968.e7-968.e11
CrossRef97
Tobias Maurer, Christos Pournaras, Juan A. Aguilar-Pimentel, Mark Thalgott, Thomas Horn, Matthias Heck, Antje Heit, Hubert Kuebler, Jürgen E. Gschwend, Roman Nawroth. (2011) Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses. Urologic Oncology: Seminars and Original Investigations
CrossRef98
Pol Specenier, Marika Rasschaert, Philippe Vroman, Jan Van den Brande, Joke Dyck, Dirk Schrijvers, Manon T. Huizing, Jan B. Vermorken. (2011) Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology 34:5, 472-477
CrossRef99
Dhwanishiva Vasani, David Y. Josephson, Courtney Carmichael, Oliver Sartor, Sumanta Kumar Pal. (2011) Recent advances in the therapy of castration-resistant prostate cancer: The price of progress. Maturitas 70:2, 194-196
CrossRef100
T. Nelius, K. Rinard, S. Filleur. (2011) Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer – Review of the literature. Cancer Treatment Reviews 37:6, 444-455
CrossRef101
K Tabata, S Kurosaka, M Watanabe, K Edamura, T Satoh, G Yang, E Abdelfattah, J Wang, A Goltsov, D Floryk, T C Thompson. (2011) Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Therapy 18:10, 969-978
CrossRef102
Vincent J. Gnanapragasam, Malcolm D. Mason, Greg L. Shaw, David E. Neal. (2011) The role of surgery in high-risk localised prostate cancer. BJU Internationalno-no
CrossRef103
Constantine Alifrangis, Ciara O'Hanlon-Brown, Mark Tuthill, Jonathan Waxman. (2011) New drugs for prostate cancer. BJU Internationalno-no
CrossRef104
Dmitri Pchejetski, Torsten Böhler, Justin Stebbing, Jonathan Waxman. (2011) Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nature Reviews Urology 8:10, 569-678
CrossRef105
J. S. de Bono, L. R. Molife, G. Sonpavde, J. P. Maroto, E. Calvo, T. H. Cartwright, D. M. Loesch, K. Feit, A. Das, E. A. Zang, J. Wanders, S. Agoulnik, D. P. Petrylak. (2011) Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Annals of Oncology
CrossRef106
E S Antonarakis, A J Armstrong. (2011) Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 14:3, 192-205
CrossRef107
Kwong Y Tsang, James L Gulley. (2011) Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer. Asian Journal of Andrology 13:5, 657-658
CrossRef108
Cora N. Sternberg. (2011) Novel treatments for castration-resistant prostate cancer. European Journal of Cancer 47, S195-S199
CrossRef109
Diletta Bianchini, Johann S. de Bono. (2011) Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer. European Journal of Cancer 47, S189-S194
CrossRef110
J.A. Harrington, R.J. Jones. (2011) Management of metastatic castration-resistant prostate cancer after first-line docetaxel. European Journal of Cancer 47:14, 2133-2142
CrossRef111
Stephen B Williams, Aaron H Lay, Clayton S Lau, David Y Josephson, Timothy G Wilson, Toni K Choueiri, Sumanta K Pal. (2011) New therapies for castrate-resistant prostate cancer. Expert Opinion on Pharmacotherapy 12:13, 2069-2074
CrossRef112
Malcolm Mason. (2011) Towards a new era in care for metastatic castrate-resistant prostate cancer. British Journal of Medical and Surgical Urology 4, S1
CrossRef113
Anna Lydon. (2011) Cabazitaxel side effects: Prevention and management. British Journal of Medical and Surgical Urology 4, S21-S27
CrossRef114
Sumanta Kumar Pal, Oliver Sartor. (2011) Current paradigms and Evolving concepts in metastatic castration-resistant prostate cancer. Asian Journal of Andrology 13:5, 683-689
CrossRef115
S C-H KAO, E HOVEY, G MARX. (2011) Second-line therapy for castrate-resistant prostate cancer: A literature review. Asia-Pacific Journal of Clinical Oncology 7:3, 212-223
CrossRef116
C. Nabhan, B. Parsons, E. Z. Touloukian, W. M. Stadler. (2011) Novel approaches and future directions in castration-resistant prostate cancer. Annals of Oncology 22:9, 1948-1957
CrossRef117
Celestia S. Higano. (2011) New treatment options for patients with metastatic castration-resistant prostate cancer. Cancer Treatment Reviews
CrossRef118
Simon J. Hall, Laurence Klotz, Allan J. Pantuck, Daniel J. George, James B. Whitmore, Mark W. Frohlich, Robert B. Sims. (2011) Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer. The Journal of Urology 186:3, 877-881
CrossRef119
Heather A. Payne, Ajay Aggarwal, David K. Woolf. (2011) The evolution and current paradigm of chemotherapy for metastatic castrate-resistant prostate cancer. British Journal of Medical and Surgical Urology 4, S2-S8
CrossRef120
Emine Elif Ozkan. (2011) Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review. Molecular and Cellular Endocrinology 344:1-2, 1-24
CrossRef121
Paul R. Womble, Peter J. VanVeldhuizen, Alan A. Nisbet, Greg A. Reed, J. Brantley Thrasher, Jeffrey M. Holzbeierlein. (2011) A Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Before Radical Prostatectomy in High Risk Patients. The Journal of Urology 186:3, 882-888
CrossRef122
Anne Chauchereau. (2011) Experimental models for the development of new medical treatments in prostate cancer. European Journal of Cancer 47, S200-S214
CrossRef123
Abhay R. Shelke, Supriya G. Mohile. (2011) Treating Prostate Cancer in Elderly Men: How Does Aging Affect the Outcome?. Current Treatment Options in Oncology 12:3, 263-275
CrossRef124
Amit Bahl, Raj Persad. (2011) Metastatic castrate-resistant prostate cancer: New landscape, new challenges. British Journal of Medical and Surgical Urology 4, S9-S13
CrossRef125
Grazia Graziani, Lucio Tentori, Pierluigi Navarra. (2011) Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacological Research
CrossRef126
Timothy A. Yap, Andrea Zivi, Aurelius Omlin, Johann S. de Bono. (2011) The changing therapeutic landscape of castration-resistant prostate cancer. Nature Reviews Clinical Oncology 8:10, 597-610
CrossRef127
A. J. Zurita, D. J. George, N. D. Shore, G. Liu, G. Wilding, T. E. Hutson, M. Kozloff, P. Mathew, C. S. Harmon, S. L. Wang, I. Chen, E. Chow Maneval, C. J. Logothetis. (2011) Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Annals of Oncology
CrossRef128
Oliver Sartor. (2011) Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer. Nature Reviews Clinical Oncology 8:9, 515-516
CrossRef129
James M. McKiernan, LaMont J. Barlow, Melissa A. Laudano, Mark J. Mann, Daniel P. Petrylak, Mitchell C. Benson. (2011) A Phase I Trial of Intravesical Nanoparticle Albumin-Bound Paclitaxel in the Treatment of Bacillus Calmette-Guérin Refractory Nonmuscle Invasive Bladder Cancer. The Journal of Urology 186:2, 448-451
CrossRef130
Aimee E Hammerstrom, Diana H Cauley, Bradley J Atkinson, Padmanee Sharma. (2011) Cancer Immunotherapy: Sipuleucel-T and Beyond. Pharmacotherapy 31:8, 813-828
CrossRef131
Lu Gan, Jianlin Wang, Huibi Xu, Xiangliang Yang. (2011) Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. The Prostate 71:11, 1158-1166
CrossRef132
Guru Sonpavde, Gerhardt Attard, Joaquim Bellmunt, Malcolm D. Mason, Bernard Malavaud, Bertrand Tombal, Cora N. Sternberg. (2011) The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature. European Urology 60:2, 270-278
CrossRef133
Franklin M. Chu, Joel Picus, Paula M. Fracasso, Robert Dreicer, Zhihui Lang, Brenda Foster. (2011) A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Investigational New Drugs 29:4, 674-679
CrossRef134
Ruth L. Vinall, Christopher M. Mahaffey, Ryan R. Davis, Zunping Luo, Regina Gandour-Edwards, Paramita M. Ghosh, Clifford G. Tepper, Ralph W. de Vere White. (2011) Dual Blockade of PKA and NF–κB Inhibits H2 Relaxin-Mediated Castrate-Resistant Growth of Prostate Cancer Sublines and Induces Apoptosis. Hormones and Cancer 2:4, 224-238
CrossRef135
Abhijit Ray, Nate Larson, Daniel B. Pike, Michele Grüner, Sachin Naik, Hillevi Bauer, Alexander Malugin, Khaled Greish, Hamidreza Ghandehari. (2011) Comparison of Active and Passive Targeting of Docetaxel for Prostate Cancer Therapy by HPMA Copolymer–RGDfK Conjugates. Molecular Pharmaceutics 8:4, 1090-1099
CrossRef136
David L. Urdal, Mark W. Frohlich. 2011. Autologous cellular immunotherapy in late-stage prostate cancer: The development history of Sipuleucel-T (PROVENGE®). , 44-55.
CrossRef137
Anna Woloszynska-Read, Candace S. Johnson, Donald L. Trump. (2011) Vitamin D and cancer: Clinical aspects. Best Practice & Research Clinical Endocrinology & Metabolism 25:4, 605-615
CrossRef138
Naomi L. Dunning, Stéphanie A. Laversin, Amanda K. Miles, Robert C. Rees. (2011) Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?. Cancer Immunology, Immunotherapy 60:8, 1181-1193
CrossRef139
Mark R Haythorn, Richard J Ablin. (2011) Prostate-specific antigen testing across the spectrum of prostate cancer. Biomarkers in Medicine 5:4, 515-526
CrossRef140
Himisha Beltran, Tomasz M. Beer, Michael A. Carducci, Johann de Bono, Martin Gleave, Maha Hussain, William K. Kelly, Fred Saad, Cora Sternberg, Scott T. Tagawa, Ian F. Tannock. (2011) New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. European Urology 60:2, 279-290
CrossRef141
Youqiang Li, Yu Zeng, Steven M. Mooney, Bo Yin, Atsushi Mizokami, Mikio Namiki, Robert H. Getzenberg. (2011) Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. Journal of Cellular Biochemistry 112:8, 2125-2137
CrossRef142
Greg L. Plosker. (2011) Sipuleucel-T in Metastatic Castration-Resistant Prostate Cancer†. BioDrugs 25:4, 255-256
CrossRef143
Benedetto Farsaci, Anna Kwilas, James W. Hodge. 2011. Design, development, and translation of poxvirus-based vaccines for cancer. , 56-77.
CrossRef144
Eddie Thara, Tanya B. Dorff, Jacek K. Pinski, David I. Quinn. (2011) Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas 69:4, 296-303
CrossRef145
Jennifer Hirsch, Christina Lisa Johnson, Thomas Nelius, Ronald Kennedy, Werner de Riese, Stéphanie Filleur. (2011) PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ. Cytokine 55:2, 202-210
CrossRef146
Emma K. Beardsley, Sebastien J. Hotte, Scott North, Susan L. Ellard, Eric Winquist, Christian Kollmannsberger, Som D. Mukherjee, Kim N. Chi. (2011) A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Investigational New Drugs
CrossRef147
Jung Jin Hwang, Yong Sook Kim, Taelim Kim, Mi Joung Kim, In Gab Jeong, Je-Hwan Lee, Jene Choi, Sejin Jang, Seonggu Ro, Choung-Soo Kim. (2011) A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Investigational New Drugs
CrossRef148
K. N. Chi, E. Beardsley, B. J. Eigl, P. Venner, S. J. Hotte, E. Winquist, Y.- J. Ko, S. S. Sridhar, D. Weber, F. Saad. (2011) A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Annals of Oncology
CrossRef149
K. L. Mahon, S. M. Henshall, R. L. Sutherland, L. G. Horvath. (2011) Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocrine Related Cancer 18:4, R103-R123
CrossRef150
Cristian Villanueva, Fernando Bazan, Stefano Kim, Martin Demarchi, Loïc Chaigneau, Antoine Thiery-Vuillemin, Thierry Nguyen, Laurent Cals, Erion Dobi, Xavier Pivot. (2011) Cabazitaxel. Drugs 71:10, 1251-1258
CrossRef151
David J. Gallagher, Angel M. Cronin, Matthew I. Milowsky, Michael J. Morris, Jasmine Bhatia, Peter T. Scardino, James A. Eastham, Kenneth Offit, Mark E. Robson. (2011) Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Internationalno-no
CrossRef152
Orazio Caffo, Lucia Fratino, Roberto Barbieri, Alessandra Perin, Thomas Martini, Teodoro Sava, Romana Segati, Emanuela Vaccher, Franco Bernardo Bassan, Antonello Veccia, Giovanni Pappagallo, Enzo Galligioni. (2011) Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study. Urologic Oncology: Seminars and Original Investigations
CrossRef153
Martino Monteverde, Federica Tonissi, Jean-Louis Fischel, Marie-Christine Etienne-Grimaldi, Gerard Milano, Marco Merlano, Cristiana Lo Nigro. (2011) Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line. Urologic Oncology: Seminars and Original Investigations
CrossRef154
Hideaki Miyake, Iori Sakai, Tomoaki Terakawa, Ken-ichi Harada, Masato Fujisawa. (2011) Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations
CrossRef155
Giuseppe Procopio, Valentina Guadalupi, Maria Olga Giganti, Luigi Mariani, Roberto Salvioni, Nicola Nicolai, Filippo Capone, Riccardo Valdagni, Emilio Bajetta. (2011) Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU International 108:2, 223-227
CrossRef156
Joyce A. Generali, Dennis J. Cada. (2011) Off-Label Drug Uses - Docetaxel/Prednisone (D+P): Metastatic Hormone-Refractory Prostate Cancer. Hospital Pharmacy 46:7, 489-493
CrossRef157
William K. Kelly. (2011) Epothilones in prostate cancer. Urologic Oncology: Seminars and Original Investigations 29:4, 358-365
CrossRef158
Shintaro Narita, Norihiko Tsuchiya, Takeshi Yuasa, Shinya Maita, Takashi Obara, Kazuyuki Numakura, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi. (2011) Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. International Journal of Clinical Oncology
CrossRef159
M. Laramas, C. Costan, A. Tessier, D. Farneti. (2011) Cancer de prostate métastatique résistant à la castration : le point de vue de l’oncologue médical. Médecine Nucléaire 35:6, 378-383
CrossRef160
Anders Ullén, Carl-Henrik Shah, Ziya Kirkali. (2011) Management of advanced prostate cancer – new drugs. Acta Oncologica 50:S1, 137-140
CrossRef161
Giuseppe Colloca, Pasquale Colloca. (2011) Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need?. Medical Oncology 28:2, 519-527
CrossRef162
Saroj Niraula, Ian F. Tannock. (2011) Broadening horizons in medical management of prostate cancer. Acta Oncologica 50:S1, 141-147
CrossRef163
Andrea L. Harzstark, Jonathan E. Rosenberg, Vivian K. Weinberg, Jeremy Sharib, Charles J. Ryan, David C. Smith, Lance C. Pagliaro, Tomasz M. Beer, Glenn Liu, Eric J. Small. (2011) Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy. Cancer 117:11, 2419-2425
CrossRef164
Ravi A Madan, Jeanny B Aragon-Ching, James L Gulley, William L Dahut. (2011) From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Review of Vaccines 10:6, 743-753
CrossRef165
M.J.A. de Jonge, H. Dumez, J.J.E.M. Kitzen, B. Beuselinck, J. Verweij, R. Courtney, A. Battista, N. Brega, P. Schöffski. (2011) Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. European Journal of Cancer 47:9, 1328-1335
CrossRef166
Tali M. Johnson. (2011) Care of the Elderly Patient with Prostate Cancer: What's New and What's the Same. The Consultant Pharmacist 26:6, 390-399
CrossRef167
Antonella Brunello, Rachna Kapoor, Martine Extermann. (2011) Hyperglycemia During Chemotherapy for Hematologic and Solid Tumors Is Correlated With Increased Toxicity. American Journal of Clinical Oncology 34:3, 292-296
CrossRef168
Bernard Haendler, Arwed Cleve. (2011) Recent developments in antiandrogens and selective androgen receptor modulators. Molecular and Cellular Endocrinology
CrossRef169
Daniel P. Petrylak. (2011) Current Clinical Trials in Castrate-Resistant Prostate Cancer. Current Urology Reports 12:3, 173-179
CrossRef170
Brian M. Olson, Douglas G. McNeel. (2011) CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunology, Immunotherapy 60:6, 781-792
CrossRef171
Stephen V Liu, Shanshan Liu, Jacek Pinski. (2011) Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opinion on Investigational Drugs 20:6, 769-778
CrossRef172
Jennie Malmberg, Mattias Sandström, Kenneth Wester, Vladimir Tolmachev, Anna Orlova. (2011) Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 Affibody. Nuclear Medicine and Biology
CrossRef173
Kouji Izumi, Atsushi Mizokami, Shingo Itai, Takashi Shima, Kazuyoshi Shigehara, Sotaro Miwa, Yuji Maeda, Hiroyuki Konaka, Eitetsu Koh, Mikio Namiki. (2011) Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis. BJU Internationalno-no
CrossRef174
Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, Melissa Brookes, Lance Leopold, William R. Berry, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, Guru Sonpavde. (2011) Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. European Urology
CrossRef175
Leonardo Oliveira Reis. (2011) Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Medical Oncology
CrossRef176
Antonarakis, Emmanuel S., Eisenberger, Mario A., . (2011) Expanding Treatment Options for Metastatic Prostate Cancer. New England Journal of Medicine 364:21, 2055-2058
Full Text177
de Bono, Johann S., Logothetis, Christopher J., Molina, Arturo, Fizazi, Karim, North, Scott, Chu, Luis, Chi, Kim N., Jones, Robert J., Goodman, Oscar B. Jr., Saad, Fred, Staffurth, John N., Mainwaring, Paul, Harland, Stephen, Flaig, Thomas W., Hutson, Thomas E., Cheng, Tina, Patterson, Helen, Hainsworth, John D., Ryan, Charles J., Sternberg, Cora N., Ellard, Susan L., Fléchon, Aude, Saleh, Mansoor, Scholz, Mark, Efstathiou, Eleni, Zivi, Andrea, Bianchini, Diletta, Loriot, Yohann, Chieffo, Nicole, Kheoh, Thian, Haqq, Christopher M., Scher, Howard I., . (2011) Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine 364:21, 1995-2005
Full Text178
Matthew R. Smith, Richard Cook, Ker-Ai Lee, Joel B. Nelson. (2011) Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 117:10, 2077-2085
CrossRef179
Justin Sturge, Matthew P. Caley, Jonathan Waxman. (2011) Bone metastasis in prostate cancer: emerging therapeutic strategies. Nature Reviews Clinical Oncology
CrossRef180
Benjamin W. Turney, Gareth D.H. Turner, Simon F. Brewster, Valentine M. Macaulay. (2011) Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU International 107:9, 1488-1499
CrossRef181
Yichao Wu, Jonathan E Rosenberg, Mary-Ellen Taplin. (2011) Novel agents and new therapeutics in castration-resistant prostate cancer. Current Opinion in Oncology 23:3, 290-296
CrossRef182
David C. Smith, Cathy M. Tangen, Peter J. Van Veldhuizen, Grant W. Harrer, Ali Golshayan, Glenn M. Mills, Nicholas J. Vogelzang, Ian M. Thompson, Maha H.A. Hussain. (2011) Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032. Urology 77:5, 1172-1176
CrossRef183
Nabanita Patra, Umasankar De, Jin-Ah Kang, Ji Mim Kim, Mee Young Ahn, Jaewon Lee, Jee H. Jung, Hae Young Chung, Hyung Ryong Moon, Hyung Sik Kim. (2011) A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. European Journal of Pharmacology 658:2-3, 98-107
CrossRef184
Oliver Sartor. (2011) Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. Asian Journal of Andrology 13:3, 366-368
CrossRef185
Eberechukwu Onukwugha, C. Daniel Mullins, Van Doren Hsu, Brian Seal, Arif Hussain. (2011) Effect of Urologists and Medical Oncologists on Treatment of Elderly Men With Stage IV Prostate Cancer. Urology 77:5, 1088-1095
CrossRef186
Guru Sonpavde, Cora N Sternberg. (2011) Contemporary management of metastatic castration-resistant prostate cancer. Current Opinion in Urology 21:3, 241-247
CrossRef187
Qiushan He, Jinlong Li, Weihua Yin, Zhichun Song, Zhen Zhang, Tienan Yi, Jia Tang, Demin Wu, Yue Lu, Zhen Wang, Dan Liu, Xiaoren Zhang, Zhiming Hu, Jimin Gao. (2011) Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer. Cancer Immunology, Immunotherapy 60:5, 715-730
CrossRef188
Sze Ue Luk, Wei Ney Yap, Yung-Tuen Chiu, Davy TW Lee, Stephanie Ma, Terence Kin Wah Lee, Raja S Vasireddy, Yong-Chuan Wong, Yick Pang Ching, Colleen Nelson, Yee Leng Yap, Ming-Tat Ling. (2011) Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. International Journal of Cancer 128:9, 2182-2191
CrossRef189
Shao-hui LIU, Xiao-yi XU, Yu-xin TIAN, Rui WANG, Tong-jun LIU, Xia-bin JIN. (2011) Inhibitory effect of docetaxel conjugate PLA-PEG block copolymers on proliferation of prostate cancer cell line PC-3. Academic Journal of Second Military Medical University 31:3, 337-338
CrossRef190
Francesco Crea, Maria A. Duhagon Serrat, Elaine M. Hurt, Suneetha B. Thomas, Romano Danesi, William L. Farrar. (2011) BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. International Journal of Cancer 128:8, 1946-1954
CrossRef191
Srikala S. Sridhar, Christina M. Canil, Kim N. Chi, Sebastien J. Hotte, Scott Ernst, Lisa Wang, Eric X. Chen, Agnes Juhasz, Yun Yen, Peter Murray, James A. Zwiebel, Malcolm J. Moore. (2011) A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 67:4, 927-933
CrossRef192
Philippe Beuzeboc. (2011) Re: Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-Label Trial. European Urology 59:4, 658
CrossRef193
Dieter Jocham, Martin Sommerauer. (2011) Re: Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomized Open-Label Trial. European Urology 59:4, 659
CrossRef194
Iori Sakai, Hideaki Miyake, Tomoaki Terakawa, Masato Fujisawa. (2011) Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Cancer Science 102:4, 769-775
CrossRef195
Jennifer N. Wu, Frederick J. Meyers, Christopher P. Evans. (2011) Palliative Care in Urology. Surgical Clinics of North America 91:2, 429-444
CrossRef196
Guo-Wen Lin, Xu-Dong Yao, Ding-Wei Ye. (2011) LOW DOSE OF KETOCONAZOLE IN PATIENTS WITH PROSTATE ADENOCARCINOMA RESISTANT TO PHARMACOLOGICAL CASTRATION. BJU International 107:8, 1326-1327
CrossRef197
Stephane Oudard. (2011) TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncology 7:4, 497-506
CrossRef198
Uday B. Dandamudi, Laurel M. Adams, Brendan Johnson, John Bauman, Shannon Morris, Sharon Murray, R. Timothy Webb, Elaina Gartner, Raymond Hohl, Lionel D. Lewis. (2011) Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. Cancer Chemotherapy and Pharmacology 67:4, 783-790
CrossRef199
Estrella Carballido, Mayer Fishman. (2011) Sipuleucel-T: Prototype for Development of Anti-tumor Vaccines. Current Oncology Reports 13:2, 112-119
CrossRef200
Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, Steven Joniau, Malcolm Mason, Vsevolod Matveev, Hans-Peter Schmid, Theo Van der Kwast, Thomas Wiegel, Filiberto Zattoni, Axel Heidenreich. (2011) EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. European Urology 59:4, 572-583
CrossRef201
Ruth Foley, Laure Marignol, John P. Keane, Thomas H. Lynch, Donal Hollywood. (2011) Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen deprivation therapy strategies. The Prostate 71:5, 550-557
CrossRef202
Saleha Sajid, Supriya G. Mohile, Russell Szmulewitz, Edwin Posadas, William Dale. (2011) Individualized Decision-Making for Older Men With Prostate Cancer: Balancing Cancer Control With Treatment Consequences Across the Clinical Spectrum. Seminars in Oncology 38:2, 309-325
CrossRef203
Dirk PJ Michielsen, Johan G Braeckman, Louis Denis. (2011) Cabazitaxel for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 12:6, 977-982
CrossRef204
Josefine Gerhardt, Corinna Steinbrech, Oralea Büchi, Silvia Behnke, Annette Bohnert, Florian Fritzsche, Heike Liewen, Frank Stenner, Peter Wild, Thomas Hermanns, Michael Müntener, Manfred Dietel, Klaus Jung, Carsten Stephan, Glen Kristiansen. (2011) The Androgen-Regulated Calcium-Activated Nucleotidase 1 (CANT1) Is Commonly Overexpressed in Prostate Cancer and Is Tumor-Biologically Relevant in Vitro. The American Journal of Pathology 178:4, 1847-1860
CrossRef205
Hui Yi Xue, Ho Lun Wong. (2011) Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 32:10, 2662-2672
CrossRef206
Mohamed Salem, Jorge A. Garcia. (2011) Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer. Current Oncology Reports 13:2, 92-96
CrossRef207
John M. Fitzpatrick, Joaquim Bellmunt, Robert Dreicer, Neil E. Fleshner, Christopher J. Logothetis, Judd W. Moul, Bertrand Tombal, Alexandre Zlotta. (2011) Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU International 107, 1-12
CrossRef208
Sergio Bracarda, Christopher Logothetis, Cora N. Sternberg, Stéphane Oudard. (2011) Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU International 107, 13-20
CrossRef209
Jeremy Cetnar, George Wilding, Douglas McNeel, Noelle K. LoConte, Thomas A. McFarland, Jens Eickhoff, Glenn Liu. (2011) A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations
CrossRef210
Mariam Anees, Peter Horak, Ahmed El-Gazzar, Martin Susani, Georg Heinze, Paul Perco, Massimo Loda, Rosina Lis, Michael Krainer, William K. Oh. (2011) Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 117:6, 1172-1182
CrossRef211
Stephen J. Freedland. (2011) Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer 117:6, 1123-1135
CrossRef212
Sidney R Grimes. (2011) A good molecular target for prostate cancer chemotherapy. Asian Journal of Andrology 13:2, 207-207
CrossRef213
Ioannis Mountzios, Evangelos Bournakis, Eleni Efstathiou, Andreas Varkaris, Sijin Wen, Michael Chrisofos, Charalambos Deliveliotis, Christos Alamanis, Ioannis Anastasiou, Constantine Constantinides, Alexandra Karadimou, Marinos Tsiatas, Christos Papadimitriou, Aristotelis Bamias, Meletios A. Dimopoulos. (2011) Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer. Urology 77:3, 682-687
CrossRef214
A. Colosio, J.-C. Eymard, A. Hadj Henni, A. Long. (2011) Thrombose veineuse rénale, hydronéphrose et cancer de la prostate. Journal de Radiologie 92:3, 247-249
CrossRef215
Thomas M. Atkinson, Barry D. Rosenfeld, Laura Sit, Tito R. Mendoza, Mike Fruscione, Dawn Lavene, Mary Shaw, Yuelin Li, Jennifer Hay, Charles S. Cleeland, Howard I. Scher, William S. Breitbart, Ethan Basch. (2011) Using Confirmatory Factor Analysis to Evaluate Construct Validity of the Brief Pain Inventory (BPI). Journal of Pain and Symptom Management 41:3, 558-565
CrossRef216
Arturo Molina, Arie Belldegrun. (2011) Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling. The Journal of Urology 185:3, 787-794
CrossRef217
Roger S. Kirby, John M. Fitzpatrick. (2011) IMPROVED SURVIVAL PROSPECTS FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER. BJU International 107:5, 697-700
CrossRef218
Evan Y. Yu, Mark Muzi, Joy A. Hackenbracht, Brian B. Rezvani, Jeanne M. Link, Robert Bruce Montgomery, Celestia S. Higano, Janet F. Eary, David A. Mankoff. (2011) C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases. Clinical Nuclear Medicine 36:3, 192-198
CrossRef219
Young E. Whang, Andrew J. Armstrong, W. Kimryn Rathmell, Paul A. Godley, William Y. Kim, Raj S. Pruthi, Eric M. Wallen, Jeffrey M. Crane, Dominic T. Moore, Gayle Grigson, Karla Morris, Catharine P. Watkins, Daniel J. George. (2011) A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations
CrossRef220
Nai-Dong Xing, Sen-Tai Ding, Ryoichi Saito, Koji Nishizawa, Takashi Kobayashi, Takahiro Inoue, Shinya Oishi, Nobutaka Fujii, Jia-Jv Lv, Osamu Ogawa, Hiroyuki Nishiyama. (2011) A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. Asian Journal of Andrology 13:2, 236-241
CrossRef221
Motoi Tobiume, Yoshiaki Yamada, Kogenta Nakamura, Shigeyuki Aoki, Kenji Zennami, Yoshiharu Kato, Genya Nishikawa, Toyoharu Yokoi, Nobuaki Honda. (2011) Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer. The Prostate 71:4, 385-393
CrossRef222
R Petrioli, A Pascucci, R Conca, G Chiriacò, E Francini, G Bargagli, A I Fiaschi, A Manganelli, G De Rubertis, G Barbanti, R Ponchietti, G Francini. (2011) Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. British Journal of Cancer 104:4, 613-619
CrossRef223
J Shamash, T Powles, S J Sarker, A Protheroe, N Mithal, R Mills, R Beard, P Wilson, N Tranter, N O'Brien, S McFaul, T Oliver. (2011) A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. British Journal of Cancer 104:4, 620-628
CrossRef224
Hai-Liang Zhang, Li-Feng Yang, Yao Zhu, Xu-Dong Yao, Shi-Lin Zhang, Bo Dai, Yi-Ping Zhu, Yi-Jun Shen, Guo-Hai Shi, Ding-Wei Ye. (2011) Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. The Prostate 71:3, 326-331
CrossRef225
Jorge A. Garcia, Thomas E. Hutson, Dale Shepard, Paul Elson, Robert Dreicer. (2011) Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer. Cancer 117:4, 752-757
CrossRef226
Il-Yeob Kim, Su-Young Park, Youra Kang, Dinesh Thapa, Han Gon Choi, Jung-Ae Kim. (2011) Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status. Archives of Pharmacal Research 34:2, 323-330
CrossRef227
Sunjoo Ahn, Dong Jin Hwang, Christina M. Barrett, Jun Yang, Charles B. Duke, Duane D. Miller, James T. Dalton. (2011) A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Cancer Chemotherapy and Pharmacology 67:2, 293-304
CrossRef228
K. Hatano, N. Nonomura, K. Nishimura, A. Kawashima, M. Mukai, A. Nagahara, Y. Nakai, M. Nakayama, H. Takayama, A. Tsujimura, A. Okuyama. (2011) Retrospective Analysis of an Oral Combination of Dexamethasone, Uracil plus Tegafur and Cyclophosphamide for Hormone-refractory Prostate Cancer. Japanese Journal of Clinical Oncology 41:2, 253-259
CrossRef229
Ravi A Madan, James L Gulley. (2011) Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Review of Vaccines 10:2, 141-150
CrossRef230
Sumanta Kumar Pal, Oliver Sartor. (2011) Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 68:2, 103-105
CrossRef231
William R. Schelman, Glenn Liu, George Wilding, Thomas Morris, De Phung, Robert Dreicer. (2011) A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Investigational New Drugs 29:1, 118-125
CrossRef232
Joel Picus, Susan Halabi, W. Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter M. Stadler, Eric J. Small, . (2011) A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer. Cancer 117:3, 526-533
CrossRef233
Lee P. Resta, Roberto Pili, Mario A. Eisenberger, Avery Spitz, Serina King, Jennifer Porter, Amy Franke, Ramesh Boinpally, Michael A. Carducci, Christopher J. Sweeney. (2011) A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer Chemotherapy and Pharmacology 67:2, 431-438
CrossRef234
Sandra Cuffe, Catherine M. Dowling, James Claffey, Clara Pampillón, Megan Hogan, John M. Fitzpatrick, Michael P. Carty, Matthias Tacke, R. William G. Watson. (2011) Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis. The Prostate 71:2, 111-124
CrossRef235
Paula Vainio, Santosh Gupta, Kirsi Ketola, Tuomas Mirtti, John-Patrick Mpindi, Pekka Kohonen, Vidal Fey, Merja Perälä, Frank Smit, Gerald Verhaegh, Jack Schalken, Kalle A. Alanen, Olli Kallioniemi, Kristiina Iljin. (2011) Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer. The American Journal of Pathology 178:2, 525-536
CrossRef236
Matteo Vergati, Vittore Cereda, Ravi A. Madan, James L. Gulley, Ngar-Yee Huen, Connie J. Rogers, Kenneth W. Hance, Philip M. Arlen, Jeffrey Schlom, Kwong Y. Tsang. (2011) Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunology, Immunotherapy 60:2, 197-206
CrossRef237
A Oliver Sartor. (2011) Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. Journal of Hematology & Oncology 4:1, 18
CrossRef238
Donald L. Trump, Heather Payne, Kurt Miller, Johann S. de Bono, Joe Stephenson, Howard A. Burris, Faith Nathan, Maria Taboada, Thomas Morris, Andreas Hubner. (2011) Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. The Prostaten/a-n/a
CrossRef239
Neeraj Agarwal, Guru Sonpavde, Oliver Sartor. (2011) Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncology 7:1, 15-24
CrossRef240
Filippo Francini, Alessandra Pascucci, Edoardo Francini, Gianluca Bargagli, Raffaele Conca, Antonella Licchetta, Giandomenico Roviello, Ignazio Martellucci, Giorgio Chiriacò, Salvatora Tindara Miano, Giuseppe Marzocca, Antonio Manganelli, Roberto Ponchietti, Vinno Savelli, Roberto Petrioli. (2011) Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel. Prostate Cancer 2011, 1-7
CrossRef241
Christopher A. Klebanoff, Nicolas Acquavella, Zhiya Yu, Nicholas P. Restifo. (2011) Therapeutic cancer vaccines: are we there yet?. Immunological Reviews 239:1, 27-44
CrossRef242
S. Leo, C. Accettura, V. Lorusso. (2011) Castration-Resistant Prostate Cancer: Targeted Therapies. Chemotherapy 57:2, 115-127
CrossRef243
S. Iannazzo, L. Pradelli, M. Carsi, M. Perachino. (2011) Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. Value in Health 14:1, 80-89
CrossRef244
Richard Flavin, Giorgia Zadra, Massimo Loda. (2011) Metabolic alterations and targeted therapies in prostate cancer. The Journal of Pathology 223:2, 284-295
CrossRef245
Masanori Noguchi, Fukuko Moriya, Shigetaka Suekane, Kei Matsuoka, Gaku Arai, Satoko Matsueda, Tetsuro Sasada, Akira Yamada, Kyogo Itoh. (2011) Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. The Prostaten/a-n/a
CrossRef246
Avinash Gupta, Mark Middleton. 2011. Cytostatic and cytotoxic drugs. , 935-962.
CrossRef247
Nobukazu Komatsu, Satoko Matsueda, Kousuke Tashiro, Tetsuya Ioji, Shigeki Shichijo, Masanori Noguchi, Akira Yamada, Atsushi Doi, Shigetaka Suekane, Fukuko Moriya, Kei Matsuoka, Satoru Kuhara, Kyogo Itoh, Tetsuro Sasada. (2011) Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancern/a-n/a
CrossRef248
Paula Vainio, Maija Wolf, Henrik Edgren, Tao He, Pekka Kohonen, John-Patrick Mpindi, Frank Smit, Gerald Verhaegh, Jack Schalken, Merja Perälä, Kristiina Iljin, Olli Kallioniemi. (2011) Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. The Prostaten/a-n/a
CrossRef249
Chang Wook Jeong, Cheol Yong Yoon, Seong Jin Jeong, Sung Kyu Hong, Seok-Soo Byun, Sang Eun Lee. (2011) Limited Expression of Cytochrome P450 17α-Hydroxylase/17,20-Lyase in Prostate Cancer Cell Lines. Korean Journal of Urology 52:7, 494
CrossRef250
J.Y. Henry, L. Lu, M. Adams, B. Meyer, J.B. Bartlett, A.G. Dalgleish, C. Galustian. (2011) Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. The Prostaten/a-n/a
CrossRef251
Irène Asmane, Jocelyn Céraline, Brigitte Duclos, Lynn Rob, Valère Litique, Philippe Barthélémy, Jean-Pierre Bergerat, Patrick Dufour, Jean-Emmanuel Kurtz. (2011) New Strategies for Medical Management of Castration-Resistant Prostate Cancer. Oncology 80:1-2, 1-11
CrossRef252
Natsuki Takaha, Koji Okihara, Kazumi Kamoi, Fumiya Hongo, Tsuyoshi Iwata, Kimihiro Yano, Takashi Ueda, Ichiro Takeuchi, Takeshi Yamada, Akihiro Kawauchi, Tsuneharu Miki. (2011) Feasibility of Tri-Weekly Docetaxel-Based Chemotherapy for Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer. Urologia Internationalis 87:3, 263-269
CrossRef253
Joon Il Choi, Yun Beom Kim, Seung Ok Yang, Jeong Kee Lee, Tae Young Jung. (2011) Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade. Korean Journal of Urology 52:7, 461
CrossRef254
Steffen Wedel, Lukasz Hudak, Jens-Michael Seibel, Jasmina Makarević, Eva Juengel, Igor Tsaur, Ana Waaga-Gasser, Axel Haferkamp, Roman A Blaheta. (2011) Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer 11:1, 375
CrossRef255
Richard J. Lee, Philip J. Saylor, Matthew R. Smith. (2011) Treatment and prevention of bone complications from prostate cancer. Bone 48:1, 88-95
CrossRef256
Lucy Heinemann, Guy R Simpson, Angela Boxall, Timothy Kottke, Kate L Relph, Richard Vile, Alan Melcher, Robin Prestwich, Kevin J Harrington, Richard Morgan, Hardev S Pandha. (2011) Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 11:1, 221
CrossRef257
Giuseppe Di Lorenzo, Carlo Buonerba, Adriana Faiella, Pasquale Rescigno, Mimma Rizzo, Riccardo Autorino, Sisto Perdonà, Nando Riccardi, Sarah Scagliorini, Florinda Scognamiglio, Daniele Masala, Matteo Ferro, Giovannella Palmieri, Michele Aieta, Alfredo Marinelli, Vincenzo Altieri, Sabino De Placido, Giacomo Cartenì. (2011) Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU International 107:2, 234-239
CrossRef258
Greg L. Plosker. (2011) Sipuleucel-T. Drugs 71:1, 101-108
CrossRef259
Ravi A Madan, James L Gulley. (2011) Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy 3:1, 27-31
CrossRef260
Bostjan Seruga, Alberto Ocana, Ian F. Tannock. (2011) Drug resistance in metastatic castration-resistant prostate cancer. Nature Reviews Clinical Oncology 8:1, 12-23
CrossRef261
Se Joong Kim, Sun Il Kim. (2011) Current Treatment Strategies for Castration-Resistant Prostate Cancer. Korean Journal of Urology 52:3, 157
CrossRef262
Jorge A. Garcia, Brian I. Rini. (2011) Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead. Cancern/a-n/a
CrossRef263
Vanna Sanna, Anna Roggio, Anna Posadino, Annalisa Cossu, Salvatore Marceddu, Alberto Mariani, Valeria Alzari, Sergio Uzzau, Gianfranco Pintus, Mario Sechi. (2011) Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Research Letters 6:1, 260
CrossRef264
Masanori Hasegawa, Akira Miyajima, Takeo Kosaka, Yota Yasumizu, Nobuyuki Tanaka, Takahiro Maeda, Suguru Shirotake, Hiroki Ide, Eiji Kikuchi, Mototsugu Oya. (2011) Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer. International Journal of Cancern/a-n/a
CrossRef265
John C. Araujo, Paul Mathew, Andrew J. Armstrong, Edward L. Braud, Edwin Posadas, Mathew Lonberg, Gary E. Gallick, Géralyn C. Trudel, Prashni Paliwal, Shruti Agrawal, Christopher J. Logothetis. (2011) Dasatinib combined with docetaxel for castration-resistant prostate cancer. Cancern/a-n/a
CrossRef266
Eddie D. Yeung, Alex Morrison, Daniel Plumeri, Jingying Wang, Chao Tong, Xiaoyan Yan, Ji Li. (2011) Alternol exerts prostate-selective antitumor effects through modulations of the AMPK signaling pathway. The Prostaten/a-n/a
CrossRef267
Russell Z. Szmulewitz, Elizabeth Chung, Hikmat Al-Ahmadie, Silver Daniel, Masha Kocherginsky, Aria Razmaria, Gregory P. Zagaja, Charles B. Brendler, Walter M. Stadler, Suzanne D. Conzen. (2011) Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. The Prostaten/a-n/a
CrossRef268
Sophie Giusiano, Virginie Baylot, Claudia Andrieu, Ladan Fazli, Martin Gleave, Juan Lucio Iovanna, Colette Taranger-Charpin, Stéphane Garcia, Palma Rocchi. (2011) TP53INP1 as new therapeutic target in castration-resistant prostate cancer. The Prostaten/a-n/a
CrossRef269
Guru Sonpavde, Gregory R. Pond, William R. Berry, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, Andrew J. Armstrong. (2011) The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancern/a-n/a
CrossRef270
Julie N. Graff, Tomasz M. Beer. (2011) Toward predictors of survival in castration-resistant prostate cancer. Cancern/a-n/a
CrossRef271
Oliver Sartor, Michael Halstead, Leah Katz. (2010) Improving Outcomes With Recent Advances in Chemotherapy for Castrate-Resistant Prostate Cancer. Clinical Genitourinary Cancer 8:1, 23-28
CrossRef272
A. Takayanagi, N. Masumori, J. Hashimoto, Y. Kyoda, M. Yanase, T. Tsukamoto. (2010) Effect of Delayed Maximal Androgen Blockade Therapy for Patients with Advanced Prostate Cancer Who Fail to Respond to Initial Androgen Deprivation Monotherapy. Japanese Journal of Clinical Oncology 40:12, 1154-1158
CrossRef273
Fred Saad, Marc Colombel. (2010) Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies. Expert Review of Anticancer Therapy 10:12, 1991-2002
CrossRef274
N. Tageja. (2010) Chemotherapy for hormone-refractory prostate cancer: a physician's dilemma. Internal Medicine Journal 40:12, 864-865
CrossRef275
M. De Santis, M. Bachner. (2010) Practice changing data and new developments in the management of prostate cancer – ASCO 2010. memo - Magazine of European Medical Oncology 3:4, 164-166
CrossRef276
Andrea Zivi, Christophe Massard, Johann De-Bono. (2010) Changing Therapeutic Paradigms in Castrate-Resistant Prostate Cancer. Clinical Genitourinary Cancer 8:1, 17-22
CrossRef277
Ravi A. Madan, James L. Gulley. (2010) The Current and Emerging Role of Immunotherapy in Prostate Cancer. Clinical Genitourinary Cancer 8:1, 10-16
CrossRef278
Anthony Koupparis, Rowan Casey, Michael Robinson, Martin E Gleave. (2010) Novel targeted agents on the horizon for castration-resistant prostate cancer. Future Oncology 6:12, 1883-1895
CrossRef279
Han Liu, Yi-qing Liu, Yong-qing Liu, Ai-hui Xu, Charles Y.F. Young, Hui-qing Yuan, Hong-xiang Lou. (2010) A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells. Chemico-Biological Interactions 188:3, 598-606
CrossRef280
Paul L DE SOUZA, Scott NORTH, Graeme B BOLGER, Harris SPIRIDONIDIS, Robert LIM, Kei Siong KHOO, James PHILLIPS, Matt FUJIMORI. (2010) A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer. Asia-Pacific Journal of Clinical Oncology 6:4, 292-297
CrossRef281
Richard J. Lee, Philip J. Saylor, Matthew R. Smith. (2010) Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer. Clinical Genitourinary Cancer 8:1, 29-36
CrossRef282
Jung Jin Hwang, Yong Sook Kim, Mi Joung Kim, Dong Eun Kim, In Gab Jeong, Choung-Soo Kim. (2010) Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells. The Journal of Urology 184:6, 2557-2564
CrossRef283
Christian Wülfing, M. Linbecker, D. Braumann, F. Würschmidt. (2010) Perspektiven für die Therapie des kastrationsrefraktären Prostatakarzinoms. best practice onkologie 5:6, 24-29
CrossRef284
B. Walter, S. Rogenhofer, M. Vogelhuber, A. Berand, W. F. Wieland, R. Andreesen, A. Reichle. (2010) Modular therapy approach in metastatic castration-refractory prostate cancer. World Journal of Urology 28:6, 745-750
CrossRef285
M. Bolla, M. Laramas. (2010) Combined hormone therapy and radiation therapy for locally advanced prostate cancer. Critical Reviews in Oncology/Hematology
CrossRef286
(2010) Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of Medicine 363:20, 1966-1968
Full Text287
Michel Bolla, Jean Michel Hannoun-Levi, Jean-Marc Ferrero, Philippe Maingon, Joëlle Buffet-Miny, Agnès Bougnoux, Jacques Bauer, Jean-Luc Descotes, Philippe Fourneret, Florence Jover, Marc Colonna. (2010) Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: Preliminary results of a multicentre phase II trial. Radiotherapy and Oncology 97:2, 312-317
CrossRef288
Michel Bolla, Geertjan Van Tienhoven, Padraig Warde, Jean Bernard Dubois, René-Olivier Mirimanoff, Guy Storme, Jacques Bernier, Abraham Kuten, Cora Sternberg, Ignace Billiet, José Lopez Torecilla, Raphael Pfeffer, Carmel Lino Cutajar, Theodore Van der Kwast, Laurence Collette. (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The Lancet Oncology 11:11, 1066-1073
CrossRef289
Philip Cornford. (2010) Evolution of docetaxel-based therapy for metastatic castrate-resistant prostate cancer. British Journal of Medical and Surgical Urology 3:6, 225-230
CrossRef290
Ahmed Dahmani, Ludmilla de Plater, Charlotte Guyader, Jean-Jacques Fontaine, Aurélie Berniard, Franck Assayag, Philippe Beuzeboc, Elisabetta Marangoni, Fariba Némati, Marie-France Poupon, Christophe Pasik, Stéphane Oudard, Didier Decaudin. (2010) A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer. Anti-Cancer Drugs 21:10, 927-931
CrossRef291
Naohiro Fujimoto, Masaki Shiota, Tatsuhiko Kubo, Tetsuro Matsumoto. (2010) Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer. Expert Review of Clinical Pharmacology 3:6, 785-795
CrossRef292
M. D. Galsky, N. J. Vogelzang. (2010) Docetaxel-based combination therapy for castration-resistant prostate cancer. Annals of Oncology 21:11, 2135-2144
CrossRef293
Praveen K. Sharma, Rajesh Singh, Kristian R. Novakovic, John W. Eaton, William E. Grizzle, Shailesh Singh. (2010) CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. International Journal of Cancer 127:9, 2020-2030
CrossRef294
N. Miura, K. Numata, Y. Kusuhara, A. Shirato, K. Hashine, Y. Sumiyoshi. (2010) Docetaxel-Prednisolone Combination Therapy for Japanese Patients with Hormone-refractory Prostate Cancer: a Single Institution Experience. Japanese Journal of Clinical Oncology 40:11, 1092-1098
CrossRef295
Alessandro Fatatis, Julia A. D'Ambrosio, Whitney L. Jamieson, Danielle L. Jernigan, Mike R. Russell. 2010. Microenvironment Factors Influencing Skeletal Metastases. , 135-160.
CrossRef296
Mu-Yi Hua, Hung-Wei Yang, Cheng-Keng Chuang, Rung-Ywan Tsai, Wen-Jauh Chen, Kun-Lung Chuang, Ying-Hsu Chang, Heng-Chang Chuang, See-Tong Pang. (2010) Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 31:28, 7355-7363
CrossRef297
Giuseppe Colloca, Antonella Venturino, Franco Checcaglini. (2010) Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: A systematic review. Cancer Treatment Reviews 36:6, 501-506
CrossRef298
Guru Sonpavde, Gregory R. Pond, William R. Berry, Ronald de Wit, Andrew J. Armstrong, Mario A. Eisenberger, Ian F. Tannock. (2010) Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic Oncology: Seminars and Original Investigations
CrossRef299
Tanya B Dorff, David I Quinn. (2010) Cabazitaxel in prostate cancer: stretching a string. The Lancet 376:9747, 1119-1120
CrossRef300
Nicholas D. James, Armelle Caty, Heather Payne, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, Stuart McIntosh, Thomas Morris, De Phung, Nancy A. Dawson. (2010) Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,. BJU International 106:7, 966-973
CrossRef301
Camilla Cervin, Martina Tinzl, Markus Johnsson, Per-Anders Abrahamsson, Fredrik Tiberg, Nishtman Dizeyi. (2010) Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model. European Journal of Pharmaceutical Sciences 41:2, 369-375
CrossRef302
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenaëlle Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen, Martin Roessner, Sunil Gupta, A Oliver Sartor. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet 376:9747, 1147-1154
CrossRef303
Jean-Christophe Eymard, Stéphane Oudard, Gwenaelle Gravis, Jean-Marc Ferrero, Christine Theodore, Florence Joly, Frank Priou, Ivan Krakowski, Alain Zannetti, Laurence Thill, Philippe Beuzeboc. (2010) Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU International 106:7, 974-978
CrossRef304
M. M. Moore, M. Stockler, R. Lim, T. S. K. Mok, M. Millward, M. J. Boyer. (2010) A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology 66:5, 845-850
CrossRef305
Yun Luo, You Ling, Wusheng Guo, Jun Pang, Weipeng Liu, Youqiang Fang, Xinqiao Wen, Kun Wei, Xin Gao. (2010) Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. Journal of Controlled Release 147:2, 278-288
CrossRef306
D. Bianchini, A. Zivi, S. Sandhu, J. S. de Bono. (2010) Horizon scanning for novel therapeutics for the treatment of prostate cancer. Annals of Oncology 21:Supplement 7, vii43-vii55
CrossRef307
Daniel Keizman, Mario Eisenberger. (2010) Is there a role for chemotherapy in nonmetastatic prostate cancer?. Current Opinion in Supportive and Palliative Care 4:3, 141-146
CrossRef308
S. Rajpar, C. Massard, A. Laplanche, E. Tournay, M. Gross-Goupil, Y. Loriot, M. Di Palma, A. Bossi, B. Escudier, A. Chauchereau, K. Fizazi. (2010) Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Annals of Oncology 21:9, 1864-1869
CrossRef309
M Flourakis, V Lehen'kyi, B Beck, M Raphaël, M Vandenberghe, F V Abeele, M Roudbaraki, G Lepage, B Mauroy, C Romanin, Y Shuba, R Skryma, N Prevarskaya. (2010) Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death and Disease 1:9, e75
CrossRef310
C. Paterson, P.D. Correa, J.M. Russell. (2010) Ductal Variant of Adenocarcinoma Prostate Responding to Docetaxel — a Case Report. Clinical Oncology 22:7, 617
CrossRef311
Andrew Lawton, Gary Sudakoff, Lisa C. Dezelan, Nancy Davis. (2010) Presentation, Treatment, and Outcomes of Dural Metastases in Men with Metastatic Castrate-Resistant Prostate Cancer: A Case Series. Journal of Palliative Medicine 13:9, 1125-1129
CrossRef312
Andrea Fontana, Alfredo Falcone, Lisa Derosa, Teresa Di Desidero, Romano Danesi, Guido Bocci. (2010) Metronomic Chemotherapy for Metastatic Prostate Cancer. Drugs & Aging 27:9, 689-696
CrossRef313
Kurt Miller. (2010) Re: Antitumour Activity of MDV3100 in Castration-Resistant Prostate Cancer: A Phase 1–2 Study. European Urology 58:3, 464-465
CrossRef314
Maria Karlou, Vassiliki Tzelepi, Eleni Efstathiou. (2010) Therapeutic targeting of the prostate cancer microenvironment. Nature Reviews Urology 7:9, 494-509
CrossRef315
Péter Nyirády, Éva Sárdi, Gabriella Bekő, Miklós Szűcs, András Horváth, Edit Székely, Klára Szentmihályi, Imre Romics, Anna Blázovics. (2010) A <i>Beta vulgaris</i> L. ssp. <i>esculenta</i> var. <i>rubra</i> bioaktív vegyületeinek hatása metasztatikus prosztatarákban. Orvosi Hetilap 151:37, 1495-1503
CrossRef316
Christian Arsov, Christian Winter, Robert Rabenalt, Peter Albers. (2010) Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel. Urologic Oncology: Seminars and Original Investigations
CrossRef317
Andrea Wang-Gillam, Susanne M. Arnold, Ronald M. Bukowski, Mace L. Rothenberg, Wendy Cooper, Kenneth K. Wang, Eric Gauthier, A. Craig Lockhart. (2010) A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors. Investigational New Drugs
CrossRef318
Jean-Pierre Droz, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michael W. Kattan, Silvio Monfardini, Judd W. Moul, Arash Naeim, Hendrik van Poppel, Fred Saad, Cora N. Sternberg. (2010) Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU International 106:4, 462-469
CrossRef319
Jonathan Shamash, Justin Stebbing, Chris Sweeney, Guru Sonpavde, Steve Harland, Guy Dawkins, Cathryn Brock, Walter Abelman, Peter Wilson, Adam Sanitt, Tim Oliver, Thomas Powles. (2010) A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer 116:15, 3595-3602
CrossRef320
R. Kvåle, B. Møller, A. Angelsen, O. Dahl, S.D. Fosså, O.J. Halvorsen, L. Hoem, A. Solberg, R. Wahlqvist, F. Bray. (2010) Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007. Cancer Epidemiology 34:4, 359-367
CrossRef321
Motohide Uemura, Seijiro Honma, Suyoun Chung, Ryo Takata, Mutsuo Furihata, Kazuo Nishimura, Norio Nonomura, Yasutomo Nasu, Tsuneharu Miki, Taro Shuin, Tomoaki Fujioka, Akihiko Okuyama, Yusuke Nakamura, Hidewaki Nakagawa. (2010) 5αDH-DOC (5α-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. Cancer Science 101:8, 1897-1904
CrossRef322
Charles G. Drake. (2010) Prostate cancer as a model for tumour immunotherapy. Nature Reviews Immunology 10:8, 580-593
CrossRef323
Kantoff, Philip W., Higano, Celestia S., Shore, Neal D., Berger, E. Roy, Small, Eric J., Penson, David F., Redfern, Charles H., Ferrari, Anna C., Dreicer, Robert, Sims, Robert B., Xu, Yi, Frohlich, Mark W., Schellhammer, Paul F., . (2010) Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of Medicine 363:5, 411-422
Full Text324
Alex Shteynshlyuger, Adam S. Kibel. (2010) Counterpoint: Prostate carcinoma treatment for the young patient—The case for radical prostatectomy. Brachytherapy 9:3, 195-198
CrossRef325
P. Singh, M. Yam, P.J. Russell, A. Khatri. (2010) Molecular and traditional chemotherapy: A united front against prostate cancer. Cancer Letters 293:1, 1-14
CrossRef326
Celestia S. Higano, Eric J. Small, Paul Schellhammer, Uma Yasothan, Steven Gubernick, Peter Kirkpatrick, Philip W. Kantoff. (2010) Sipuleucel-T. Nature Reviews Drug Discovery 9:7, 513-514
CrossRef327
Guo-hai Shi, Ding-wei Ye, Xu-dong Yao, Shi-ling Zhang, Bo Dai, Hai-liang Zhang, Yi-jun Shen, Yao Zhu, Yi-ping Zhu, Wen-jun Xiao, Chun-guang Ma. (2010) Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacologica Sinica 31:7, 867-873
CrossRef328
Helen K. Tomkinson, John V. Kemp, Thomas Wollseifen, Thomas Morris, Stuart D. Oliver. (2010) An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers. Clinical Therapeutics 32:7, 1372-1386
CrossRef329
Weihua Yin, Qiushan He, Zhiming Hu, Zhong Chen, Mao Qifeng, Song Zhichun, Qu Zhihui, Nie Xiaoxia, Jinlong Li, Jimin Gao. (2010) A novel therapeutic vaccine of GM-CSF/TNFα surface-modified RM-1 cells against the orthotopic prostatic cancer. Vaccine 28:31, 4937-4944
CrossRef330
M.H. Strijbos, J.W. Gratama, P.I.M. Schmitz, C. Rao, W. Onstenk, G.V. Doyle, M.C. Miller, R. de Wit, L.W.M.M. Terstappen, S. Sleijfer. (2010) Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. European Journal of Cancer 46:11, 2027-2035
CrossRef331
Yohann Loriot, Christophe Massard, Marine Gross-Goupil, Mario Di Palma, Bernard Escudier, Alberto Bossi, Anne Chauchereau, Karim Fizazi. (2010) The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. European Journal of Cancer 46:10, 1770-1772
CrossRef332
Yoshihiro Nakagami, Makoto Ohori, Noboru Sakamoto, Shoji Koga, Riu Hamada, Tadashi Hatano, Masaaki Tachibana. (2010) Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients. International Journal of Urology 17:7, 629-634
CrossRef333
Basir Tareen, Joseph Kimmel, William C Huang. (2010) Contemporary treatment of high-risk localized prostate cancer. Expert Review of Anticancer Therapy 10:7, 1069-1076
CrossRef334
Rajasubramaniam Shanmugam, Praveen Kusumanchi, Liang Cheng, Peter Crooks, Sundar Neelakantan, William Matthews, Harikrishna Nakshatri, Christopher J. Sweeney. (2010) A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFκB and generating reactive oxygen species. The Prostate 70:10, 1074-1086
CrossRef335
Daniel J Lewinshtein, Christopher R Porter, Peter S Nelson. (2010) Genomic predictors of prostate cancer therapy outcomes. Expert Review of Molecular Diagnostics 10:5, 619-636
CrossRef336
David T. Eton, Daniel H. Shevrin, Jennifer Beaumont, David Victorson, David Cella. (2010) Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer. Value in Health 13:5, 613-623
CrossRef337
Trine Zeeberg Buch-Hansen, Lise Bentzen, Steinbjoern Hansen, Morten Hoeyer, Niels Viggo Jensen, Charlotte Saxe, Lisa Sengeloev. (2010) Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. Cancer Chemotherapy and Pharmacology 66:2, 295-301
CrossRef338
Lawrence L. Yeung, Charles J. Rosser. 2010. Surgical Treatment Options for Locally Advanced Prostate Cancer. , 267-278.
CrossRef339
Helen H.L. Chiu, Theresa M.K. Yong, Jun Wang, Yuwei Wang, Robert L. Vessella, Takeshi Ueda, Yu-Zhuo Wang, Marianne D. Sadar. (2010) Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. Cancer Letters 292:2, 176-185
CrossRef340
M. Khasraw, N. Pavlakis, S. McCowatt, C. Underhill, S. Begbie, P. de Souza, A. Boyce, F. Parnis, V. Lim, R. Harvie, G. Marx. (2010) Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology 21:6, 1302-1307
CrossRef341
Sonia M. Seng, Che-Kai Tsao, Matthew D. Galsky, William K. Oh. (2010) Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond. Drug Discovery Today: Therapeutic Strategies 7:1-2, 17-22
CrossRef342
Michael J. Burdick, Oliver Sartor. (2010) Bone-targeted therapy in metastatic prostate cancer: osteoclast inhibitors and bone-seeking radiopharmaceuticals. Drug Discovery Today: Therapeutic Strategies 7:1-2, 23-29
CrossRef343
Jean-Pierre Droz, Catherine Terret. (2010) Assessing older prostate cancer patients for chemotherapy: recommendations from the International Society of Geriatric Oncology. Aging Health 6:3, 365-369
CrossRef344
James L. Gulley. (2010) New frontiers in therapy for metastatic prostate cancer. Drug Discovery Today: Therapeutic Strategies 7:1-2, 1-3
CrossRef345
David E. Adelberg, William L. Dahut. (2010) Antiangiogenic agents in the treatment of prostate cancer. Drug Discovery Today: Therapeutic Strategies 7:1-2, 9-15
CrossRef346
Thomas Nelius, Tobias Klatte, Werner Riese, Allan Haynes, Stephanie Filleur. (2010) Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Medical Oncology 27:2, 363-367
CrossRef347
Jeanny B. Aragon-Ching, William L. Dahut. (2010) Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer. Drug Discovery Today: Therapeutic Strategies 7:1-2, 31-35
CrossRef348
Christopher R. Heery, Ravi A. Madan. (2010) Modern immunotherapy for the treatment of prostate cancer. Drug Discovery Today: Therapeutic Strategies 7:1-2, 37-42
CrossRef349
Jinming Zhou, Guoyan Geng, Jian Hui Wu. (2010) Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Investigational New Drugs 28:3, 291-298
CrossRef350
Xiong Li, Youhong Liu, Yong Tang, Phipps Roger, Meei-Huey Jeng, Chinghai Kao. (2010) Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution. The Journal of Gene Medicine 12:6, 516-527
CrossRef351
Julia Rotow, Sofia R. Gameiro, Ravi A. Madan, James L. Gulley, Jeffrey Schlom, James W. Hodge. (2010) Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer. Clinical and Translational Science 3:3, 116-122
CrossRef352
A J Armstrong, D J George. (2010) Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer and Prostatic Diseases 13:2, 108-116
CrossRef353
Tomihiko Yasufuku, Katsumi Shigemura, Osamu Matsumoto, Soichi Arakawa, Masato Fujisawa. (2010) Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer. Journal of Infection and Chemotherapy 16:3, 200-205
CrossRef354
William D. Figg, Sukyung Woo, Wenhui Zhu, Xiaohong Chen, A. Seun Ajiboye, Seth M. Steinberg, Douglas K. Price, John J. Wright, Howard L. Parnes, Philip M. Arlen, James L. Gulley, William L. Dahut. (2010) A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer. The Journal of Urology 183:6, 2219-2226
CrossRef355
Francesc Casas, Josep María Borràs, Ferran Ferrer, Núria Guanyabens, Rafael Gutiérrez del Pozo, Concha León, José López Torrecilla, Begoña Mellado, Joan Morote, Manel Puig, María José Ribal, Carme Ruscalleda, Agustí Serra, Valentí Valls, Almudena Zapatero. (2010) Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment. Clinical and Translational Oncology 12:5, 346-355
CrossRef356
Cleo YF Lee, Luke XX Bu, Arrigo DeBenedetti, B Jill Williams, Paul S Rennie, William WG Jia. (2010) Transcriptional and Translational Dual-regulated Oncolytic Herpes Simplex Virus Type 1 for Targeting Prostate Tumors. Molecular Therapy 18:5, 929-935
CrossRef357
Bernard G. Cipolla, René Havouis, Jacques-Philippe Moulinoux. (2010) Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. Biomedicine & Pharmacotherapy 64:5, 363-368
CrossRef358
A. Horwich, C. Parker, C. Bangma, V. Kataja, . (2010) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v129-v133
CrossRef359
James L. Gulley, Philip M. Arlen, Ravi A. Madan, Kwong-Yok Tsang, Mary P. Pazdur, Lisa Skarupa, Jacquin L. Jones, Diane J. Poole, Jack P. Higgins, James W. Hodge, Vittore Cereda, Matteo Vergati, Seth M. Steinberg, Susan Halabi, Elizabeth Jones, Clara Chen, Howard Parnes, John J. Wright, William L. Dahut, Jeffrey Schlom. (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunology, Immunotherapy 59:5, 663-674
CrossRef360
Levent Turkeri, Fikret Fatih Onol, Mustafa Ozyurek. (2010) Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens. Urologic Oncology: Seminars and Original Investigations 28:3, 290-295
CrossRef361
Dana Rathkopf, Bryan Y. Wong, Robert W. Ross, Aseem Anand, Erika Tanaka, Margaret M. Woo, Jing Hu, Andy Dzik-Jurasz, Wei Yang, Howard I. Scher. (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 66:1, 181-189
CrossRef362
Luai Zarour, Joshi Alumkal. (2010) Emerging Therapies in Castrate-Resistant Prostate Cancer. Current Urology Reports 11:3, 152-158
CrossRef363
Andrea Fontana, Guido Bocci, Luca Galli, Manolo D'Arcangelo, Lisa Derosa, Anna Fioravanti, Paola Orlandi, Maria Teresa Barletta, Lorenza Landi, Simona Bursi, Gabriele Minuti, Eleonora Bona, Ilaria Grazzini, Romano Danesi, Alfredo Falcone. (2010) METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER. Journal of the American Geriatrics Society 58:5, 986-988
CrossRef364
Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger. (2010) Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Letters 291:1, 1-13
CrossRef365
Robert L Grubb, Adam S Kibel. (2010) High-risk localized prostate cancer: role of radical prostatectomy. Current Opinion in Urology 20:3, 204-210
CrossRef366
J. Lehmann. (2010) Vinflunin in der Zweitlinienbehandlung des Urothelkarzinoms. Der Onkologe 16:5, 523-526
CrossRef367
Neeraj Agarwal, Thomas E Hutson, Nicholas J Vogelzang, Guru Sonpavde. (2010) Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncology 6:5, 665-679
CrossRef368
Charles G. Drake, Emmanuel S. Antonarakis. (2010) Update: Immunological Strategies for Prostate Cancer. Current Urology Reports 11:3, 202-207
CrossRef369
Mark Garzotto, Arthur Y. Hung. (2010) Contemporary Management of High-risk Localized Prostate Cancer. Current Urology Reports 11:3, 159-164
CrossRef370
Matthew D. Morse, Douglas G. McNeel. (2010) Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Human Immunology 71:5, 496-504
CrossRef371
J. Zhang, Y. Lu, K. J. Pienta. (2010) Multiple Roles of Chemokine (C-C Motif) Ligand 2 in Promoting Prostate Cancer Growth. JNCI Journal of the National Cancer Institute 102:8, 522-528
CrossRef372
Ashley L. Hilchie, Suzanne J. Furlong, Kimberly Sutton, Angela Richardson, Matthew R. J. Robichaud, Carman A. Giacomantonio, Neale D. Ridgway, David W. Hoskin. (2010) Curcumin-Induced Apoptosis in PC3 Prostate Carcinoma Cells Is Caspase-Independent and Involves Cellular Ceramide Accumulation and Damage to Mitochondria. Nutrition and Cancer 62:3, 379-389
CrossRef373
Dong Xiao, Shivendra Vikram Singh. (2010) Phenethyl Isothiocyanate Sensitizes Androgen-Independent Human Prostate Cancer Cells to Docetaxel-Induced Apoptosis In Vitro and In Vivo. Pharmaceutical Research 27:4, 722-731
CrossRef374
Tomasz M. Beer, Charles Ryan, Joshi Alumkal, Christopher W. Ryan, Janine Sun, Kristine M. Eilers. (2010) A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anti-Cancer Drugs 21:4, 433-438
CrossRef375
B. Tran, M.A. Rosenthal. (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. Journal of Clinical Neuroscience 17:4, 417-421
CrossRef376
Mark Garzotto, Celestia S. Higano, Catherine O'Brien, Brooks L. S. Rademacher, Nicole Janeba, Ladan Fazli, Paul H. Lange, Stephen Lieberman, Tomasz M. Beer. (2010) Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 116:7, 1699-1708
CrossRef377
Flora Stavridi, Eleni M. Karapanagiotou, Kostas N. Syrigos. (2010) Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treatment Reviews 36:2, 122-130
CrossRef378
C Andrieu, D Taieb, V Baylot, S Ettinger, P Soubeyran, A De-Thonel, C Nelson, C Garrido, A So, L Fazli, F Bladou, M Gleave, J L Iovanna, P Rocchi. (2010) Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 29:13, 1883-1896
CrossRef379
Zachery R. Halford, Dominic A. Solimando, Jr, J. Aubrey Waddell. (2010) Cancer Chemotherapy Update - Docetaxel and Prednisone (DP) for Advanced Prostate Cancer. Hospital Pharmacy 45:4, 293-300, 302
CrossRef380
Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Nobuhiro Ijichi, Kazuhiro Ikeda, Jinpei Kumagai, Taro Murata, Kenichi Takayama, Kuniko Horie-Inoue, Yasuyoshi Ouchi, Masami Muramatsu, Yukio Homma, Satoshi Inoue. (2010) Differential expression of estrogen-related receptors β and γ (ERRβ and ERRγ) and their clinical significance in human prostate cancer. Cancer Science 101:3, 646-651
CrossRef381
John D. Hainsworth, Anthony A. Meluch, Cassie M. Lane, David R. Spigel, Howard A. Burris, Jitendra G. Gandhi, Edward J. Crane, Michael A. Stipanov, F. Anthony Greco. (2010) Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium. Cancer Investigation 28:3, 275-279
CrossRef382
Guru Sonpavde, Cora N Sternberg. (2010) The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. International Journal of Urology 17:3, 228-240
CrossRef383
Joan Carles, Miguel Nogue, Josep M. Sole, Palmira Foro, Montserrat Domenech, Marta Suarez, Enrique Gallardo, Darío García, Ferrán Ferrer, Antoni Gelabert-Mas, Javier Gayo, Xavier Fabregat. (2010) Phase II Study of Vinorelbine and Estramustine in Combination With Conformational Radiotherapy for Patients With High-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 76:4, 1085-1091
CrossRef384
Karim Fizazi, Cora N. Sternberg, John M. Fitzpatrick, R. William Watson, Majid Tabesh. (2010) Role of targeted therapy in the treatment of advanced prostate cancer. BJU International 105:6, 748-767
CrossRef385
J A Jiménez, X Li, Y-P Zhang, K H Bae, Y Mohammadi, P Pandya, C Kao, T A Gardner. (2010) Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Cancer Gene Therapy 17:3, 180-191
CrossRef386
Wenhui Zhu, David S Zhu, Ravi A Madan, James L Gulley, William D Figg, William L Dahut. (2010) Treatment of Castration-Resistant Prostate Cancer: Updates on Therapeutics Targeting the Androgen Receptor Signaling Pathway. American Journal of Therapeutics 17:2, 176-181
CrossRef387
G Ploussard, B Paule, L Salomon, Y Allory, S Terry, D Vordos, A Hoznek, F Vacherot, C-C Abbou, S Culine, A de la Taille. (2010) Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. Prostate Cancer and Prostatic Diseases 13:1, 97-101
CrossRef388
Mark A ROSENTHAL, Peter DAVIDSON, Frederic ROLLAND, Mario CAMPONE, Lingling XUE, Tae H HAN, Anish MEHTA, Yuliya BERD, Weili HE, Antonio LOMBARDI. (2010) Evaluation of the safety, pharmacokinetics and treatment effects of an α ν β 3 integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia-Pacific Journal of Clinical Oncology 6:1, 42-48
CrossRef389
Orazio Caffo, Teodoro Sava, Evi Comploj, Maria Anna Giampaolo, Romana Segati, Francesco Valduga, Gianluigi Cetto, Enzo Galligioni. (2010) Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urologic Oncology: Seminars and Original Investigations 28:2, 152-156
CrossRef390
R. Venkitaraman, S.A. Sohaib, Y. Barbachano, C.C. Parker, R.A. Huddart, A. Horwich, D. Dearnaley. (2010) Frequency of Screening Magnetic Resonance Imaging to Detect Occult Spinal Cord Compromise and to Prevent Neurological Deficit in Metastatic Castration-resistant Prostate Cancer. Clinical Oncology 22:2, 147-152
CrossRef391
S. Sewak, S. Kosmider, V. Ganju, A. Woollett, E. G. Yeow, B. Le, M. Henry, M. A. Debrincat, R. Bell. (2010) Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting. Internal Medicine Journal 40:3, 201-208
CrossRef392
Hirotsugu Uemura, Kiyohide Fujimoto, Takashi Mine, Shigeya Uejima, Marco A. de Velasco, Yoshihiko Hirao, Nobukazu Komatsu, Akira Yamada, Kyogo Itoh. (2010) Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Science 101:3, 601-608
CrossRef393
Thomas M. Atkinson, Tito R. Mendoza, Laura Sit, Steven Passik, Howard I. Scher, Charles Cleeland, Ethan Basch. (2010) The Brief Pain Inventory and Its “Pain At Its Worst in the Last 24 Hours” Item: Clinical Trial Endpoint Considerations. Pain Medicine 11:3, 337-346
CrossRef394
Scott T. Tagawa, Himisha Beltran, Shankar Vallabhajosula, Stanley J. Goldsmith, Joseph Osborne, Dan Matulich, Kristen Petrillo, Sarojben Parmar, David M. Nanus, Neil H. Bander. (2010) Anti-prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116:S4, 1075-1083
CrossRef395
Fabio A.B. Schutz, William K. Oh. (2010) Neoadjuvant and Adjuvant Therapies in Prostate Cancer. Urologic Clinics of North America 37:1, 97-104
CrossRef396
Robyn J. Macfarlane, Kim N. Chi. (2010) Novel Targeted Therapies for Prostate Cancer. Urologic Clinics of North America 37:1, 105-119
CrossRef397
Takahito Hara, Kazutaka Ushio, Mayumi Nishiwaki, Jin Kouno, Hideo Araki, Yukiko Hikichi, Masahiko Hattori, Yumi Imai, Masuo Yamaoka. (2010) A mutation in β-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. Cell Biology International 34:2, 177-184
CrossRef398
Charles G. Drake. (2010) Immunotherapy for Prostate Cancer: An Emerging Treatment Modality. Urologic Clinics of North America 37:1, 121-129
CrossRef399
Andrew J. Armstrong, Ian F. Tannock, Ronald de Wit, Daniel J. George, Mario Eisenberger, Susan Halabi. (2010) The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. European Journal of Cancer 46:3, 517-525
CrossRef400
J. Michels, S. L. Ellard, L. Le, C. Kollmannsberger, N. Murray, E. S. Tomlinson Guns, R. Carr, K. N. Chi. (2010) A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Annals of Oncology 21:2, 305-311
CrossRef401
B. Wörmann, J.M. Wolff. (2010) Die systemische Therapie des metastasierten Prostatakarzinoms. Der Urologe 49:2, 221-227
CrossRef402
G. Sonpavde, P. O. Periman, D. Bernold, D. Weckstein, M. T. Fleming, M. D. Galsky, W. R. Berry, F. Zhan, K. A. Boehm, L. Asmar, T. E. Hutson. (2010) Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Annals of Oncology 21:2, 319-324
CrossRef403
M. M. Regan, E. K. O'Donnell, W. K. Kelly, S. Halabi, W. Berry, S. Urakami, N. Kikuno, W. K. Oh. (2010) Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Annals of Oncology 21:2, 312-318
CrossRef404
Aurélie Cabrespine-Faugeras, Mathilde Bayet-Robert, Jacques-Olivier Bay, Philippe Chollet, Chantal Barthomeuf. (2010) Possible Benefits of Curcumin Regimen in Combination With Taxane Chemotherapy for Hormone-Refractory Prostate Cancer Treatment. Nutrition and Cancer 62:2, 148-153
CrossRef405
Mohammad Reza Safarinejad. (2010) Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: A Phase II study. Urologic Oncology: Seminars and Original Investigations 28:1, 21-27
CrossRef406
Donald L. Trump, Kristin K. Deeb, Candace S. Johnson. (2010) Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and Therapy. The Cancer Journal 16:1, 1-9
CrossRef407
Seth A. Rosenthal, Howard M. Sandler. (2010) Treatment strategies for high-risk locally advanced prostate cancer. Nature Reviews Urology 7:1, 31-38
CrossRef408
C.-H. Ohlmann, M. Stöckle. (2010) Was kommt nach Docetaxel?. Der Urologe 49:1, 64-68
CrossRef409
Shawna B. Matthews, George A. Vielhauer, Craig A. Manthe, Vamsee K. Chaguturu, Kristen Szabla, Robert L. Matts, Alison C. Donnelly, Brian S. J. Blagg, Jeffrey M. Holzbeierlein. (2010) Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. The Prostate 70:1, 27-36
CrossRef410
Jeanny B. Aragon-Ching, Ravi A. Madan, William L. Dahut. (2010) Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises. Journal of Oncology 2010, 1-7
CrossRef411
David E. Victorson, Jennifer L. Beaumont, Sarah K. Rosenbloom, Daniel Shevrin, David Cella. (2010) Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. Psycho-Oncologyn/a-n/a
CrossRef412
H. Ide, E. Kikuchi, H. Kono, H. Nagata, A. Miyajima, K. Nakagawa, T. Ohigashi, J. Nakashima, M. Oya. (2010) Docetaxel in Combination with Prednisolone for Hormone Refractory Prostate Cancer. Japanese Journal of Clinical Oncology 40:1, 79-84
CrossRef413
Jochen Greiner, Rainer Küfer, Sven N. Reske, Volker Martin, Hartmut Döhner, Mark Ringhoffer. (2010) Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer. Case Reports in Medicine 2010, 1-4
CrossRef414
Takahito Hara. (2010) Research and development of hormone-related anti-prostate cancer drugs—17, 20-lyase inhibitors for prostate cancer. Folia Pharmacologica Japonica 136:4, 192-197
CrossRef415
Kenya Yamaguchi. (2010) Chemoprevention of Prostate Cancer. Journal of Nihon University Medical Association 69:2, 75-81
CrossRef416
Hanka Jähnisch, Susanne Füssel, Andrea Kiessling, Rebekka Wehner, Stefan Zastrow, Michael Bachmann, Ernst Peter Rieber, Manfred P. Wirth, Marc Schmitz. (2010) Dendritic Cell-Based Immunotherapy for Prostate Cancer. Clinical and Developmental Immunology 2010, 1-8
CrossRef417
Jun Hyuk Hong. (2010) What's New in Hormone-refractory Prostate Cancer Treatment. Journal of Korean Medical Association 53:2, 126
CrossRef418
YouQiang Li, Atsushi Mizokami, Kouji Izumi, Kazutaka Narimoto, Takashi Shima, Jian Zhang, Jinlu Dai, Evan T. Keller, Mikio Namiki. (2010) CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. The Prostate 70:1, 48-60
CrossRef419
Jean-Pierre Droz, Lodovico Balducci, Michel Bolla, Mark Emberton, John M. Fitzpatrick, Steven Joniau, Michael W. Kattan, Silvio Monfardini, Judd W. Moul, Arash Naeim, Hendrik van Poppel, Fred Saad, Cora N. Sternberg. (2010) Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical Reviews in Oncology/Hematology 73:1, 68-91
CrossRef420
L. R. Molife, G. Attard, P. C. Fong, V. Karavasilis, A. H. M. Reid, S. Patterson, C. E. Riggs, C. Higano, W. M. Stadler, W. McCulloch, D. Dearnaley, C. Parker, J. S. de Bono. (2010) Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Annals of Oncology 21:1, 109-113
CrossRef421
Dale R. Shepard, Derek Raghavan. (2010) Innovations in the systemic therapy of prostate cancer. Nature Reviews Clinical Oncology 7:1, 13-21
CrossRef422
Jae-Lyun Lee, Jeong Eun Kim, Jin-Hee Ahn, Dae-Ho Lee, Jungshin Lee, Choung-Soo Kim, Jun Hyuk Hong, Bumsik Hong, Cheryn Song, Hanjong Ahn. (2010) Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea. Cancer Research and Treatment 42:1, 12
CrossRef423
Alysa Fairchild, Amanda Hird, Edward Chow. 2010. Pain Control with Palliative Radiotherapy in Bone Metastases. , 295-311.
CrossRef424
Sara De Dosso, Fernanda G. Herrera, Dominik R. Berthold. 2010. Bone Metastases of Prostatic Cancer. , 449-456.
CrossRef425
Deborah Bradley, Dana Rathkopf, Rodney Dunn, Walter M. Stadler, Glenn Liu, David C. Smith, Roberto Pili, James Zwiebel, Howard Scher, Maha Hussain. (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862). Cancer 115:23, 5541-5549
CrossRef426
N. M. Hahn, R. T. Zon, M. Yu, F. O. Ademuyiwa, T. Jones, W. Dugan, C. Whalen, R. Shanmugam, T. Skaar, C. J. Sweeney. (2009) A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Annals of Oncology 20:12, 1971-1976
CrossRef427
T. Nelius, S. Filleur. (2009) PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. The Prostate 69:16, 1802-1807
CrossRef428
Gongjie Liu, Stacey A. Taylor, Cindy H. Marrinan, Yunsheng Hsieh, W. Robert Bishop, Paul Kirschmeier, Brian J. Long. (2009) Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. International Journal of Cancer 125:11, 2711-2720
CrossRef429
Lysann Sauer, Joao Nunes, Vishal Salunkhe, Lenka Skalska, Takafumi Kohama, Olivier Cuvillier, Jonathan Waxman, Dmitry Pchejetski. (2009) Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. International Journal of Cancer 125:11, 2728-2736
CrossRef430
Tammy L. Romanuik, Takeshi Ueda, Nhu Le, Simon Haile, Theresa M.K. Yong, Thomas Thomson, Robert L. Vessella, Marianne D. Sadar. (2009) Novel Biomarkers for Prostate Cancer Including Noncoding Transcripts. The American Journal of Pathology 175:6, 2264-2276
CrossRef431
T Terakawa, H Miyake, J Furukawa, S L Ettinger, M E Gleave, M Fujisawa. (2009) Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. British Journal of Cancer 101:10, 1731-1739
CrossRef432
A. Bradshaw, J. Lyons, J.P. Logue, A. Choudhury. (2009) Thirty-day Mortality for Patients with Genitourinary Malignancies Being Treated with Chemotherapy. Clinical Oncology 21:9, 730
CrossRef433
Bruce Turner, Lawrence Drudge-Coates. (2009) The management of metastatic prostate cancer. International Journal of Urological Nursing 3:3, 93-103
CrossRef434
F. Finter, L. Rinnab, K. Gust, R. Küfer. (2009) Palliative Systemtherapie des kastrationsresistenten Prostatakarzinoms. Der Urologe 48:11, 1295-1301
CrossRef435
Matthew R. Smith, Gordon A. Brown, Fred Saad. (2009) New opportunities in the management of prostate cancer–related bone complications. Urologic Oncology: Seminars and Original Investigations 27:6, S1-S20
CrossRef436
Deborah L Marrocco-Tallarigo, Margaret M Centenera, Howard I Scher, Wayne D Tilley, Lisa M Butler. (2009) Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology 2:6, 619-630
CrossRef437
Suyoun Chung, Kenji Tamura, Mutsuo Furihata, Motohide Uemura, Yataro Daigo, Yasutomo Nasu, Tsuneharu Miki, Taro Shuin, Tomoaki Fujioka, Yusuke Nakamura, Hidewaki Nakagawa. (2009) Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. Cancer Science 100:11, 2109-2114
CrossRef438
Omar S. Din, Narottam Thanvi, Catherine J. Ferguson, Peter Kirkbride. (2009) Palliative prostate radiotherapy for symptomatic advanced prostate cancer. Radiotherapy and Oncology 93:2, 192-196
CrossRef439
Stuart M Lichtman. (2009) Chemotherapy in the elderly: are their needs being met?. Therapy 6:6, 893-902
CrossRef440
Karim Fizazi, Kurt Miller. (2009) SPECIFIC ENDOTHELIN-A RECEPTOR ANTAGONISM FOR THE TREATMENT OF ADVANCED PROSTATE CANCER. BJU International 104:10, 1423-1425
CrossRef441
Jonathan C. Picard, Ali-Reza Golshayan, David T. Marshall, Krisha J. Opfermann, Thomas E. Keane. (2009) The multi-disciplinary management of high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations
CrossRef442
B Mellado, A Font, A Alcaraz, L A Aparicio, F J G Veiga, J Areal, E Gallardo, N Hannaoui, J R M Lorenzo, A Sousa, P L Fernandez, P Gascon. (2009) Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. British Journal of Cancer 101:8, 1248-1252
CrossRef443
O Bratt, M Häggman, G Ahlgren, Ö Nordle, A Björk, J-E Damber. (2009) Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. British Journal of Cancer 101:8, 1233-1240
CrossRef444
Cristina Falci, Elisabetta Morello, Jean Pierre Droz. (2009) Treatment of prostate cancer in unfit senior adult patients. Cancer Treatment Reviews 35:6, 522-527
CrossRef445
Kim N. Chi, Anders Bjartell, David Dearnaley, Fred Saad, Fritz H. Schröder, Cora Sternberg, Bertrand Tombal, Tapio Visakorpi. (2009) Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. European Urology 56:4, 594-605
CrossRef446
Yu Chen, Nicola J Clegg, Howard I Scher. (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. The Lancet Oncology 10:10, 981-991
CrossRef447
Kenji Kuroda, He Liu, Sae Kim, Ming Guo, Vincent Navarro, Neil H. Bander. (2009) Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy. The Prostate 69:14, 1579-1585
CrossRef448
LaMont Barlow, James McKiernan, Ihor Sawczuk, Mitchell Benson. (2009) A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU International 104:8, 1098-1102
CrossRef449
Catherine Sánchez, Patricia Mendoza, Héctor R. Contreras, Jorge Vergara, James A. McCubrey, Christian Huidobro, Enrique A. Castellón. (2009) Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. The Prostate 69:13, 1448-1459
CrossRef450
S Terry, G Ploussard, Y Allory, N Nicolaiew, F Boissière-Michot, P Maillé, L Kheuang, E Coppolani, A Ali, F Bibeau, S Culine, R Buttyan, A de la Taille, F Vacherot. (2009) Increased expression of class III β-tubulin in castration-resistant human prostate cancer. British Journal of Cancer 101:6, 951-956
CrossRef451
Chadi Nabhan, Timothy M. Lestingi, Angel Galvez, Kathy Tolzien, Susan K. Kelby, Dean Tsarwhas, Steven Newman, Jacob D. Bitran. (2009) Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial. Urology 74:3, 665-671
CrossRef452
Hielke J. Meulenbeld, Paul Hamberg, Ronald de Wit. (2009) Chemotherapy in patients with castration-resistant prostate cancer. European Journal of Cancer 45, 161-171
CrossRef453
Xavier Pivot, Antoine Thierry-Vuillemin, Cristian Villanueva, Fernando Bazan. (2009) Response Rates. The Cancer Journal 15:5, 361-365
CrossRef454
C. Thomas, B.A. Hadaschik, J.W. Thüroff, C. Wiesner. (2009) Docetaxel-refraktäre Patienten mit metastasiertem hormonrefraktären Prostatakarzinom. Der Urologe 48:9, 1070-1074
CrossRef455
A. Mitra, V. Khoo. (2009) Adjuvant therapy after radical prostatectomy: Clinical considerations. Surgical Oncology 18:3, 247-254
CrossRef456
Guru Sonpavde, Cora N Sternberg. (2009) Satraplatin for the therapy of castration-resistant prostate cancer. Future Oncology 5:7, 931-940
CrossRef457
Kurt Miller, Arnulf Stenzl, Bertrand Tombal. (2009) Advances in the Therapy of Prostate Cancer–Induced Bone Disease: Current Insights and Future Perspectives on the RANK/RANKL Pathways. European Urology Supplements 8:9, 747-752
CrossRef458
Jonathan Shamash. (2009) Future directions in non-endocrine systemic treatment of metastatic prostate cancer. Surgical Oncology 18:3, 283-288
CrossRef459
(2009) Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. International Journal of Urology 16:9, 731-732
CrossRef460
Rishi Nayyar, Nitin Sharma, Narmada P Gupta. (2009) Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. International Journal of Urology 16:9, 726-731
CrossRef461
Sebastian A. Müller, Korbinian Holzapfel, Christof Seidl, Uwe Treiber, Bernd J. Krause, Reingard Senekowitsch-Schmidtke. (2009) Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment. European Journal of Nuclear Medicine and Molecular Imaging 36:9, 1434-1442
CrossRef462
John M. Fitzpatrick, Cora N. Sternberg, Fred Saad, Martine Extermann, Orazio Caffo, Susan Halabi, Gero Kramer, Stéphane Oudard, Ronald de Wit. (2009) Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. European Urology Supplements 8:9, 738-746
CrossRef463
G. Shaw, R.T.D. Oliver. (2009) Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer. Surgical Oncology 18:3, 275-282
CrossRef464
P F Mulders, J A Schalken. (2009) Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 12:3, 241-246
CrossRef465
JianHua Zhou, Lü Huang, WeiWei Wang, Jun Pang, Yang Zou, XinTao Shuai, Xin Gao. (2009) Prostate cancer targeted MRI nanoprobe based on superparamagnetic iron oxide and copolymer of poly(ethylene glycol) and polyethyleneimin. Chinese Science Bulletin 54:18, 3137-3146
CrossRef466
Marnix G. E. H. Lam, Tjitske B. Bosma, Peter P. Rijk, Bernard A. Zonnenberg. (2009) 188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. European Journal of Nuclear Medicine and Molecular Imaging 36:9, 1425-1433
CrossRef467
Karim Fizazi, Christophe Massard. (2009) New agents in metastatic prostate cancer. European Journal of Cancer 45, 379-380
CrossRef468
Alison K. Ramsay, Hing Y. Leung. (2009) Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clinical Science 117:6, 209-228
CrossRef469
S Chung, M Furihata, K Tamura, M Uemura, Y Daigo, Y Nasu, T Miki, T Shuin, T Fujioka, Y Nakamura, H Nakagawa. (2009) Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways. Oncogene 28:32, 2849-2859
CrossRef470
Xiao-xuan Liu, Palma Rocchi, Fan-qi Qu, Shu-quan Zheng, Zi-cai Liang, Martin Gleave, Juan Iovanna, Ling Peng. (2009) PAMAM Dendrimers Mediate siRNA Delivery to Target Hsp27 and Produce Potent Antiproliferative Effects on Prostate Cancer Cells. ChemMedChem 4:8, 1302-1310
CrossRef471
Akihiro Matsumoto, Atsushi Inoue, Satoshi Yokoi, Kazuyoshi Nozumi, Kanetaka Miyazaki, Shigeru Hosoki, Maki Nagata, Kunio Yamaguchi. (2009) Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. International Journal of Urology 16:8, 687-691
CrossRef472
Peter Jantscheff, Norbert Esser, Ralph Graeser, Vittorio Ziroli, Jessica Kluth, Clemens Unger, Ulrich Massing. (2009) Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts. The Prostate 69:11, 1151-1163
CrossRef473
Seung Chol Park, Joung Sik Rim, Han Yong Choi, Choung Soo Kim, Sung Joon Hong, Wun Jae Kim, Sang Eun Lee, Jae Mann Song, Jin Han Yoon. (2009) Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: Predictive factors. International Journal of Urology 16:8, 670-675
CrossRef474
André N. Vis, Fritz H. Schröder. (2009) Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU International 104:4, 438-448
CrossRef475
Sandi A. Kwee, Marc N. Coel, Bevan H. Ly, John Lim. (2009) 18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer. Annals of Nuclear Medicine 23:6, 541-548
CrossRef476
Philippe O. Gannon, Alexis O. Poisson, Nathalie Delvoye, Réjean Lapointe, Anne-Marie Mes-Masson, Fred Saad. (2009) Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. Journal of Immunological Methods 348:1-2, 9-17
CrossRef477
T Koreckij, H Nguyen, L G Brown, E Y Yu, R L Vessella, E Corey. (2009) Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. British Journal of Cancer 101:2, 263-268
CrossRef478
M.A. Reiter, J. Pfitzenmaier, M. Hohenfellner, A. Haferkamp. (2009) Immunmodulatorische Therapieansätze beim Prostatakarzinom. Der Urologe 48:7, 755-763
CrossRef479
Guo-Wen Lin, Xu-Dong Yao, Shi-Lin Zhang, Bo Dai, Chun-Guang Ma, Hai-Liang Zhang, Yi-Jun Shen, Yao Zhu, Yi-Ping Zhu, Guo-Hai Shi, Xiao-Jian Qin, Ding-Wei Ye. (2009) Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian Journal of Andrology 11:4, 443-450
CrossRef480
Russell Szmulewitz, Supriya Mohile, Edwin Posadas, Rangesh Kunnavakkam, Theodore Karrison, Elizabeth Manchen, Walter M. Stadler. (2009) A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer. European Urology 56:1, 97-104
CrossRef481
Phillip G. Febbo. (2009) Genomic approaches to outcome prediction in prostate cancer. Cancer 115:S13, 3046-3057
CrossRef482
Qianben Wang, Wei Li, Yong Zhang, Xin Yuan, Kexin Xu, Jindan Yu, Zhong Chen, Rameen Beroukhim, Hongyun Wang, Mathieu Lupien, Tao Wu, Meredith M. Regan, Clifford A. Meyer, Jason S. Carroll, Arjun Kumar Manrai, Olli A. Jänne, Steven P. Balk, Rohit Mehra, Bo Han, Arul M. Chinnaiyan, Mark A. Rubin, Lawrence True, Michelangelo Fiorentino, Christopher Fiore, Massimo Loda, Philip W. Kantoff, X. Shirley Liu, Myles Brown. (2009) Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer. Cell 138:2, 245-256
CrossRef483
C. N. Sternberg, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, F. Calabro, L. Collette, D. Lacombe, . (2009) Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Annals of Oncology 20:7, 1264-1269
CrossRef484
Cigdem Erten, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Mustafa K. Gul, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli, Ruchan Uslu. (2009) Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU International 104:1, 107-114
CrossRef485
Scott C Morgan, David P Dearnaley. (2009) Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?. Expert Review of Anticancer Therapy 9:7, 939-951
CrossRef486
S. H. Waters, A. Gillibrand, H. Berry, S. Kumar, G. Velikova, D. J. Dodwell, Timothy J. Perren. (2009) Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer. Cancer Chemotherapy and Pharmacology 64:2, 407-412
CrossRef487
Kazuhiko Ogawa, Katsumasa Nakamura, Tomonari Sasaki, Hiroshi Onishi, Masahiko Koizumi, Yoshiyuki Shioyama, Masayuki Araya, Nobutaka Mukumoto, Michihide Mitsumori, Teruki Teshima. (2009) External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer: Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months. International Journal of Radiation Oncology*Biology*Physics 74:3, 759-765
CrossRef488
U. Wedding. (2009) Schmerztherapie bei onkologischen Patienten. Der Onkologe 15:7, 663-668
CrossRef489
Nancy A Dawson, Sean P Collins. (2009) Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy. Expert Review of Anticancer Therapy 9:7, 953-962
CrossRef490
Hildo J.K. Ananias, Marius C. van den Heuvel, Wijnand Helfrich, Igle J. de Jong. (2009) Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. The Prostate 69:10, 1101-1108
CrossRef491
Ulka N. Vaishampayan, Shanthi Marur, Lance K. Heilbrun, Michael L. Cher, Brenda Dickow, Daryn W. Smith, Samir A. Al Hasan, James Eliason. (2009) Phase II Trial of Capecitabine and Weekly Docetaxel for Metastatic Castrate Resistant Prostate Cancer. The Journal of Urology 182:1, 317-323
CrossRef492
LaMont J. Barlow, James M. McKiernan, Mitchell C. Benson. (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World Journal of Urology 27:3, 331-335
CrossRef493
Antoine Italiano, Karim Fizazi. (2009) Rebuttal from Authors re: Joaquim Bellmunt. Chemotherapy for Prostate Cancer in Senior Adults: Are We Treating the Elderly or the Frail? Eur Urol 2009;55:1310–2. European Urology 55:6, 1313-1314
CrossRef494
Stéphane Oudard, Eugeniu Banu, Jacques Medioni, Florian Scotte, Adela Banu, Eric Levy, Johana Wasserman, Gabriel Kacso, Jean-Marie Andrieu. (2009) What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?. BJU International 103:12, 1641-1646
CrossRef495
Mark A. Rosenthal. (2009) Editorial Comment on: Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer. European Urology 55:6, 1375-1376
CrossRef496
H. Boyle, V. Girre, C. Mertens, C. Falandry, F. Gouttenoire, G. Freyer, E. G. C. Brain. (2009) Recherche clinique en oncogériatrie. Oncologie 11:6, 331-336
CrossRef497
Jeanny B. Aragon-Ching, Lokesh Jain, James L. Gulley, Philip M. Arlen, John J. Wright, Seth M. Steinberg, David Draper, Jürgen Venitz, Elizabeth Jones, Clara C. Chen, William D. Figg, William L. Dahut. (2009) Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU International 103:12, 1636-1640
CrossRef498
Laura Biganzoli, Sara Licitra, Erica Moretti, Marta Pestrin, Elena Zafarana, Angelo Di Leo. (2009) Taxanes in the elderly: Can we gain as much and be less toxic?. Critical Reviews in Oncology/Hematology 70:3, 262-271
CrossRef499
Antoine Italiano, Cécile Ortholan, Stéphane Oudard, Damien Pouessel, Gwenaëlle Gravis, Philippe Beuzeboc, Emmanuelle Bompas, Aude Fléchon, Florence Joly, Jean-Marc Ferrero, Karim Fizazi. (2009) Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer. European Urology 55:6, 1368-1376
CrossRef500
Xingqiao Wen, Xiaojuan Li, Bing Liao, Yong Liu, Jieying Wu, Xiaoxu Yuan, Bin Ouyang, Qipeng Sun, Xin Gao. (2009) Knockdown of p21-activated Kinase 6 Inhibits Prostate Cancer Growth and Enhances Chemosensitivity to Docetaxel. Urology 73:6, 1407-1411
CrossRef501
Joaquim Bellmunt. (2009) Chemotherapy for Prostate Cancer in Senior Adults: Are We Treating the Elderly or the Frail?. European Urology 55:6, 1310-1312
CrossRef502
Yong Hyun Park, In Sik Hwang, Chang Wook Jeong, Hyeon Hoe Kim, Sang Eun Lee, Cheol Kwak. (2009) Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer. The Journal of Urology 181:6, 2520-2525
CrossRef503
Matteo Landriscina, Cinzia Bagalà, Annamaria Piscazzi, Giovanni Schinzari, Michela Quirino, Annarita Fabiano, Sara Bianchetti, Alessandra Cassano, Gigliola Sica, Carlo Barone. (2009) Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. The Prostate 69:7, 744-754
CrossRef504
A. Horwich, C. Parker, V. Kataja, . (2009) Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv76-iv78
CrossRef505
Kenji Tamura, Mutsuo Furihata, Su-Yong Chung, Motohide Uemura, Hiroki Yoshioka, Tatsuo Iiyama, Shingo Ashida, Yasutomo Nasu, Tomoaki Fujioka, Taro Shuin, Yusuke Nakamura, Hidewaki Nakagawa. (2009) Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Science 100:5, 914-919
CrossRef506
C. Serrate, Y. Loriot, T. De La Motte Rouge, M. Gross-Goupil, C. Massard, B. Escudier, A. Bossi, K. Fizazi. (2009) Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Annals of Oncology 20:5, 965-965
CrossRef507
Nicholas D. James, Armelle Caty, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, Thomas Morris, De Phung, Nancy A. Dawson. (2009) Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial. European Urology 55:5, 1112-1123
CrossRef508
James P. Dean, Celestia S. Higano. (2009) Does chemotherapy have a role before hormone-resistant disease develops?. Current Urology Reports 10:3, 226-235
CrossRef509
Raj A. Persad, Amit Bahl. (2009) Modern chemotherapy strategies for management of ‘Hormone Resistant Prostate Cancer’ (HRPC)—When should the urologist refer?. British Journal of Medical and Surgical Urology 2:3, 92-99
CrossRef510
M. Dror Michaelson, M. M. Regan, W. K. Oh, D. S. Kaufman, K. Olivier, S. Z. Michaelson, B. Spicer, C. Gurski, P. W. Kantoff, M. R. Smith. (2009) Phase II study of sunitinib in men with advanced prostate cancer. Annals of Oncology 20:5, 913-920
CrossRef511
Teresita Reiner, Alicia de las Pozas, Lourdes A. Gomez, Carlos Perez-Stable. (2009) Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis. Cancer Letters 276:1, 21-31
CrossRef512
József Horti, Anders Widmark, Arnulf Stenzl, Miriam H. Federico, Raymond P. Abratt, Nick Sanders, Gillian M. Pover, István Bodrogi. (2009) A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer. Cancer Biotherapy & Radiopharmaceuticals 24:2, 175-180
CrossRef513
Joaquim Bellmunt. (2009) Role of Chemotherapy in Nonmetastatic Hormone-Refractory Prostate Cancer. European Urology Supplements 8:5, 448-452
CrossRef514
Haluk Ozen, Sertac Yazici, Kubilay Inci. (2009) Management of High-Risk Localised Prostate Cancer. European Urology Supplements 8:5, 439-447
CrossRef515
Norihito Soga, Manabu Kato, Kouhei Nishikawa, Yoshihiro Hasegawa, Yasushi Yamada, Hideaki Kise, Kiminobu Arima, Yoshiki Sugimura. (2009) Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. International Journal of Clinical Oncology 14:2, 130-135
CrossRef516
Calin O. Marian, Jerry W. Shay. (2009) Prostate tumor-initiating cells: A new target for telomerase inhibition therapy?. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1792:4, 289-296
CrossRef517
D.R. Shepard, R. Dreicer, J. Garcia, P. Elson, C. Magi-Galluzzi, D. Raghavan, A.J. Stephenson, E.A. Klein. (2009) Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy. The Journal of Urology 181:4, 1672-1677
CrossRef518
Guru Sonpavde, Matthew D. Galsky, Thomas E. Hutson, Daniel D. Von Hoff. (2009) Patient Selection for Phase II Trials. American Journal of Clinical Oncology 32:2, 216-219
CrossRef519
H. Maeda, G.Y. Bharate, J. Daruwalla. (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. European Journal of Pharmaceutics and Biopharmaceutics 71:3, 409-419
CrossRef520
Patrick C. Walsh. (2009) Urological Oncology: Prostate Cancer. The Journal of Urology 181:3, 1121-1124
CrossRef521
Seth A. Rosenthal, Kyoungwha Bae, Kenneth J. Pienta, Mark L. Sobczak, Sucha O. Asbell, Raghu Rajan, Kevin J. Kerlin, Jeff M. Michalski, Howard M. Sandler. (2009) Phase III Multi-Institutional Trial of Adjuvant Chemotherapy With Paclitaxel, Estramustine, and Oral Etoposide Combined With Long-Term Androgen Suppression Therapy and Radiotherapy Versus Long-Term Androgen Suppression Plus Radiotherapy Alone for High-Risk Prostate Cancer: Preliminary Toxicity Analysis of RTOG 99-02. International Journal of Radiation Oncology*Biology*Physics 73:3, 672-678
CrossRef522
Ian M. Thompson, Catherine M. Tangen, Jorge Paradelo, M. Scott Lucia, Gary Miller, Dean Troyer, Edward Messing, Jeffrey Forman, Joseph Chin, Gregory Swanson, Edith Canby-Hagino, E. David Crawford. (2009) Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial. The Journal of Urology 181:3, 956-962
CrossRef523
A Michael, K Syrigos, H Pandha. (2009) Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer and Prostatic Diseases 12:1, 13-16
CrossRef524
Robert J. Amato, Bin S. Teh, Haby Henary, Muhammad Khan, Somyata Saxena. (2009) A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urologic Oncology: Seminars and Original Investigations 27:2, 165-169
CrossRef525
A J Armstrong, S Halabi, R de Wit, I F Tannock, M Eisenberger. (2009) The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer and Prostatic Diseases 12:1, 88-93
CrossRef526
Ayman EM Mahdy, Joseph C Cheng, Jun Li, Saeed Elojeimy, William D Meacham, Lorianne S Turner, Aiping Bai, Christopher R Gault, Alex S McPherson, Nicole Garcia, Thomas H Beckham, Antonio Saad, Alicja Bielawska, Jacek Bielawski, Yusuf A Hannun, Thomas E Keane, Mohhammed I Taha, Hisham M Hammouda, James S Norris, Xiang Liu. (2009) Acid Ceramidase Upregulation in Prostate Cancer Cells Confers Resistance to Radiation: AC Inhibition, a Potential Radiosensitizer. Molecular Therapy 17:3, 430-438
CrossRef527
Cora N. Sternberg. (2009) A medical oncologist's perspective on the treatment of patients with genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations 27:2, 122-125
CrossRef528
R A C McPherson, P T Galettis, P L de Souza. (2009) Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. British Journal of Cancer 100:4, 649-655
CrossRef529
Jacqueline Vuky, Christopher Porter, Christina Isacson, Matthew Vaughan, Paul Kozlowski, Vincent Picozzi, John Corman. (2009) Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 115:4, 784-791
CrossRef530
Gary G. Schwartz. (2009) Vitamin D and Intervention Trials in Prostate Cancer: From Theory to Therapy. Annals of Epidemiology 19:2, 96-102
CrossRef531
David Knight, Amy C. Peterson, Brian I. Rini, Helena Harlin, Thomas F. Gajewski, Walter M. Stadler. (2009) The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. The Prostate 69:2, 142-148
CrossRef532
D. Schilling, G. Gakis, U. Bökeler, A. Stenzl, M.A. Kuczyk, A.S. Merseburger. (2009) Sekundäre Hormonablation beim hormonunabhängigen Prostatakarzinom. Der Urologe 48:2, 183-190
CrossRef533
Joaquim Bellmunt, Joan Carles, Joan Albanell. (2009) Predictive modelling in hormone-refractory prostate cancer (HRPC). Clinical and Translational Oncology 11:2, 82-85
CrossRef534
Jackie Baker, Jaffer Ajani, Florian Scotté, Dorte Winther, Miguel Martin, Matti S. Aapro, Gunter von Minckwitz. (2009) Docetaxel-related side effects and their management. European Journal of Oncology Nursing 13:1, 49-59
CrossRef535
Nicholas D. James, Matthew R. Sydes, Noel W. Clarke, Malcolm D. Mason, David P. Dearnaley, John Anderson, Richard J. Popert, Karen Sanders, Rachel C. Morgan, Jim Stansfeld, John Dwyer, John Masters, Mahesh K.B. Parmar. (2009) Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU International 103:4, 464-469
CrossRef536
James J Lee, W Kevin Kelly. (2009) Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nature Clinical Practice Oncology 6:2, 85-92
CrossRef537
Y. Loriot, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, A. Bossi, K. Fizazi. (2009) Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Annals of Oncology 20:4, 703-708
CrossRef538
W M van Weerden, C Bangma, R de Wit. (2009) Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. British Journal of Cancer 100:1, 13-18
CrossRef539
Chen Tan, Li-Qun Cai, Wendy Wu, Yaming Qiao, Julianne Imperato-McGinley, Guo-Qiang Chen, Yuan-Shan Zhu. (2009) NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells. Cancer Chemotherapy and Pharmacology 63:2, 303-312
CrossRef540
Hui Qing Wang, Bo Yang, Chuan Liang Xu, Lin Hui Wang, Yu Xi Zhang, Bin Xu, Jia Tao Ji, Ying Hao Sun. (2009) Differential phosphoprotein levels and pathway analysis identify the transition mechanism of LNCaP cells into androgen-independent cells. The Prostaten/a-n/a
CrossRef541
Sam S. Chang, Adam S. Kibel. (2009) The role of systemic cytotoxic therapy for prostate cancer. BJU International 103:1, 8-17
CrossRef542
Celestia S. Higano. (2009) Positive surgical margins: The argument for androgen deprivation and chemotherapy. Urologic Oncology: Seminars and Original Investigations 27:1, 89-91
CrossRef543
Don W.W. Newling. (2009) Issues with the Use of Prostate-Specific Antigen as a Surrogate End Point in Hormone-Resistant Prostate Cancer. European Urology Supplements 8:1, 13-19
CrossRef544
Kurt Miller. (2009) Challenges and Opportunities in Hormone-Resistant Prostate Cancer. European Urology Supplements 8:1, 36-45
CrossRef545
Anna-Katharina Thomas-Kaskel, Hendrik Veelken. (2009) Dendritic-cell vaccination for prostate cancer. Immunotherapy 1:1, 63-72
CrossRef546
Ian D. Schnadig, Tomasz M. Beer. (2009) Optimal timing of chemotherapy in androgen independent prostate cancer. Urologic Oncology: Seminars and Original Investigations 27:1, 97-100
CrossRef547
Kazuhiro OZAWA, Hironobu MINAMI, Hitoshi SATO. (2009) Clinical Trial Simulations for Dosage Optimization of Docetaxel in Patients with Liver Dysfunction, Based on a Log-binominal Regression for Febrile Neutropenia. YAKUGAKU ZASSHI 129:6, 749-757
CrossRef548
Kurt Miller. (2009) Introduction. European Urology Supplements 8:1, 1-3
CrossRef549
Massimo Maffezzini. (2009) Highlighting Unmet Needs: Real Patients, Difficult Choices. European Urology Supplements 8:1, 4-12
CrossRef550
Yong Li, Paul J. Cozzi. (2009) Angiogenesis as a strategic target for prostate cancer therapy. Medicinal Research Reviewsn/a-n/a
CrossRef551
XiaoMei Liu, Alejandro Gomez-Pinillos, XiaoJun Liu, Edward M. Johnson, Anna C. Ferrari. (2009) Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Purα-mediated decrease in androgen receptor levels. The Prostaten/a-n/a
CrossRef552
Hironobu Minami, Kenji Kawada, Yasutsuna Sasaki, Makoto Tahara, Tadahiko Igarashi, Kuniaki Itoh, Hirofumi Fujii, Toshiaki Saeki, Kazuhiro Ozawa, Hitoshi Sato. (2009) Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science 100:1, 144-149
CrossRef553
Marine Gross-Goupil, Christophe Massard, Karim Fizazi. (2009) Integrating Molecular Oncology into Therapeutic Strategies for Prostate Cancer. European Urology Supplements 8:3, 114-119
CrossRef554
Yingming Li, Bahaa S. Malaeb, Zhong-ze Li, Melissa G. Thompson, Zhi Chen, David R. Corey, Jer-Tsong Hsieh, Jerry W. Shay, Kenneth S. Koeneman. (2009) Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer. The Prostaten/a-n/a
CrossRef555
Yong Li, Paul J. Cozzi, Pamela J. Russell. (2009) Promising tumor-associated antigens for future prostate cancer therapy. Medicinal Research Reviewsn/a-n/a
CrossRef556
Kazuyuki Numakura, Norihiko Tsuchiya, Tomonori Habuchi, Naoto Takahashi. (2009) THERAPY RELATED LEUKEMIA WITH 11q23 ABNORMALITY INDUCED BY CHEMOTHERAPY CONSISTED OF DOCETAXEL FOR ADVANCED PROSTATIC CARCINOMA: CASE REPORT. The Japanese Journal of Urology 100:5, 580-585
CrossRef557
C Wilson, P Scullin, J Worthington, A Seaton, P Maxwell, D O'Rourke, P G Johnston, S R McKeown, R H Wilson, J M O'Sullivan, D J J Waugh. (2008) Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. British Journal of Cancer 99:12, 2054-2064
CrossRef558
Robert J. Amato, Joan Hernandez-McClain, Haby Henary. (2008) Bone-Targeted Therapy. American Journal of Clinical Oncology 31:6, 532-538
CrossRef559
P C Stone, R F Murphy, H E Matar, M Q Almerie. (2008) Measuring the individual quality of life of patients with prostate cancer. Prostate Cancer and Prostatic Diseases 11:4, 390-396
CrossRef560
Elmar Heinrich, Andrew V. Schally, Stefan Buchholz, Ferenc G. Rick, Gabor Halmos, Melinda Mile, Kate Groot, Florian Hohla, Marta Zarandi, Jozsef L. Varga. (2008) Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. The Prostate 68:16, 1763-1772
CrossRef561
Joseph S. Chan, Tomasz M. Beer, David I. Quinn, Jacek K. Pinski, Mark Garzotto, Mitchell Sokoloff, Daniel R. Dehaze, Christopher W. Ryan. (2008) A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU International 102:11, 1601-1606
CrossRef562
Roberto Petrioli, Anna Ida Fiaschi, Edoardo Francini, Alessandra Pascucci, Guido Francini. (2008) The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treatment Reviews 34:8, 710-718
CrossRef563
Masayasu Naito, Kyogo Itoh, Nobukazu Komatsu, Yuichi Yamashita, Takafumi Shirakusa, Akira Yamada, Fukuko Moriya, Hitoshi Ayatuka, Elnisr Rashed Mohamed, Kei Matsuoka, Masanori Noguchi. (2008) Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. The Prostate 68:16, 1753-1762
CrossRef564
Daniel P Petrylak, Hideyuki Akaza, Dean G Assimos, Yoshihide Ogawa, Martin E Gleave, Tomohiko Ichikawa, Peter T Nieh, Authony V D'Amico, Hiromitsu Mimata, Yoshihiko Tomita, Michael B Chancellor, Momokazu Gotoh, Akihiko Okuyama. (2008) Third Joint Meeting of the American Urological Association and the Japanese Urological Association International Program at the 103rd Annual Meeting of the American Urological Association at Orlando 2008. International Journal of Urology 15:12, 1086-1090
CrossRef565
Albrecht Reichle, Thomas Vogt. (2008) Systems Biology: A Therapeutic Target for Tumor Therapy. Cancer Microenvironment 1:1, 159-170
CrossRef566
Avishay Sella, Cora N. Sternberg, Iwona Skoneczna, Svetlana Kovel. (2008) Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU International 102:11, 1607-1609
CrossRef567
Dominique Levêque. (2008) Off-label use of anticancer drugs. The Lancet Oncology 9:11, 1102-1107
CrossRef568
Oudard Stéphane. (2008) Editorial Comment on: Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. European Urology 54:5, 1094-1096
CrossRef569
Todd J. Lehrfeld, David I. Lee. (2008) Dendritic cell vaccines for the treatment of prostate cancer. Urologic Oncology: Seminars and Original Investigations 26:6, 576-580
CrossRef570
Orazio Caffo, Teodoro Sava, Evi Comploj, Annamaria Fariello, Fable Zustovich, Romana Segati, Cosimo Sacco, Francesco Valduga, Gianluigi Cetto, Enzo Galligioni. (2008) Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU International 102:9, 1080-1085
CrossRef571
M. Gross-Goupil, K. Fizazi. (2008) Cancer de la prostate métastatique: quoi de neuf depuis le docétaxel ?. Oncologie 10:11, 648-652
CrossRef572
Nancy A. Dawson. (2008) Targeted therapy in prostate cancer-Are we our own worst enemy?. Cancer 113:9, 2376-2378
CrossRef573
Peter Stephens. (2008) Cancer in the older person. Reviews in Clinical Gerontology 18:04, 313
CrossRef574
Yukio Kageyama. (2008) Development of drugs against hormone-refractory prostate cancer. Drug Development Research 69:7, 431-450
CrossRef575
John F. Ward, Lance C. Pagliaro, Louis L. Pisters. (2008) Salvage Therapy for Radiorecurrent Prostate Cancer. Current Problems in Cancer 32:6, 242-271
CrossRef576
Joel B. Nelson, William Love, Joseph L. Chin, Fred Saad, Claude C. Schulman, Darryl J. Sleep, Jiang Qian, Joyce Steinberg, Michael Carducci, . (2008) Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113:9, 2478-2487
CrossRef577
Gert De Meerleer, Valérie Fonteyne, Sabine Meersschout, Caroline Van den Broecke, Geert Villeirs, Nicolaas Lumen, Piet Ost, Katrien Vandecasteele, Wilfried De Neve. (2008) Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiotherapy and Oncology 89:2, 205-213
CrossRef578
Giuseppe Di Lorenzo, William D. Figg, Sophie D. Fossa, Vincenzo Mirone, Riccardo Autorino, Nicola Longo, Ciro Imbimbo, Sisto Perdonà, Antonio Giordano, Mario Giuliano, Roberto Labianca, Sabino De Placido. (2008) Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. European Urology 54:5, 1089-1096
CrossRef579
D Olmos, H-T Arkenau, J E Ang, J S de Bono, I Judson, S B Kaye. (2008) Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience. British Journal of Cancer 99:8, 1365-1365
CrossRef580
A. Hussain, R. S. DiPaola, A. D. Baron, C. S. Higano, N. S. Tchekmedyian, A. R. Johri. (2008) Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Annals of Oncology 20:3, 492-497
CrossRef581
G. Spitaleri, D. V. Matei, G. Curigliano, S. Detti, F. Verweij, S. Zambito, E. Scardino, B. Rocco, F. Nole, L. Ariu, T. De Pas, F. de Braud, O. De Cobelli. (2008) Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. Annals of Oncology 20:3, 498-502
CrossRef582
C. Massard, A. Chauchereau, K. Fizazi. (2008) The quest for the 'bony Grail' of detecting circulating tumour cells in patients with prostate cancer. Annals of Oncology 20:2, 197-199
CrossRef583
David Robinson, Gabriel Sandblom, Robert Johansson, Hans Garmo, Gunnar Aus, Per Olov Hedlund, Eberhard Varenhorst. (2008) PSA Kinetics Provide Improved Prediction of Survival in Metastatic Hormone-Refractory Prostate Cancer. Urology 72:4, 903-907
CrossRef584
John M. Fitzpatrick, John Anderson, Cora N. Sternberg, Neil Fleshner, Karim Fizazi, Xavier Rébillard, Luigi Dogliotti, Giario Conti, Ingela Turesson, Nicholas James, Axel Heidenreich, Eduardo Solsona, Vicente Guillem, Daniel Herchenhorn, Judd Moul, Jeroen van Moorselaar, Lance J.E. Coetzee, Andrew Wilson, Aristotelis Bamias, Ronald De Wit, Michael Chrisofos. (2008) Optimizing treatment for men with advanced prostate cancer: Expert recommendations and the multidisciplinary approach. Critical Reviews in Oncology/Hematology 68:1, S9-S22
CrossRef585
D. Schilling, R. Küfer, S. Kruck, A. Stenzl, M.A. Kuczyk, A.S. Merseburger. (2008) Somatostatin-Analoga in der Therapie des fortgeschrittenen hormonrefraktären Prostatakarzinoms. Der Urologe 47:10, 1334-1338
CrossRef586
N.D. James, M.R. Sydes, N.W. Clarke, M.D. Mason, D.P. Dearnaley, J. Anderson, R.J. Popert, K. Sanders, R.C. Morgan, J. Stansfeld, J. Dwyer, J. Masters, M.K.B. Parmar. (2008) STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled Trial. Clinical Oncology 20:8, 577-581
CrossRef587
John Anderson, Cora N. Sternberg. (2008) Adapting treatment for prostate cancer according to risk of disease progression. Critical Reviews in Oncology/Hematology 68:1, S23-S31
CrossRef588
Ian Haines. (2008) Docetaxel for hormone-refractory prostate cancer. The Lancet 372:9648, 1461
CrossRef589
C. Börgermann, F. Dorp, M. Schenck, M. Becker, J. Heß, H. Rübben. (2008) Der Stellenwert der Targeted-Therapie beim Prostatakarzinom. Der Urologe 47:10, 1315-1319
CrossRef590
I.A. Adamietz, K. Czeloth, U. Ganswindt, K. Miller, S. Perner, S.N. Reske, J. Walz, J. Wierecky. (2008) Prostatakarzinom. Der Onkologe 14:10, 1087-1102
CrossRef591
F.A. Bashir, J.M. Parry, P.M. Windsor. (2008) Use of a Modified Hemi-body Irradiation Technique for Metastatic Carcinoma of the Prostate: Report of a 10-year Experience. Clinical Oncology 20:8, 591-598
CrossRef592
Hiroyoshi Suzuki, Naoto Kamiya, Takashi Imamoto, Koji Kawamura, Masashi Yano, Makoto Takano, Takanobu Utsumi, Yukio Naya, Tomohiko Ichikawa. (2008) Current topics and perspectives relating to hormone therapy for prostate cancer. International Journal of Clinical Oncology 13:5, 401-410
CrossRef593
Kevin Art, Jeffrey M Holzbeierlein. (2008) Hormonal and chemotherapeutic options in advanced prostate cancer. Aging Health 4:5, 455-462
CrossRef594
Wengang Cao, Kathleen T. Shiverick, Kazunori Namiki, Yoshihisa Sakai, Stacy Porvasnik, Cydney Urbanek, Charles J. Rosser. (2008) Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World Journal of Urology 26:5, 509-516
CrossRef595
Henrik Suttmann, Aleksandar Grgic, Jan Lehmann, Ulrike Zwergel, Jörn Kamradt, Eric Gouverneur, Jörg Pinkert, Michael Stöckle, Carl-Martin Kirsch, Ursula Nestle. (2008) Combining 153 Sm-Lexidronam and Docetaxel for the Treatment of Patients with Hormone-Refractory Prostate Cancer: First Experience. Cancer Biotherapy & Radiopharmaceuticals 23:5, 609-618
CrossRef596
C Falci, A Brunello, U Basso, A Roma, S Monfardini. (2008) Medical approach to advanced prostate cancer in older patients. Aging Health 4:5, 481-494
CrossRef597
C. Montagut, J. Albanell, J. Bellmunt. (2008) Prostate cancer. Critical Reviews in Oncology/Hematology 68:1, S32-S36
CrossRef598
Jean-Pierre Droz, Matti Aapro, Lodovico Balducci. (2008) Overcoming challenges associated with chemotherapy treatment in the senior adult population. Critical Reviews in Oncology/Hematology 68:1, S1-S8
CrossRef599
Manpreet K. Chadha, Umeer Ashraf, David Lawrence, Lili Tian, Ellis Levine, Carrie Silliman, Paul Escott, Valencia Payne, Donald L. Trump. (2008) Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancer. The Prostate 68:13, 1461-1466
CrossRef600
Celestia S. Higano, John M. Corman, David C. Smith, Arthur S. Centeno, Christopher P. Steidle, Marc Gittleman, Jonathan W. Simons, Natalie Sacks, Junko Aimi, Eric J. Small. (2008) Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113:5, 975-984
CrossRef601
A. Heidenreich, F. Finke. (2008) Klinische Netzwerkstrukturen in der Uroonkologie. Der Urologe 47:9, 1128-1132
CrossRef602
C.-H. Ohlmann, E. Markert, M. Gerharz, D. Pfister, H.-P. Dienes, U. Engelmann, A. Heidenreich. (2008) Molekular getriggerte Therapie des hormonrefraktären Prostatakarzinoms. Der Urologe 47:9, 1218-1223
CrossRef603
Erin Grothey, Tara Gibson, Oliver Sartor, Ronald Bukowski. (2008) Highlights from: The 2008 Meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, IL. Clinical Genitourinary Cancer 6:2, 65-72
CrossRef604
Fred Saad, Dean Ruether, Scott Ernst, Scott North, Tina Cheng, Paul Perrotte, Pierre Karakiewicz, Eric Winquist. (2008) The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU International 102:5, 551-555
CrossRef605
Danish Mazhar, Jonathan Waxman. (2008) Early chemotherapy in prostate cancer. Nature Clinical Practice Urology 5:9, 486-493
CrossRef606
Olav Lindqvist, Birgit H. Rasmussen, Anders Widmark. (2008) Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases. European Journal of Oncology Nursing 12:4, 283-290
CrossRef607
Brian Schurko, William K Oh. (2008) Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Clinical Practice Oncology 5:9, 506-507
CrossRef608
Emma K Beardsley, Kim N Chi. (2008) Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Current Opinion in Supportive and Palliative Care 2:3, 161-166
CrossRef609
Marklyn J. Jones, Kenneth S. Koeneman. (2008) Local-regional prostate cancer. Urologic Oncology: Seminars and Original Investigations 26:5, 516-521
CrossRef610
Cristiana Lo Nigro, Monica Maffi, Jean Louis Fischel, Patricia Formento, Gerard Milano, Marco Merlano. (2008) The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU International 102:5, 622-627
CrossRef611
Bruce Montgomery, Philip Lavori, Mark Garzotto, Kelvin Lee, Mary Brophy, Surai Thaneemit-Chen, William Kelly, Joseph Basler, Robert Ringer, Wei Yu, Alice Whittemore, Daniel W. Lin. (2008) Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a Phase III Randomized Study of Prostatectomy Versus Prostatectomy with Adjuvant Docetaxel for Patients with High-Risk, Localized Prostate Cancer. Urology 72:3, 474-480
CrossRef612
Richard D. Sowery, Boris A. Hadaschik, Alan I. So, Amina Zoubeidi, Ladan Fazli, Antonio Hurtado-Coll, Martin E. Gleave. (2008) Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU International 102:3, 389-397
CrossRef613
Chulso Moon, Jong Chul Park, Young Kwang Chae, Jin Han Yun, Saechul Kim. (2008) Current status of experimental therapeutics for prostate cancer. Cancer Letters 266:2, 116-134
CrossRef614
Paul R. Hutson, Kurt Oettel, Jeff Douglas, Mark Ritter, Ed Messing, Mary Jane Staab, Dona Alberti, Dorthea Horvath, George Wilding. (2008) Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemotherapy and Pharmacology 62:3, 373-377
CrossRef615
Sara De Dosso, Dominik R Berthold. (2008) Docetaxel in the management of prostate cancer: current standard of care and future directions. Expert Opinion on Pharmacotherapy 9:11, 1969-1979
CrossRef616
Josenilson C. Oliveira, Kellen K. Souza, Marília M. Dias, Marcel C. Faria, Eduardo R. Ropelle, Marcelo B. S. Flores, Mirian Ueno, Lício A. Velloso, Sara T. Saad, Mario J. A. Saad, José B. C. Carvalheira. (2008) Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts. Journal of Cancer Research and Clinical Oncology 134:8, 833-839
CrossRef617
C Lin, S Turner, H Gurney, A Peduto. (2008) Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: An effect of improved systemic therapy?. Journal of Medical Imaging and Radiation Oncology 52:4, 376-381
CrossRef618
William C. Zamboni, Sandra Strychor, Erin Joseph, Robert A. Parise, Merrill J. Egorin, Julie L. Eiseman. (2008) Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer Chemotherapy and Pharmacology 62:3, 417-426
CrossRef619
Ruth Warren, Glenn Liu. (2008) ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opinion on Investigational Drugs 17:8, 1237-1245
CrossRef620
Kim N. Chi, Joseph L. Chin, Eric Winquist, Laurence Klotz, Fred Saad, Martin E. Gleave. (2008) Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer. The Journal of Urology 180:2, 565-570
CrossRef621
Jinsang Yoo, Sung-Soo Park, Yong J. Lee. (2008) Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells. Journal of Cellular Biochemistry 104:5, 1636-1646
CrossRef622
Verena Jendrossek, Marco Henkel, Jrg Hennenlotter, Ulrich Vogel, Ute Ganswindt, Ilka Mller, Rene Handrick, Aristoteles G. Anastasiadis, Markus Kuczyk, Arnulf Stenzl, Claus Belka. (2008) Analysis of complex protein kinase B signalling pathways in human prostate cancer samples. BJU International 102:3, 371-382
CrossRef623
Robert Dreicer. (2008) Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations 26:4, 426-429
CrossRef624
Fred Saad. (2008) RESEARCH IN GENITOURINARY ONCOLOGY: THE CANADIAN URO-ONCOLOGY GROUP MULTIDISCIPLINARY MODEL. BJU International 102:1, 7-8
CrossRef625
Hatem A. Azim, Tony Mok. (2008) Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients?? survival and quality of life. Anti-Cancer Drugs 19:6, 645-653
CrossRef626
Marnix G. E. H. Lam, Bernard A. Zonnenberg. (2008) Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases. European Journal of Nuclear Medicine and Molecular Imaging 35:7, 1394-1395
CrossRef627
Michael Rauchenwald, Maria De Santis, Eleonore Fink, Wolfgang Höltl, Gero Kramer, Isabella-Carolina Marei, Hans-Jörg Neumann, Andreas Reissigl, Nikolaus Schmeller, Walter Stackl, Alfred Hobisch, Michael Krainer. (2008) Chemotherapie beim Prostatakarzinom. Wiener klinische Wochenschrift 120:13-14, 440-449
CrossRef628
Fernando J. Bianco. (2008) Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era. Urologic Oncology: Seminars and Original Investigations 26:4, 408-414
CrossRef629
Andrew J. Armstrong, Daniel J. George. (2008) New drug development in metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations 26:4, 430-437
CrossRef630
Maria T.S. Bertilaccio, Matteo Grioni, Brent W. Sutherland, Elena Degl'Innocenti, Massimo Freschi, Elena Jachetti, Norman M. Greenberg, Angelo Corti, Matteo Bellone. (2008) Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. The Prostate 68:10, 1105-1115
CrossRef631
Robert Matthew Strother, Christopher Sweeney. (2008) Lessons learned from development of docetaxel. Expert Opinion on Drug Metabolism & Toxicology 4:7, 1007-1019
CrossRef632
Christopher J. Shepherd, Siân Rizzo, Ioanna Ledaki, Melissa Davies, Daniel Brewer, Gerhardt Attard, Johann de Bono, David L. Hudson. (2008) Expression profiling of CD133 + and CD133 - epithelial cells from human prostate. The Prostate 68:9, 1007-1024
CrossRef633
D. R. Berthold, G. R. Pond, R. de Wit, M. Eisenberger, I. F. Tannock, . (2008) Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Annals of Oncology 19:10, 1749-1753
CrossRef634
P. Hamberg, P.C.M.S. Verhagen, R. de Wit. (2008) When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?. European Journal of Cancer 44:9, 1193-1197
CrossRef635
Tomasz M. Beer, Alshad S. Lalani, Stella Lee, Motomi Mori, Kristine M. Eilers, John G. Curd, W. David Henner, Christopher W. Ryan, Peter Venner, J. Dean Ruether, Kim N. Chi, . (2008) C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer. Cancer 112:11, 2377-2383
CrossRef636
Stuart M. Lichtman, Manpreet K. Boparai. (2008) Anticancer Drug Therapy in the Older Cancer Patient: Pharmacology and Polypharmacy. Current Treatment Options in Oncology 9:2-3, 191-203
CrossRef637
Todd M. Morgan, Tiffany E.M. Pitts, Ted S. Gross, Sandra L. Poliachik, Robert L. Vessella, Eva Corey. (2008) RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. The Prostate 68:8, 861-871
CrossRef638
Michel C. Tchan, Mathew George, Mahiban Thomas. (2008) Metastatic Prostate Cancer Mimicking Primary Osteosarcoma of the Jaw: An Infrequent Clinical Case. Southern Medical Journal 101:6, 657-659
CrossRef639
P Paparel, J Y Chapelon, A Bissery, S Chesnais, L Curiel, A Gelet. (2008) Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study. Prostate Cancer and Prostatic Diseases 11:2, 181-186
CrossRef640
George Lainakis, Antoniou Nikos, Alivizatos Gerassimos, Chrisofos Michael, Mitsoyiannis Iraklis, Livadas Konstantinos, Varkarakis Ioannis, Katsifotis Harilaos, Meletios A. Dimopoulos, Aristotelis Bamias. (2008) Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer. Urology 71:6, 1181-1185
CrossRef641
Marta Santisteban, José Luis Pérez-Gracia, Jaime Ceballos, Isabel Vivas, Jesús García-Foncillas. (2008) Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma. Clinical and Translational Oncology 10:6, 372-374
CrossRef642
Boris A. Hadaschik, Susan Ettinger, Richard D. Sowery, Amina Zoubeidi, Raymond J. Andersen, Michel Roberge, Martin E. Gleave. (2008) Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. International Journal of Cancer 122:10, 2368-2376
CrossRef643
G. Gravis, F. Bladou, N. Salem, A. Goncalves, B. Esterni, J. Walz, S. Bagattini, M. Marcy, S. Brunelle, P. Viens. (2008) Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Annals of Oncology 19:9, 1624-1628
CrossRef644
A. J. Armstrong, E. L. Garrett-Mayer, M. Eisenberger. (2008) Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. JNCI Journal of the National Cancer Institute 100:9, 681-682
CrossRef645
Umberto Basso, Singora Tonti, Catia Bassi, Antonella Brunello, Lara Maria Pasetto, Daniela Scaglione, Cristina Falci, Manuela Beda, Savina Maria Luciana Aversa, Micaela Stefani, Eugenio Castegnaro, Fabio Tamellini, Silvio Monfardini. (2008) Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program. Critical Reviews in Oncology/Hematology 66:2, 163-170
CrossRef646
Jessica Huamani, Christopher Willey, Dinesh Thotala, Kenneth J. Niermann, Michelle Reyzer, Lauren Leavitt, Cameron Jones, Arthur Fleishcher, Richard Caprioli, Dennis E. Hallahan, Dong Wook Nathan Kim. (2008) Differential Efficacy of Combined Therapy With Radiation and AEE788 in High and Low EGFR-Expressing Androgen-Independent Prostate Tumor Models. International Journal of Radiation Oncology*Biology*Physics 71:1, 237-246
CrossRef647
Edward W. Howard, Davy T. Lee, Yung Tuen Chiu, Chee Wai Chua, Xianghong Wang, Yong Chuan Wong. (2008) Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer. International Journal of Cancer 122:9, 1941-1948
CrossRef648
Veshana Ramiah, Daniel J George, Andrew J Armstrong. (2008) Clinical endpoints for drug development in prostate cancer. Current Opinion in Urology 18:3, 303-308
CrossRef649
Robert E Mitchell, Sam S Chang. (2008) Current controversies in the treatment of high-risk prostate cancer. Current Opinion in Urology 18:3, 263-268
CrossRef650
Kazuma Kiyotani, Taisei Mushiroda, Michiaki Kubo, Hitoshi Zembutsu, Yuichi Sugiyama, Yusuke Nakamura. (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Science 99:5, 967-972
CrossRef651
Zhaomei Mu, Paul Hachem, Harvey Hensley, Radka Stoyanova, Hae Won Kwon, Alexandra L. Hanlon, Sudhir Agrawal, Alan Pollack. (2008) Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. The Prostate 68:6, 599-609
CrossRef652
Jeremy P. Cetnar, S. Bruce Malkowicz, Steven C. Palmer, Alan J. Wein, David J. Vaughn. (2008) Pilot Trial of Adjuvant Paclitaxel Plus Estramustine in Resected High-Risk Prostate Cancer. Urology 71:5, 942-946
CrossRef653
Jan-Erik Damber, Gunnar Aus. (2008) Prostate cancer. The Lancet 371:9625, 1710-1721
CrossRef654
Aristotelis Bamias, Meletios A. Dimopoulos. (2008) Editorial Comment on: New treatment approaches for prostate cancer based on peptide analogues. European Urology 53:5, 899-900
CrossRef655
Ased S. M. Ali, Freddie C. Hamdy. (2008) The spectrum of prostate cancer care: From curative intent to palliation. Current Prostate Reports 6:2, 56-63
CrossRef656
Anthony V. D'Amico, Susan Halabi, Robin Vollmer, Marian Loffredo, Elizabeth McMahon, Ben Sanford, Laura Archer, Nicholas J. Vogelzang, Eric J. Small, Philip W. Kantoff. (2008) p53 Protein Expression Status and Recurrence in Men Treated with Radiation and Androgen Suppression Therapy for Higher-Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology 71:5, 933-937
CrossRef657
Michael Perrotti, Todd Doyle, Parvesh Kumar, Daryl McLeod, William Badger, Susan Prater, Michael Moran, Stuart Rosenberg, Cora Bonatsos, Carrie Kreitner, Ralf Kiehl, Theodore Chang, Michael Kolodziej. (2008) Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urologic Oncology: Seminars and Original Investigations 26:3, 276-280
CrossRef658
Robert G. Uzzo, Naomi B. Haas, Paul L. Crispen, Vladimir M. Kolenko. (2008) Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Cancer 112:8, 1660-1671
CrossRef659
Christian Doehn. (2008) Immunotherapy of Prostate Cancer. European Urology 53:4, 681-683
CrossRef660
M.-C. Labarthe, P. Theocharous, N. Russell, S. Todryk, C. Bangma, P. Thraves, A. G. Dalgleish, M. A. Whelan. (2008) A novel murine model of allogeneic vaccination against prostate cancer. Cancer Immunology, Immunotherapy 57:4, 453-465
CrossRef661
Jesús M. Fernández Gómez, Miguel Álvarez Múgica, Antonio Jalón Monzón, Jorge García Rodríguez. (2008) Efectividad de los bisfosfonatos en el cáncer de próstata avanzado. Medicina Clínica 130:12, 459-462
CrossRef662
Nicolas Mottet, Jack A. Schalken, Axel Heidenreich, Patrick J. Bastian, Jacques Irani, Laurent Salomon, Michel Soulié. (2008) Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. European Urology Supplements 7:6, 460-476
CrossRef663
Haruhito Azuma, Takeshi Sakamoto, Satoshi Kiyama, Takanobu Ubai, Yatsugu Kotake, Teruo Inamoto, Kiyoshi Takahara, Yasuichiro Nishimura, Naoki Segawa, Yoji Katsuoka. (2008) Anticancer Effect of Combination Therapy of VP16 and Fosfesterol in Hormone-Refractory Prostate Cancer. American Journal of Clinical Oncology 31:2, 188-194
CrossRef664
Fred Saad. (2008) New research findings on zoledronic acid: Survival, pain, and anti-tumour effects. Cancer Treatment Reviews 34:2, 183-192
CrossRef665
Nicolas Mottet. (2008) Prostate Cancer: When the Hormonal Treatment Is No Longer Working. European Urology Supplements 7:5, 416-421
CrossRef666
Lionel Apetoh, Grégoire Mignot, Theocharis Panaretakis, Guido Kroemer, Laurence Zitvogel. (2008) Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends in Molecular Medicine 14:4, 141-151
CrossRef667
R. Thuret, C. Massard, M. Gross-Goupil, B. Escudier, M. Di Palma, A. Bossi, R. de Crevoisier, A. Chauchereau, K. Fizazi. (2008) The postchemotherapy PSA surge syndrome. Annals of Oncology 19:7, 1308-1311
CrossRef668
S P Blagden, L R Molife, A Seebaran, M Payne, A H M Reid, A S Protheroe, L S Vasist, D D Williams, C Bowen, S J Kathman, J P Hodge, M M Dar, J S de Bono, M R Middleton. (2008) A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. British Journal of Cancer 98:5, 894-899
CrossRef669
Judah Friedman, Rodney L. Dunn, David Wood, Ulka Vaishampayan, Angela Wu, Deborah Bradley, James Montie, Fazlul H. Sarkar, Rajal B. Shah, Maha Hussain. (2008) Neoadjuvant Docetaxel and Capecitabine in Patients With High Risk Prostate Cancer. The Journal of Urology 179:3, 911-916
CrossRef670
Peter Kirkbride, Ian F Tannock. (2008) Trials in palliative treatment—have the goal posts been moved?. The Lancet Oncology 9:3, 186-187
CrossRef671
Ronald de Wit. (2008) Chemotherapy in hormone-refractory prostate cancer. BJU International 101, 11-15
CrossRef672
Anthony R BARNETSON, Christopher MILROSS, Pamela J RUSSELL. (2008) An investigation of fludarabine as a potential radiation sensitizer of human prostate cancer cells in vitro. Asia-Pacific Journal of Clinical Oncology 4:1, 48-54
CrossRef673
Neelima Denduluri, Sandra M Swain. (2008) Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opinion on Investigational Drugs 17:3, 423-435
CrossRef674
Steven Joniau, Hein Van Poppel. (2008) Localized prostate cancer: can we better define who is at risk of unfavourable outcome?. BJU International 101, 5-10
CrossRef675
Patrick J. Bastian. (2008) Re: Limited Tissue Penetration of Taxanes: A Mechanism for Resistance in Solid Tumors. European Urology 53:3, 666-667
CrossRef676
Jean-Pierre Droz, Agnieska Chaladaj. (2008) Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU International 101, 23-29
CrossRef677
B. Paule. (2008) Le traitement des cancers de la prostate hormonorésistants. African Journal of Urology 14:1, 29-36
CrossRef678
Thomas Nelius, Tobias Klatte, Werner Riese, Stephanie Filleur. (2008) Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. International Urology and Nephrology 40:1, 97-104
CrossRef679
Sari Laitinen, Paula M. Martikainen, Teemu Tolonen, Jorma Isola, Teuvo L.J. Tammela, Tapio Visakorpi. (2008) EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. International Journal of Cancer 122:3, 595-602
CrossRef680
Mari Nakabayashi, Oliver Sartor, Susanna Jacobus, Meredith M. Regan, David McKearn, Robert W. Ross, Philip W. Kantoff, Mary-Ellen Taplin, William K. Oh. (2008) Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU International 101:3, 308-312
CrossRef681
Robert W. Ross, Tomasz M. Beer, Susanna Jacobus, Glenn J. Bubley, Mary-Ellen Taplin, Christopher W. Ryan, Jiaoti Huang, William K. Oh, . (2008) A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 112:3, 521-526
CrossRef682
Giuseppe Di Lorenzo. (2008) Editorial Comment on: Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience. European Urology 53:2, 332
CrossRef683
Shinya Sato, Mitsuru Futakuchi, Kumiko Ogawa, Makoto Asamoto, Kimihisa Nakao, Kiyofumi Asai, Tomoyuki Shirai. (2008) Transforming growth factor β derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Science 99:2, 316-323
CrossRef684
Michael J Manyak. (2008) Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Review of Anticancer Therapy 8:2, 175-181
CrossRef685
Ulka Vaishampayan, Maha Hussain. (2008) Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Review of Anticancer Therapy 8:2, 269-281
CrossRef686
Sergio Bracarda. (2008) Editorial Comment on: Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience. European Urology 53:2, 331
CrossRef687
Aristotle Bamias, George Bozas, Nikolaos Antoniou, Iraklis Poulias, Harilaos Katsifotis, Andreas Skolarikos, Dionysios Mitropoulos, Christos Alamanis, Gerassimos Alivizatos, Haralambos Deliveliotis, Meletios A. Dimopoulos. (2008) Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience. European Urology 53:2, 323-332
CrossRef688
Joseph G. Kattan, Fady S. Farhat, Georges Y. Chahine, Fady L. Nasr, Walid T. Moukadem, Fariha C. Younes, Nadine J. Yazbeck, Marwan G. Ghosn, . (2008) Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Investigational New Drugs 26:1, 75-79
CrossRef689
Avishay Sella, Amnon Zisman, Svetlana Kovel, Nirit Yarom, Dany Leibovici, Arie Lindner. (2008) Neoadjuvant Chemohormonal Therapy in Poor-Prognosis Localized Prostate Cancer. Urology 71:2, 323-327
CrossRef690
R A Cox, S Sundar. (2008) Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. British Journal of Cancer 98:1, 238-239
CrossRef691
Tomasz M. Beer, Christopher W. Ryan, Peter M. Venner, Daniel P. Petrylak, Gurkamal S. Chatta, J. Dean Ruether, Kim N. Chi, James Young, W. David Henner, . (2008) Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer. Cancer 112:2, 326-330
CrossRef692
J Shamash, A Davies, W Ansell, S Mcfaul, P Wilson, T Oliver, T Powles. (2008) A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. British Journal of Cancer 98:1, 22-24
CrossRef693
Jeanny B. Aragon-Ching, William L. Dahut. (2008) The Role of Angiogenesis Inhibitors in Prostate Cancer. The Cancer Journal 14:1, 20-25
CrossRef694
Sadao Kamidono, Shinichi Ohshima, Yoshihiko Hirao, Kazuhiro Suzuki, Yoichi Arai, Hiroyuki Fujimoto, Shin Egawa, Hideyuki Akaza, Isao Hara, Shiro Hinotsu, Yoshiyuki Kakehi, Tomonori Hasegawa. (2008) Evidence-based Clinical Practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition). International Journal of Urology 15:1, 1-18
CrossRef695
Richard J Lee, Matthew R Smith. (2008) Osteoclast-targeted therapy for metastatic prostate cancer. Therapy 5:1, 63-72
CrossRef696
Yaacov Richard Lawrence, Adam P Dicker. (2008) Research Highlights. Therapy 5:1, 19-22
CrossRef697
Franklin L. Chen, Andrew J. Armstrong, Daniel J. George. (2008) Cell Signaling Modifiers in Prostate Cancer. The Cancer Journal 14:1, 40-45
CrossRef698
Deborah A. Bradley, Maha Hussain, Cora N. Sternberg. (2008) A new era in prostate cancer therapy: new targets and novel therapeutics. Targeted Oncology 3:1, 31-39
CrossRef699
ES Koh, VT Do, MB Barton. (2008) Cancer care in Australia. Biomedical Imaging and Intervention Journal 4:3,
CrossRef700
Deborah A. Bradley, Maha Hussain. (2008) Promising Novel Cytotoxic Agents and Combinations in Metastatic Prostate Cancer. The Cancer Journal 14:1, 15-19
CrossRef701
Joyson Karakunnel, William Dahut. (2008) Castrate-resistant prostate cancer: the right targets and combinations. Therapy 5:1, 57-61
CrossRef702
Barbara Haley, Eugene Frenkel. (2008) Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and Original Investigations 26:1, 57-64
CrossRef703
Laurence Collette. (2008) Prostate-Specific Antigen (PSA) as a Surrogate End Point for Survival in Prostate Cancer Clinical Trials. European Urology 53:1, 6-9
CrossRef704
Christine S. Chung, Ming-Hui Chen, Jennifer Cullen, David McLeod, Peter Carroll, Anthony V. D’Amico. (2008) Time to Prostate-Specific Antigen Nadir After Androgen Suppression Therapy for Postoperative or Postradiation PSA Failure and Risk of Prostate Cancer-Specific Mortality. Urology 71:1, 136-140
CrossRef705
Mark J McKeage. (2008) The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opinion on Investigational Drugs 17:1, 23-29
CrossRef706
David Robinson, Gabriel Sandblom, Robert Johansson, Hans Garmo, Pär Stattin, Sören Mommsen, Eberhard Varenhorst. (2008) Prediction of Survival of Metastatic Prostate Cancer Based on Early Serial Measurements of Prostate Specific Antigen and Alkaline Phosphatase. The Journal of Urology 179:1, 117-123
CrossRef707
Philip M Arlen. (2008) Novel approaches for the treatment of prostate cancer. Therapy 5:1, 1-2
CrossRef708
Christian Doehn, Torsten Böhmer, Ingo Kausch, Martin Sommerauer, Dieter Jocham. (2008) Prostate Cancer Vaccines. BioDrugs 22:2, 71-84
CrossRef709
Jae Young Joung, In Gab Jeong, Kyung Seok Han, Taek Sang Kim, Seung Ok Yang, Ho Kyung Seo, Jinsoo Chung, Kang Su Cho, Kang Hyun Lee. (2008) Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel. Yonsei Medical Journal 49:5, 775
CrossRef710
Axel Heidenreich, Gunnar Aus, Michel Bolla, Steven Joniau, Vsevolod B. Matveev, Hans Peter Schmid, Filliberto Zattoni. (2008) EAU Guidelines on Prostate Cancer. European Urology 53:1, 68-80
CrossRef711
L Galli, A Fontana, C Galli, L Landi, E Fontana, A Antonuzzo, M Andreuccetti, E Aitini, R Barbieri, R Di Marsico, A Falcone. (2007) Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer. British Journal of Cancer 97:12, 1613-1617
CrossRef712
Guru Sonpavde, Kim N. Chi, Thomas Powles, Christopher J. Sweeney, Noah Hahn, Thomas E. Hutson, Matthew D. Galsky, William R. Berry, Dov Kadmon. (2007) Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 110:12, 2628-2639
CrossRef713
S Steinbild, K Mross, A Frost, R Morant, S Gillessen, C Dittrich, D Strumberg, A Hochhaus, A-R Hanauske, L Edler, I Burkholder, M Scheulen. (2007) A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. British Journal of Cancer 97:11, 1480-1485
CrossRef714
S Gupta, C G Silliman, D L Trump. (2007) Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation. Prostate Cancer and Prostatic Diseases 10:4, 396-397
CrossRef715
G. S. Higgins, G. D. Stewart, S. A. McNeill, D. B. McLaren. (2007) A long and winding road: the role of chemotherapy for hormone-refractory prostate cancer. International Journal of Clinical Practice 61:12, 1964-1965
CrossRef716
S. Chowdhury, S. Burbridge, P. G. Harper. (2007) Chemotherapy for the treatment of hormone-refractory prostate cancer. International Journal of Clinical Practice 61:12, 2064-2070
CrossRef717
Hiroki Mitsuyama, Kent Wallner, Gregory Merrick, Jeffrey Virgin, Peter Orio, Bruce Montgomery, Lawrence D. True. (2007) The Prognostic Significance of Gleason Pattern 5 in Prostate Cancer Patients Treated With Pd-103 Brachytherapy. American Journal of Clinical Oncology 30:6, 597-600
CrossRef718
Sergio Bracarda. (2007) Editorial Comment on: Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study. European Urology 52:6, 1698-1699
CrossRef719
Sophie D. Fosså, Anne-Birgitte Jacobsen, Claes Ginman, Inga N. Jacobsen, Sissel Overn, Jon R. Iversen, Thomas Urnes, Alv A. Dahl, Marijke Veenstra, Berit Sandstad. (2007) Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study. European Urology 52:6, 1691-1699
CrossRef720
B Hindson, S Turner, V Do. (2007) Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer. Australasian Radiology 51:6, 584-588
CrossRef721
James E Ward, Douglas G McNeel. (2007) GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opinion on Biological Therapy 7:12, 1893-1902
CrossRef722
T. Jäger, H. Rübben, C. Börgermann. (2007) Differenzialtherapie des Prostatakarzinoms. Der Internist 48:12, 1382-1388
CrossRef723
Michael J. Morris, W. Kevin Kelly, Susan Slovin, Charles Ryan, Caitlin Eicher, Glenn Heller, Howard I. Scher. (2007) A Phase II Trial of Bortezomib and Prednisone for Castration Resistant Metastatic Prostate Cancer. The Journal of Urology 178:6, 2378-2384
CrossRef724
P. F. Thall, C. Logothetis, L. C. Pagliaro, S. Wen, M. A. Brown, D. Williams, R. E. Millikan. (2007) Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens. JNCI Journal of the National Cancer Institute 99:21, 1613-1622
CrossRef725
Motohide Uemura, Kenji Tamura, Suyoun Chung, Seijiro Honma, Akihiko Okuyama, Yusuke Nakamura, Hidewaki Nakagawa. (2007) Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Science 0:0, 071106234520001-???
CrossRef726
O. Guérin, P. Formento, C. Lo Nigro, P. Hofman, J. L. Fischel, M. C. Etienne-Grimaldi, M. Merlano, J. M. Ferrero, G. Milano. (2007) Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. Journal of Cancer Research and Clinical Oncology 134:1, 51-57
CrossRef727
J Carles, A Font, B Mellado, M Domenech, E Gallardo, J L González-Larriba, G Catalan, J Alfaro, A Gonzalez del Alba, M Nogué, P Lianes, J M Tello. (2007) Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. British Journal of Cancer 97:9, 1206-1210
CrossRef728
Guru Sonpavde, David M. Spencer, Kevin M. Slawin. (2007) Vaccine therapy for prostate cancer. Urologic Oncology: Seminars and Original Investigations 25:6, 451-459
CrossRef729
Daniel Wei Lin. (2007) Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: A multi-institutional pilot study. Urologic Oncology: Seminars and Original Investigations 25:6, 528-529
CrossRef730
Karim Fizazi, Aurelie Le Maitre, Gary Hudes, William R Berry, W Kevin Kelly, Jean-Christophe Eymard, Christopher J Logothetis, Jean-Pierre Pignon, Stefan Michiels. (2007) Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. The Lancet Oncology 8:11, 994-1000
CrossRef731
S. Burbridge, S. Chowdhury, P. G. Harper. (2007) Targeted therapy in hormone refractory prostate cancer. Targeted Oncology 2:4, 235-240
CrossRef732
Michael A. Carducci, Fred Saad, Per-Anders Abrahamsson, David P. Dearnaley, Claude C. Schulman, Scott A. North, Darryl J. Sleep, Jeffrey D. Isaacson, Joel B. Nelson, . (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:9, 1959-1966
CrossRef733
Giuseppe Di Lorenzo. (2007) Estramustine in prostate cancer: new look at an old drug. The Lancet Oncology 8:11, 959-961
CrossRef734
Ramachandran Venkitaraman, Karen Thomas, Robert A. Huddart, Alan Horwich, David P. Dearnaley, Chris C. Parker. (2007) Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU International 0:0, 071017160927007-???
CrossRef735
Dana Rathkopf, Howard I. Scher. 2007. Multidisciplinary Management of Genitourinary Malignancies. .
CrossRef736
Craig P CARDEN, Mark A ROSENTHAL. (2007) Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer. Asia-Pacific Journal of Clinical Oncology 0:0, 071011204603001-???
CrossRef737
Yoshihiro Wada, Ken Kikuchi, Wataru Takahashi, Jiro Honda, Juro Nakanishi, Koichiro Matsumoto, Tomohiro Kuwahara, Nobuyuki Kai, Hiroaki Kikukawa, Shoichi Ueda. (2007) Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer. Cancer Chemotherapy and Pharmacology 61:1, 53-61
CrossRef738
Roberto Petrioli, Alessandra Pascucci, Edoardo Francini, Stefania Marsili, Angela Sciandivasci, Giovanni De Rubertis, Gabriele Barbanti, Antonio Manganelli, Francesco Salvestrini, Guido Francini. (2007) Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU International 100:4, 775-779
CrossRef739
Baptiste Albouy, Jean-Marc Tourani, Patrick Allain, Frederic Rolland, Frederic Staerman, Pascal Eschwege, Christian Pfister. (2007) Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer. BJU International 100:4, 770-774
CrossRef740
Alessandro Sciarra, Stefano Salciccia. (2007) New Treatment Strategies in the Management of Hormone Refractory Prostate Cancer (HRPC): Only Chemotherapy?. European Urology 52:4, 945-947
CrossRef741
C. M. Moinpour, G. W. Donaldson, M. W. Redman. (2007) Do General Dimensions of Quality of Life Add Clinical Value to Symptom Data?. JNCI Monographs 2007:37, 31-38
CrossRef742
Eugeniu Banu, Adela Banu, Jacques Medioni, Eric Levy, Nicolas Thiounn, Arnaud Mejean, Jean-Marie Andrieu, Stephane Oudard. (2007) Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: Modelization using a standardized set of response criteria. The Prostate 67:14, 1543-1549
CrossRef743
Vinod K. Podichetty, Lisa T. Weiss, Gilbert J. Fanciullo, John C. Baird. (2007) Web-based Health Survey Systems in Outcome Assessment and Management of Pain. Pain Medicine 8:s3 Computer and, S189-S198
CrossRef744
Amy M Lin, Eric J Small. (2007) Management of hormone refractory prostate cancer. Current Opinion in Supportive and Palliative Care 1:3, 187-191
CrossRef745
Giuseppe Di Lorenzo, Riccardo Autorino, Sisto Perdonà, Michele De Laurentiis, Massimo D’Armiento, Giuseppe Cancello, Vincenzo Mirone, Ciro Imbimbo, Nicola Longo, Vincenzo Altieri, Gianpaolo Tortora, William D. Figg, Sabino De Placido. (2007) Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study. European Urology 52:4, 1020-1027
CrossRef746
Eric J. Small, Joseph Fontana, Nizar Tannir, Robert S. DiPaola, George Wilding, Mark Rubin, Renee Bailey Iacona, Fairooz F. Kabbinavar. (2007) A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU International 100:4, 765-769
CrossRef747
Philip M. Arlen, Lisa Skarupa, Mary Pazdur, Mahesh Seetharam, Kwong Y. Tsang, Douglas W. Grosenbach, Jarett Feldman, Diane J. Poole, Mary Litzinger, Seth M. Steinberg, Elizabeth Jones, Clara Chen, Jennifer Marte, Howard Parnes, John Wright, William Dahut, Jeffrey Schlom, James L. Gulley. (2007) Clinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy. The Journal of Urology 178:4, 1515-1520
CrossRef748
C.-H. Ohlmann, S. Kohlmorgen, D. Sahi, U. Engelmann, A. Heidenreich. (2007) Letaler Ausgang einer Chemotherapie mit Docetaxel. Der Urologe 46:10, 1425-1427
CrossRef749
Tomasz M. Beer, Celestia S. Higano, Mansoor Saleh, Robert Dreicer, Gary Hudes, Joel Picus, Mark Rarick, Louis Fehrenbacher, Alison L. Hannah. (2007) Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Investigational New Drugs 25:6, 565-570
CrossRef750
Cristina Magi-Galluzzi, Ming Zhou, Alwyn M. Reuther, Robert Dreicer, Eric A. Klein. (2007) Neoadjuvant docetaxel treatment for locally advanced prostate cancer. Cancer 110:6, 1248-1254
CrossRef751
Carlo Leonetti, Annamaria Biroccio, Carmen D'Angelo, Sean. C. Semple, Marco Scarsella, Gabriella Zupi. (2007) Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. The Prostate 67:13, 1475-1485
CrossRef752
Russel S. Taichman, Robert D. Loberg, Rohit Mehra, Kenneth J. Pienta. (2007) The evolving biology and treatment of prostate cancer. Journal of Clinical Investigation 117:9, 2351-2361
CrossRef753
Joaquim Bellmunt, Santiago Albiol, Joan Albanell. (2007) INTERMITTENT CHEMOTHERAPY IN METASTATIC ANDROGEN-INDEPENDENT PROSTATE CANCER. BJU International 100:3, 490-492
CrossRef754
Evan Y Yu, David A Mankoff. (2007) Positron emission tomography imaging as a cancer biomarker. Expert Review of Molecular Diagnostics 7:5, 659-672
CrossRef755
Boris A. Hadaschik, Martin E. Gleave. (2007) Therapeutic options for hormone-refractory prostate cancer in 2007. Urologic Oncology: Seminars and Original Investigations 25:5, 413-419
CrossRef756
R. Bruce Montgomery, Peter S. Nelson, Daniel Lin, Christopher W. Ryan, Mark Garzotto, Tomasz M. Beer. (2007) Diethylstilbestrol and docetaxel. Cancer 110:5, 996-1002
CrossRef757
Paul Mathew, Robert DiPaola. (2007) Taxane Refractory Prostate Cancer. The Journal of Urology 178:3, S36-S41
CrossRef758
Elizabeth HOVEY, Gabriel GABRIEL, Monika GEORGE, Jeremy SHAPIRO, Boris CHERN, Eugene MOYLAN. (2007) Experience with docetaxel in hormone-refractory prostate cancer (HRPC) at three Australian cancer centers: A retrospective study. Asia-Pacific Journal of Clinical Oncology 3:3, 156-162
CrossRef759
Stéphane Culine, Mounira El Demery, Pierre-Jean Lamy, François Iborra, Christophe Avancès, Frédéric Pinguet. (2007) Docetaxel and Cisplatin in Patients With Metastatic Androgen Independent Prostate Cancer and Circulating Neuroendocrine Markers. The Journal of Urology 178:3, 844-848
CrossRef760
Manisha Gupta, Erin Grothey, Ronald Bukowski, Oliver Sartor. (2007) Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL. Clinical Genitourinary Cancer 5:6, 362-370
CrossRef761
Ian D DAVIS, Guy TONER, Adam BROAD, Louise M CAMPANO, Mark ROSENTHAL. (2007) Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer. Asia-Pacific Journal of Clinical Oncology 3:3, 148-155
CrossRef762
Komal RAINA, Rajesh AGARWAL. (2007) Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacologica Sinica 28:9, 1466-1475
CrossRef763
Nicolas Mottet. (2007) Advances in Oncological Urology—the Oncoforum Programme. European Urology Supplements 6:15, 821-828
CrossRef764
Avishay Sella, Cora Sternberg, Svetlana Kovel, Nirit Yarom, Iwona Skoneczna. (2007) Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. BJU International 100:3, 533-535
CrossRef765
C. Börgermann, G. Matnjani, T. Wiegel, S. Krege. (2007) Prostatakarzinom. Der Onkologe 13:9, 840-846
CrossRef766
Deborah A. Bradley, Maha Hussain, Robert S. DiPaola, Philip Kantoff. (2007) Bone Directed Therapies for Prostate Cancer. The Journal of Urology 178:3, S42-S48
CrossRef767
A. Heidenreich, C.H. Ohlmann, E. Özgür, D. Pfister, D. Sahi, D. Thüer, U.H. Engelmann. (2007) Behandlungsoptimierung fortgeschrittener urologischer Malignome. Der Urologe 46:9, 1278-1284
CrossRef768
Gretchen A. Gignac, Michael J. Morris, Maha Hussain. (2007) Castration Resistant, Taxane Naïve Metastatic Prostate Cancer: Current Clinical Approaches and Future Directions. The Journal of Urology 178:3, S30-S35
CrossRef769
Robert J Amato. (2007) 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opinion on Biological Therapy 7:9, 1463-1469
CrossRef770
Victor Valdespino, Panagiotis Tsagozis, Pavel Pisa. (2007) Current perspectives in the treatment of advanced prostate cancer. Medical Oncology 24:3, 273-286
CrossRef771
Agustin A. Garcia, John A. Blessing, Luis Vaccarello, Lynda D. Roman. (2007) Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix. American Journal of Clinical Oncology 30:4, 428-431
CrossRef772
Zhengwang Zhang, Jennifer Stanfield, Eugene Frenkel, Wareef Kabbani, Jer-Tsong Hsieh. (2007) Enhanced Therapeutic Effect on Androgen-Independent Prostate Cancer by Depsipeptide (FK228), a Histone Deacetylase Inhibitor, in Combination with Docetaxel. Urology 70:2, 396-401
CrossRef773
Jeffrey N. Bryan, Matthew R. Keeler, Carolyn J. Henry, Margaret E. Bryan, Allen W. Hahn, Charles W. Caldwell. (2007) A population study of neutering status as a risk factor for canine prostate cancer. The Prostate 67:11, 1174-1181
CrossRef774
J. Wierecky, C. Bokemeyer. (2007) Metastasiertes hormonrefraktäres Prostatakarzinom. Der Onkologe 13:8, 726-731
CrossRef775
Andrea L Harzstark, Eric J Small. (2007) Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge ® ). Expert Opinion on Biological Therapy 7:8, 1275-1280
CrossRef776
Anna-Katharina Thomas-Kaskel, Cornelius F. Waller, Wolfgang Schultze-Seemann, Hendrik Veelken. (2007) Immunotherapy with dendritic cells for prostate cancer. International Journal of Cancer 121:3, 467-473
CrossRef777
Brian M. Alexander, Ming-Hui Chen, Peter Carroll, Anthony V. D’Amico. (2007) Prostate-Specific Antigen Level at Initiation of Hormonal Therapy After Prostate-Specific Antigen Failure Following Prostatectomy or Radiotherapy and Therapeutic Response. Urology 70:2, 320-323
CrossRef778
Jonathan E. Rosenberg, Vivian K. Weinberg, W. Kevin Kelly, Dror Michaelson, Maha H. Hussain, George Wilding, Mitchell Gross, Douglass Hutcheon, Eric J. Small. (2007) Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients. Cancer 110:3, 556-563
CrossRef779
A. Caty, V. Ravery. (2007) Cancer avancé de la prostate et maladie osseuse métastatique. Oncologie 9:7-8, 564-572
CrossRef780
Katja Wosikowski, Lou Lamphere, Gerhard Unteregger, Volker Jung, Faith Kaplan, Jimmy P. Xu, Benno Rattel, Maureen Caligiuri. (2007) Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemotherapy and Pharmacology 60:4, 589-600
CrossRef781
Silvia Romero, Gail Stanton, Joseph DeFelice, Fred Schreiber, Randy Rago, Mayer Fishman. (2007) Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy. Urologic Oncology: Seminars and Original Investigations 25:4, 284-290
CrossRef782
Douglas G. McNeel. (2007) Cellular immunotherapies for prostate cancer. Biomedicine & Pharmacotherapy 61:6, 315-322
CrossRef783
Anthony V. D'Amico, Ming-Hui Chen, William J. Catalona, Leon Sun, Kimberly A. Roehl, Judd W. Moul. (2007) Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110:1, 56-61
CrossRef784
Michael Koutsilieris, Theodore Dimopoulos, Constantine Milathianakis, John Bogdanos, Dimitrios Karamanolakis, Nicholas Pissimissis, Antonis Halapas, Peter Lembessis, Andreas Papaioannou, Antigone Sourla. (2007) Combination of somatostatin analogues and dexamethasone (antisurvival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. BJU International 100:s2 Prostate Can, 60-62
CrossRef785
C Y-F Lee, L X Bu, P S Rennie, W W-G Jia. (2007) An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Therapy 14:7, 652-660
CrossRef786
B. Alt-Epping, W. Jung, F. Nauck. (2007) Symptomkontrollierende Effekte der Chemotherapie. Der Onkologe 13:7, 619-624
CrossRef787
Shawn Malone, Gad Perry, Libni Eapen, Roanne Segal, Victor Gallant, Simone Dahrouge, Juanita Crook, Johanna N. Spaans. (2007) Mature Results of the Ottawa Phase II Study of Intermittent Androgen-Suppression Therapy in Prostate Cancer: Clinical Predictors of Outcome. International Journal of Radiation Oncology*Biology*Physics 68:3, 699-706
CrossRef788
S. Krege, M. Schenck. (2007) Urologische Aspekte in der Palliativmedizin. Der Onkologe 13:7, 602-608
CrossRef789
Sten Nilsson, Lars Franzén, Christopher Parker, Christopher Tyrrell, René Blom, Jan Tennvall, Bo Lennernäs, Ulf Petersson, Dag C Johannessen, Michael Sokal, Katharine Pigott, Jeffrey Yachnin, Michael Garkavij, Peter Strang, Johan Harmenberg, Bjørg Bolstad, Øyvind S Bruland. (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The Lancet Oncology 8:7, 587-594
CrossRef790
Lisa G. Horvath, Jayne E. Lelliott, James G. Kench, C.-Soon Lee, Elizabeth D. Williams, Darren N. Saunders, John J. Grygiel, Robert L. Sutherland, Susan M. Henshall. (2007) Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. The Prostate 67:10, 1081-1090
CrossRef791
Manfred P. Wirth. (2007) Hormone-refractory prostate cancer: what have we learned?. BJU International 100:s2 Prostate Can, 56-59
CrossRef792
Mike D Shelley, Malcolm D Mason. (2007) Radium-223 for men with hormone-refractory prostate cancer and bone metastases. The Lancet Oncology 8:7, 564-565
CrossRef793
Bob Djavan. (2007) Editorial. BJU International 100:s2 Prostate Can, 1-1
CrossRef794
Agnieszka Morgenroth, Marc Cartellieri, Marc Schmitz, Serap Günes, Bernd Weigle, Michael Bachmann, Hinrich Abken, Ernst Peter Rieber, Achim Temme. (2007) Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. The Prostate 67:10, 1121-1131
CrossRef795
Masashi Takeda, Atsushi Mizokami, Kiminori Mamiya, You Qiang Li, Jian Zhang, Evan T. Keller, Mikio Namiki. (2007) The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. The Prostate 67:9, 955-967
CrossRef796
Sergio Ricci, Giuseppe Boni, Ilaria Pastina, Dario Genovesi, Claudia Cianci, Serena Chiacchio, Cinzia Orlandini, Mariano Grosso, Abedallatif AlSharif, Aldo Chioni, Samantha Donato, Francesco Francesca, Cesare Selli, Domenico Rubello, Giuliano Mariani. (2007) Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 34:7, 1023-1030
CrossRef797
Isabella Chiappino, Paolo Destefanis, Alfredo Addeo, Alessandra Galetto, Giuseppina Cucchiarale, Fernando Munoz, Andrea Zitella, Ugo Ferrando, Dario Fontana, Umberto Ricardi, Alessandro Tizzani, Oscar Bertetto. (2007) Activity of Weekly Paclitaxel in Advanced Hormone-Refractory Prostate Cancer. American Journal of Clinical Oncology 30:3, 234-238
CrossRef798
Michael Krainer, Sandra Tomek, Katarzyna Elandt, Peter Horak, Walter Albrecht, Michael Eisenmenger, Wolfgang Höltl, Paul Schramek, Walter Stackl, Christoph Zielinski, Jochen Reibenwein. (2007) A Prospective, Open Label, Randomized Phase II Trial of Weekly Docetaxel Versus Weekly Vinorelbine as First Line Chemotherapy in Patients With Androgen Independent Prostate Cancer. The Journal of Urology 177:6, 2141-2145
CrossRef799
Rami Ben-Yosef, Alex Starr, Victoria Karaush, Vered Loew, Shahar Lev-Ari, Itay Barnea, Ghalib Lidawi, Alexander Shtabsky, Yoel Greif, Yosef Yarden, Akiva Vexler. (2007) ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. The Prostate 67:8, 871-880
CrossRef800
L. Michael Glode. (2007) Editorial Comment. The Journal of Urology 177:6, 2140
CrossRef801
Richard Khafagy, David Shackley, Joanne Samuel, Kieran O'Flynn, Chris Betts, Noel Clarke. (2007) Complications Arising in the Final Year of Life in Men Dying from Advanced Prostate Cancer. Journal of Palliative Medicine 10:3, 705-711
CrossRef802
Ian R. Logan, Hesta V. McNeill, Susan Cook, Xiaohong Lu, John Lunec, Craig N. Robson. (2007) Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. The Prostate 67:8, 900-906
CrossRef803
Ian Thompson, James Brantley Thrasher, Gunnar Aus, Arthur L. Burnett, Edith D. Canby-Hagino, Michael S. Cookson, Anthony V. D’Amico, Roger R. Dmochowski, David T. Eton, Jeffrey D. Forman, S. Larry Goldenberg, Javier Hernandez, Celestia S. Higano, Stephen R. Kraus, Judd W. Moul, Catherine M. Tangen. (2007) Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update. The Journal of Urology 177:6, 2106-2131
CrossRef804
N.V. Rajeshkumar, George Matwyshyn, Anil Gulati. (2007) IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats. The Prostate 67:7, 701-713
CrossRef805
Chia-Chi Lin, Chih-Hung Hsu, Tzyh-Chyuan Hour, Ann-Lii Cheng, Chao-Yuan Huang, Kuo-How Huang, Jun Chen, Yeong-Shiau Pu. (2007) Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial. Urologic Oncology: Seminars and Original Investigations 25:3, 207-213
CrossRef806
Nobuyuki Kikuno, Shinji Urakami, Shigeru Nakamura, Takeo Hiraoka, Taijyu Hyuga, Naoko Arichi, Kouji Wake, Masahiro Sumura, Tatsuaki Yoneda, Hirofumi Kishi, Kazushi Shigeno, Hiroaki Shiina, Mikio Igawa. (2007) Phase-II Study of Docetaxel, Estramustine Phosphate, and Carboplatin in Patients with Hormone-Refractory Prostate Cancer. European Urology 51:5, 1252-1258
CrossRef807
Otis W. Brawley, Ashesh B. Jani, Veraj Master. (2007) Prostate Cancer and Race. Current Problems in Cancer 31:3, 211-225
CrossRef808
. (2007) Chemotherapie bij hormoonrefractair prostaatcarcinoom. Huisarts en Wetenschap 50:5, 361-362
CrossRef809
B.A. Hadaschik, S.W. Melchior, R.D. Sowery, A.I. So, M.E. Gleave. (2007) Stressproteine bei der Pathogenese des Prostatakarzinoms. Der Urologe 46:5, 516-520
CrossRef810
Bertrand Tombal. (2007) Docetaxel and Beyond. European Urology 51:5, 1159-1161
CrossRef811
Patrick W. Sullivan, Parvez M. Mulani, Mayer Fishman, Darryl Sleep. (2007) Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Quality of Life Research 16:4, 571-575
CrossRef812
Adam S. Kibel, Eli Rosenbaum, Michael W. Kattan, Joel Picus, Robert Dreicer, Eric A. Klein, Gurkamal S. Chatta, Joel B. Nelson, Robert S. DiPaola, Bruce J. Roth, Michael S. Cookson, George Wilding, David F. Jarrard, Tomasz M. Beer, Christopher W. Ryan, Daniel P. Petrylak, Mitchell C. Benson, Alan W. Partin, Elizabeth Garrett-Mayer, Mario A. Eisenberger. (2007) Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study. The Journal of Urology 177:5, 1777-1781
CrossRef813
William D. Figg, Haiqing Li, Tristan Sissung, Avi Retter, Shenhong Wu, James L. Gulley, Phil Arlen, John J. Wright, Howard Parnes, Kathy Fedenko, Lea Latham, Seth M. Steinberg, Elizabeth Jones, Clara Chen, William Dahut. (2007) Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU International 99:5, 1047-1055
CrossRef814
Kazunori Namiki, Charles J Rosser. (2007) Neoadjuvant therapy and prostate cancer: what a urologist should know. Current Opinion in Urology 17:3, 188-193
CrossRef815
Ravi A Madan, Ron Lieberman, James L Gulley, William Dahut, Philip M Arlen. (2007) Significant Prostate-Specific Antigen (PSA) Response to Low-Dose Ketoconazole in a Patient With Non-Metastatic Androgen-Independent Prostate Cancer (AIPC) and a Review of the Literature. American Journal of Therapeutics 14:3, 310-313
CrossRef816
Jonathan A Storey, Frank M Torti. (2007) Bone metastases in prostate cancer: a targeted approach. Current Opinion in Oncology 19:3, 254-258
CrossRef817
Douglas G McNeel. (2007) Prostate cancer immunotherapy. Current Opinion in Urology 17:3, 175-181
CrossRef818
Bulent Akduman, E. David Crawford. (2007) Bone metabolism and new targets for intervention. Current Urology Reports 8:3, 233-238
CrossRef819
A S Kibel, J B Nelson. (2007) Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy. Prostate Cancer and Prostatic Diseases 10:2, 119-126
CrossRef820
Thomas W. Flaig, Lih-Jen Su, Gail Harrison, Rajesh Agarwal, Leonard Michael Glodé. (2007) Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. International Journal of Cancer 120:9, 2028-2033
CrossRef821
Bulent Akduman, E. David Crawford. (2007) Bone metabolism and new targets for intervention. Current Prostate Reports 5:2, 55-60
CrossRef822
Ased S. M. Ali, Freddie C. Hamdy. (2007) The spectrum of prostate cancer care: From curative intent to palliation. Current Urology Reports 8:3, 245-252
CrossRef823
Boris A Hadaschik, Richard D Sowery, Martin E Gleave. (2007) Novel targets and approaches in advanced prostate cancer. Current Opinion in Urology 17:3, 182-187
CrossRef824
A. González-Martín, E. Fernández, M. A. Vaz, J. Burgos, M. López García, R. Rodríguez Patrón, C. Guillén, T. Mayayo, A. Allona, F. Arias, A. Moyano. (2007) Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients. Clinical and Translational Oncology 9:5, 323-328
CrossRef825
Daniel P. Petrylak. (2007) Clinical trials in metastatic hormone-refractory prostate cancer: Improving docetaxel therapy by targeting bone-related growth factors. Current Oncology Reports 9:3, 211-212
CrossRef826
Arne Berg, Aasmund Berner, Wolfgang Lilleby, Øyvind S. Bruland, Sophie D. Fosså, Jahn M. Nesland, Gunnar Kvalheim. (2007) Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. International Journal of Cancer 120:8, 1603-1609
CrossRef827
Anthony V. D'Amico, David G. McLeod, Peter R. Carroll, Jennifer Cullen, Ming-Hui Chen. (2007) Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer 109:7, 1290-1295
CrossRef828
Stefan Kudlacek, Johannes G. Meran, Dora Beke. (2007) Das hormonrefraktäre Prostatakarzinom – eine internistische Herausforderung. Wiener Medizinische Wochenschrift 157:7-8, 145-148
CrossRef829
Damien Pouessel, Blandine Gallet, Frédéric Bibeau, Christophe Avancès, François Iborra, Pierre Sénesse, Stéphane Culine. (2007) Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU International 99:4, 807-811
CrossRef830
Christoph Wiesner, R. Daniel Bonfil, Zhong Dong, Hamilto Yamamoto, Sanaa M. Nabha, Hong Meng, Allen Saliganan, Aaron Sabbota, Michael L. Cher. (2007) Heterogeneous Activation of MMP-9 Due to Prostate Cancer-Bone Interaction. Urology 69:4, 795-799
CrossRef831
B. Hildenbrand, B. Sauer, O. Kalis, C. Stoll, M.A. Freudenberg, G. Niedermann, J.M. Giesler, E. Jüttner, J.H. Peters, B. Häring, R. Leo, C. Unger, M. Azemar. (2007) Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells—A pilot study. The Prostate 67:5, 500-508
CrossRef832
Huei-Ju Ting, Jeffery Hsu, Bo-Yin Bao, Yi-Fen Lee. (2007) Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1α,25-dihydroxyvitamin D3. Cancer Letters 247:1, 122-129
CrossRef833
Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani, Frédéric Staerman, Claude C Schulman. (2007) What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006. European Urology Supplements 6:4, 404-412
CrossRef834
Mari Nakabayashi, Jonathan Ling, Wanling Xie, Meredith M. Regan, William K. Oh. (2007) Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer. The Cancer Journal 13:2, 125-129
CrossRef835
A. Chaladaj, C. Terret, G. Albrand, P. Courpron, J. -P. Droz. (2007) Quelle évaluation gérontologique faut-il utiliser pour les essais multicentriques?. Oncologie 9:3, 186-191
CrossRef836
Hazel Templeton. (2007) Prostate cancer ? presentation, diagnosis and treatment: what does the literature say?. International Journal of Urological Nursing 1:1, 6-17
CrossRef837
Shenhong L. Wu, Elizabeth Jones, James L. Gulley, Philip M. Arlen, Clara C. Chen, William D. Figg, William L. Dahut. (2007) Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. BJU International 99:3, 525-528
CrossRef838
Walter Stadler. (2007) Fuzzy thinking on biomarkers. Urologic Oncology: Seminars and Original Investigations 25:2, 97-100
CrossRef839
Laurence Klotz, Koichiro Akakura, David Gillatt, Eduardo Solsona, Bertrand Tombal. (2007) Advanced Prostate Cancer: Hormones and Beyond. European Urology Supplements 6:3, 354-364
CrossRef840
Manisha Gupta, Erin Grothey, Tara Gibson, Oliver Sartor. (2007) Highlights from: The 2007 Prostate Cancer Symposium, February 22–24, 2007; Orlando, FL. Clinical Genitourinary Cancer 5:4, 249-255
CrossRef841
Amy M. Lin, Charles J. Ryan, Eric J. Small. (2007) Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Critical Reviews in Oncology/Hematology 61:3, 243-254
CrossRef842
Eric C Nelson, Angelo J Cambio, Joy C Yang, Primo N Lara, Christopher P Evans. (2007) Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nature Clinical Practice Urology 4:2, 82-94
CrossRef843
Fred Saad, Cora N Sternberg. (2007) Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nature Clinical Practice Urology 4, S3-S13
CrossRef844
Giuseppe Di Lorenzo, Riccardo Autorino, Mario Giuliano, Emilio Morelli, Antonio Giordano, Giorgio Napodano, Aniello Russo, Giuseppe Benincasa, Massimino D’Armiento, Vincenzo Altieri, Sabino De Placido. (2007) Phase II Trial of Gemcitabine, Prednisone, and Zoledronic Acid in Pretreated Patients with Hormone Refractory Prostate Cancer. Urology 69:2, 347-351
CrossRef845
Andrea Marrari, Manuela Iero, Lorenzo Pilla, Sergio Villa, Roberto Salvioni, Riccardo Valdagni, Giorgio Parmiani, Licia Rivoltini. (2007) Vaccination therapy in prostate cancer. Cancer Immunology, Immunotherapy 56:4, 429-445
CrossRef846
Mark Pomerantz, Philip Kantoff. (2007) Advances in the Treatment of Prostate Cancer. Annual Review of Medicine 58:1, 205-220
CrossRef847
Val??rie Martinez, Olivier Mir, Julien D??mont, Didier Bouscary, Fran??ois Goldwasser. (2007) Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer. Anti-Cancer Drugs 18:2, 233-235
CrossRef848
John Anderson, Hein Van Poppel, Joaquim Bellmunt, Kurt Miller, Jean-Pierre Droz, John M. Fitzpatrick. (2007) Chemotherapy for older patients with prostate cancer. BJU International 99:2, 269-273
CrossRef849
Andrea Mancuso, Stephan Oudard, Cora N. Sternberg. (2007) Effective chemotherapy for hormone-refractory prostate cancer (HRPC): Present status and perspectives with taxane-based treatments. Critical Reviews in Oncology/Hematology 61:2, 176-185
CrossRef850
William K. Oh, Miah-Hiang Tay, Jiaoti Huang. (2007) Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?. Cancer 109:3, 477-486
CrossRef851
Janet R. Walczak, Michael A. Carducci. (2007) Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease. Mayo Clinic Proceedings 82:2, 243-249
CrossRef852
J. R. Walczak, M. A. Carducci. (2007) Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease. Mayo Clinic Proceedings 82:2, 243-249
CrossRef853
Michel B. Choueiri, Shi-Ming Tu, Li-Yuan Yu-Lee, Sue-Hwa Lin. (2007) The central role of osteoblasts in the metastasis of prostate cancer. Cancer and Metastasis Reviews 25:4, 601-609
CrossRef854
Maria Nieto, Stephen Finn, Massimo Loda, William C. Hahn. (2007) Prostate cancer: Re-focusing on androgen receptor signaling. The International Journal of Biochemistry & Cell Biology 39:9, 1562-1568
CrossRef855
Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson. (2007) Looking Back at PCPT: Looking Forward to New Paradigms in Prostate Cancer Screening and Prevention. European Urology 51:1, 27-33
CrossRef856
Steven B Zeliadt, David F Penson. (2007) Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer. PharmacoEconomics 25:4, 309-327
CrossRef857
CORA N. STERNBERG, MICHAEL KRAINER, WILLIAM K. OH, SERGIO BRACARDA, JOAQUIM BELLMUNT, HALUK OZEN, ALEXANDRE ZLOTTA, TOMASZ M. BEER, STEPHANE OUDARD, MICHAEL RAUCHENWALD, IWONA SKONECZNA, MARKUS M. BORNER, JOHN M. FITZPATRICK. (2007) The medical management of prostate cancer: a multidisciplinary team approach. BJU International 99:1, 22-27
CrossRef858
T. Maurer, M. Retz, J.E. Gschwend. (2007) Palliative und supportive Therapie bei Patienten mit fortgeschrittenem Prostatakarzinom. Der Urologe 46:1, 30-35
CrossRef859
John Pendleton, Louis L. Pisters, Kogenta Nakamura, Satoshi Anai, Charles J. Rosser. (2007) Neoadjuvant therapy before radical prostatectomy: Where have we been? Where are we going?. Urologic Oncology: Seminars and Original Investigations 25:1, 11-18
CrossRef860
I. Alexandre, O. Rixe. (2007) C??ncer de pr??stata hormonorresistente. EMC - Urolog??a 39:2, 1-7
CrossRef861
Fabio Calabrò, Cora N. Sternberg. (2007) Current Indications for Chemotherapy in Prostate Cancer Patients. European Urology 51:1, 17-26
CrossRef862
Giuseppe Di Lorenzo, Riccardo Autorino, William D Figg, Sabino De Placido. (2007) Hormone-Refractory Prostate Cancer. Drugs 67:8, 1109-1124
CrossRef863
Richard D. Sowery, Alan I. So, Martin E. Gleave. (2007) Therapeutic options in advanced prostate cancer: Present and future. Current Urology Reports 8:1, 53-59
CrossRef864
Michael Basler, Marcus Groettrup. (2007) Advances in Prostate Cancer Immunotherapies. Drugs & Aging 24:3, 197-221
CrossRef865
Roberto Petrioli, Loretta Paolelli, Edoardo Francini, Antonio Manganelli, Francesco Salvestrini, Guido Francini. (2007) Weekly Docetaxel and Epirubicin in Treatment of Advanced Hormone-Refractory Prostate Cancer. Urology 69:1, 142-146
CrossRef866
Luigi Dogliotti. (2007) Advanced Prostate Cancer: At Last a Role for Medical Oncologists. European Urology 51:1, 4-5
CrossRef867
Kyung Seok Han, Kang Su Cho, Seung Hwan Lee, Sung Joon Hong. (2007) Estramustine Phosphate Based Chemotherapy for Hormone Refractory Prostate Cancer. Korean Journal of Urology 48:7, 684
CrossRef868
Mark J McKeage. (2007) Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types. Drugs 67:6, 859-869
CrossRef869
Christopher Sweeney. (2006) The Case for Systemic Therapy Alone for Prostate Cancer. The Journal of Urology 176:6, S42-S46
CrossRef870
P. Paula Hruska, Joel Picus. (2006) The role of primary chemotherapy for prostate cancer: Has the time come?. Current Prostate Reports 4:4, 157-162
CrossRef871
Ying Waeckerle-Men, Edith Uetz-von Allmen, Markus Fopp, Roger Moos, Christel Böhme, Hans-Peter Schmid, Daniel Ackermann, Thomas Cerny, Burkhard Ludewig, Marcus Groettrup, Silke Gillessen. (2006) Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunology, Immunotherapy 55:12, 1524-1533
CrossRef872
Anthony V. D’Amico, Ming Hui-Chen, Andrew A. Renshaw, Brenda Sussman, Kimberly A. Roehl, William J. Catalona. (2006) Identifying Men Diagnosed With Clinically Localized Prostate Cancer Who are at High Risk for Death From Prostate Cancer. The Journal of Urology 176:6, S11-S15
CrossRef873
Mark T Fleming, Michael J Morris, Glenn Heller, Howard I Scher. (2006) Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nature Clinical Practice Oncology 3:12, 658-667
CrossRef874
Henry K. Tsai, Ming-Hui Chen, David G. McLeod, Peter R. Carroll, Jerome P. Richie, Anthony V. D'Amico. (2006) Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 107:11, 2597-2603
CrossRef875
L. Michael Glodé. (2006) The Case for Adjuvant Therapy for Prostate Cancer. The Journal of Urology 176:6, S30-S33
CrossRef876
Jian Wang, Syed M. Abbas Rizvi, Michele C. Madigan, Paul J. Cozzi, Carl A. Power, Chang F. Qu, Alfred Morgenstern, Christos Apostolidis, Pamela J. Russell, Barry J. Allen, Yong Li. (2006) Control of prostate cancer spheroid growth using213Bi-labeled multiple targeted α radioimmunoconjugates. The Prostate 66:16, 1753-1767
CrossRef877
Aimee Lucas, Daniel P. Petrylak. (2006) The Case for Early Chemotherapy for the Treatment of Metastatic Disease. The Journal of Urology 176:6, S72-S75
CrossRef878
Timothy C. Brand, Anthony W. Tolcher. (2006) Management of High Risk Metastatic Prostate Cancer: The Case for Novel Therapies. The Journal of Urology 176:6, S76-S80
CrossRef879
Anna-K. Thomas-Kaskel, Robert Zeiser, Rosa Jochim, Christian Robbel, Wolfgang Schultze-Seemann, Cornelius F. Waller, Hendrik Veelken. (2006) Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. International Journal of Cancer 119:10, 2428-2434
CrossRef880
L. Weißbach, J. Riese. (2006) Off-Label-Use in der Onkologie: ein Thema ohne Ende?!. Der Urologe 45:11, 1410-1414
CrossRef881
T. Böhmer, C. Doehn. (2006) Vakzinetherapie des Prostatakarzinoms mit autologen dendritischen Zellen zeigt Überlebensvorteil. Der Onkologe 12:11, 1150-1152
CrossRef882
Tanya B Dorff, Marcus L Quek, Siamak Daneshmand, Jacek Pinski. (2006) Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Review of Anticancer Therapy 6:11, 1639-1651
CrossRef883
Janos Nadas, Duxin Sun. (2006) Anthracyclines as effective anticancer drugs. Expert Opinion on Drug Discovery 1:6, 549-568
CrossRef884
Patrick W. Sullivan, Joel B. Nelson, Parvez M. Mulani, Darryl Sleep. (2006) Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Quality of Life Research 15:8, 1297-1306
CrossRef885
Mike Shelley, Craig Harrison, Bernadette Coles, John Stafforth, Timothy Wilt, Malcolm Mason, Mike Shelley. 2006. Chemotherapy for hormone-refractory prostate cancer. .
CrossRef886
G Attard, D Sarker, A Reid, R Molife, C Parker, J S de Bono. (2006) Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. British Journal of Cancer 95:7, 767-774
CrossRef887
S G Patterson, S Wei, X Chen, D A Sallman, D L Gilvary, B Zhong, J Pow-Sang, T Yeatman, J Y Djeu. (2006) Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25:45, 6113-6122
CrossRef888
Colby L. Eaton, Kate D. Linton, Freddie C. Hamdy. 2006. Bone-Directed Therapy in Prostate Cancer: Rationale and Novel Approaches. , 223-236.
CrossRef889
Michael J. Morris, Howard I. Scher, Neeta Pandit-Taksar, Chaitanya Divgi, Steven Larson. 2006. Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer. , 291-313.
CrossRef890
William D. Figg, Michael C. Cox, Tania Alachalabi, William L. Dahut. 2006. Angiogenesis Inhibitors in Prostate Cancer. , 127-141.
CrossRef891
Danish Mazhar, Sarah Ngan, Jonathan Waxman. (2006) Improving outcomes in early prostate cancer: Part I ? adjuvant treatment. BJU International 98:4, 725-730
CrossRef892
Henry T. Tsai, Jonathan W. Simons. 2006. Gene Therapy and Novel Clinical Trial Design. , 103-125.
CrossRef893
Jacques-Pierre Moreau, Patrick Delavault, Joëlle Blumberg. (2006) Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy. Clinical Therapeutics 28:10, 1485-1508
CrossRef894
Teresita Reiner, Alicia de las Pozas, Carlos Perez-Stable. (2006) Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Gγ/T-15 transgenic mouse model of prostate cancer. The Prostate 66:14, 1487-1497
CrossRef895
Michael J Morris. (2006) Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study. Nature Clinical Practice Oncology 3:10, 536-537
CrossRef896
Arif Hussain, Richard Schraeder. 2006. Other Novel Therapies. , 281-289.
CrossRef897
Rebecca A. Moss, Daniel P. Petrylak. (2006) Cytotoxic chemotherapy for prostate cancer: Who and when?. Current Treatment Options in Oncology 7:5, 370-377
CrossRef898
Shinya Yamamoto, Jyunji Yonese, Satoru Kawakami, Tetsuro Tsukamoto, Yuhei Ohkubo, Manabu Tatokoro, Iwao Fukui. (2006) Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer. International Journal of Clinical Oncology 11:4, 326-328
CrossRef899
Jonathan W. Simons, Natalie Sacks. (2006) Granulocyte-macrophage colony-stimulating factor−transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancer. Urologic Oncology: Seminars and Original Investigations 24:5, 419-424
CrossRef900
Mario Eisenberger. (2006) Treatment of Prostate Cancer in the 21st Century—Future Directions. European Urology Supplements 5:15, 824-829
CrossRef901
Ross C. Semeniuk, Peter M. Venner, Scott North. (2006) Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 68:3, 565-569
CrossRef902
Noel W. Clarke. (2006) Management of the Spectrum of Hormone Refractory Prostate Cancer. European Urology 50:3, 428-439
CrossRef903
N D James, D Bloomfield, C Luscombe. (2006) The changing pattern of management for hormone-refractory, metastatic prostate cancer. Prostate Cancer and Prostatic Diseases 9:3, 221-229
CrossRef904
Mari Nakabayashi, Wanling Xie, Meredith M. Regan, David M. Jackman, Philip W. Kantoff, William K. Oh. (2006) Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 107:5, 975-981
CrossRef905
Peter Jochen Olbert, Axel Hegele, Petra Kraeuter, Axel Heidenreich, Rainer Hofmann, Andres Jan Schrader. (2006) Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anti-Cancer Drugs 17:8, 993-996
CrossRef906
THOMAS NELIUS, TOBIAS KLATTE, RON YAP, THOMAS KALINSKI, ALBRECHT ROPKE, STEPHANIE FILLEUR, ERNST P. ALLHOFF. (2006) A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU International 98:3, 580-585
CrossRef907
Ronald de Wit. (2006) New Hope for Patients with Metastatic Hormone-Refractory Prostate Cancer. European Urology Supplements 5:15, 817-823
CrossRef908
Sas Barmoshe, Alexandre R Zlotta. (2006) Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. Expert Opinion on Pharmacotherapy 7:13, 1685-1699
CrossRef909
Amy M. Lin, Robert M. Hershberg, Eric J. Small. (2006) Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urologic Oncology: Seminars and Original Investigations 24:5, 434-441
CrossRef910
Charles J. Ryan, Eric P. Elkin, Eric J. Small, Janeen Duchane, Peter Carroll. (2006) Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CaPSURE™. Urologic Oncology: Seminars and Original Investigations 24:5, 396-402
CrossRef911
Rosendo So-Rosillo, Eric J Small. (2006) Sipuleucel-T (APC8015) for prostate cancer. Expert Review of Anticancer Therapy 6:9, 1163-1167
CrossRef912
R Collins, R Trowman, G Norman, K Light, A Birtle, E Fenwick, S Palmer, R Riemsma. (2006) A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. British Journal of Cancer 95:4, 457-462
CrossRef913
Jean-Marc Ferrero, Emmanuel Chamorey, Stephane Oudard, Sabine Dides, Gerard Lesbats, Gerard Cavaglione, Pierre Nouyrigat, Cyril Foa, Regis Kaphan. (2006) Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 107:4, 738-745
CrossRef914
Yoshifumi Takei, Kenji Kadomatsu, Tatsunori Goto, Takashi Muramatsu. (2006) Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 107:4, 864-873
CrossRef915
J. M. O’Sullivan, A. R. Norman, V. R. McCready, G. Flux, F. M. Buffa, B. Johnson, J. Coffey, G. Cook, J. Treleaven, A. Horwich, R. A. Huddart, C. C. Parker, D. P. Dearnaley. (2006) A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. European Journal of Nuclear Medicine and Molecular Imaging 33:9, 1055-1061
CrossRef916
Victoria J. Sinibaldi, Kathy Elza-Brown, Jill Schmidt, Mario A. Eisenberger, Eli Rosenbaum, Samuel R. Denmeade, Roberto Pili, Janet Walczak, Sharyn D. Baker, Marianna Zahurak, Michael A. Carducci. (2006) Phase II Evaluation of Docetaxel Plus Exisulind in Patients With Androgen Independent Prostate Carcinoma. American Journal of Clinical Oncology 29:4, 395-398
CrossRef917
JOHN S. LAM, DAVID B. SELIGSON, HONG YU, AI LI, MERVI EEVA, ALLAN J. PANTUCK, GANG ZENG, STEVE HORVATH, ARIE S. BELLDEGRUN. (2006) Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU International 98:2, 445-451
CrossRef918
Malcolm Mason. (2006) What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?. Journal of Cancer Research and Clinical Oncology 132:S1, 27-35
CrossRef919
Neesha A. Rodrigues, Ming-Hui Chen, William J. Catalona, Kimberly A. Roehl, Jerome P. Richie, Anthony V. D'Amico. (2006) Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer 107:3, 514-520
CrossRef920
Robert Dreicer. (2006) Chemotherapy for Advanced Prostate Cancer: Docetaxel and Beyond. Hematology/Oncology Clinics of North America 20:4, 935-946
CrossRef921
Gregory P. Swanson, James Faulkner, Stephen R. Smalley, Mark J. Noble, Ronald L. Stephens, Timothy J. O’Rourke, Geoffrey R. Weiss, Donald P. Quick, Ian M. Thompson, E. David Crawford. (2006) Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024. The Journal of Urology 176:2, 548-553
CrossRef922
Damian A. Laber, Shawn D. Glisson, Jeffery B. Hargis, Rodney E. Kosfeld, George Goldsmith, Alfonso Cervera, Renato V. La Rocca. (2006) A Phase II Study of Higher Dose Docetaxel in Androgen-Independent Prostate Cancer. American Journal of Clinical Oncology 29:4, 389-394
CrossRef923
Sameer A. Siddiqui, Brant A. Inman, Shomik Sengupta, Jeffrey M. Slezak, Eric J. Bergstralh, Bradley C. Leibovich, Horst Zincke, Michael L. Blute. (2006) Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer 107:3, 521-529
CrossRef924
John P. O'Neill, Chidambaram Natesa Velalar, Dong Ik Lee, Bin Zhang, Takeo Nakanishi, Yao Tang, Florin Selaru, Douglas Ross, Stephen J. Meltzer, Arif Hussain. (2006) Thapsigargin resistance in human prostate cancer cells. Cancer 107:3, 649-659
CrossRef925
Jean-Louis Fischel, Joseph Ciccolini, Patricia Formento, Jean-Marc Ferrero, G??rard Milano. (2006) Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel???erlotinib and 5-fluoro-5???-deoxyuridine. Anti-Cancer Drugs 17:7, 807-813
CrossRef926
Thomas W. Flaig, Albaha Barqawi, Gary Miller, Madeleine Kane, Chan Zeng, E. David Crawford, L. Michael Glodé. (2006) A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 107:2, 266-274
CrossRef927
Yoshitaka Nishio, Yoshiaki Yamada, Hiroto Kokubo, Kogenta Nakamura, Shigeyuki Aoki, Tomohiro Taki, Nobuaki Honda, Atsuko Nakagawa, Shinsuke Saga, Kazuo Hara. (2006) Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 68:1, 110-115
CrossRef928
Hak Choy. (2006) Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Review of Anticancer Therapy 6:7, 973-982
CrossRef929
Michael Koutsilieris, John Bogdanos, Constantine Milathianakis, Peter Dimopoulos, Theodoros Dimopoulos, Dimitrios Karamanolakis, Antonis Halapas, Roxane Tenta, Haralampos Katopodis, Effie Papageorgiou, Nea Pitulis, Nikos Pissimissis, Peter Lembessis, Antigone Sourla. (2006) Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opinion on Investigational Drugs 15:7, 795-804
CrossRef930
William Tester, Joann Ackler, Lukman Tijani, John Leighton. (2006) Phase I/II Study of Weekly Docetaxel and Vinblastine in the Treatment of Metastatic Hormone-Refractory Prostate Carcinoma. The Cancer Journal 12:4, 299-304
CrossRef931
Nancy A Dawson. (2006) New molecular targets in advanced prostate cancer. Expert Review of Anticancer Therapy 6:7, 993-1002
CrossRef932
K. O'Connor, C. Gill, M. Tacke, F.-J. K. Rehmann, K. Strohfeldt, N. Sweeney, J. M. Fitzpatrick, R. W. G. Watson. (2006) Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells. Apoptosis 11:7, 1205-1214
CrossRef933
Daniel Von Hoff. 2006. Horizons for Cancer Chemotherapy (and Nonchemotherapy). , 445-457.
CrossRef934
Niklas J. Mackler, Rodney L. Dunn, Beth Hellerstedt, Kathleen A. Cooney, Judith Fardig, Karin Olson, Kenneth J. Pienta, David C. Smith. (2006) Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer 106:12, 2617-2623
CrossRef935
William K. Oh, Judith Manola, Vladana Babcic, Neesha Harnam, Philip W. Kantoff. (2006) Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 67:6, 1235-1240
CrossRef936
Daniele Bernardi, Domenico Errante, Umberto Tirelli, Luigi Salvagno, Antonio Bianco, Ian S. Fentiman. (2006) Insight into the treatment of cancer in older patients: Developments in the last decade. Cancer Treatment Reviews 32:4, 277-288
CrossRef937
Polly E Kintzel, Laura B Michaud, Marianne K Lange. (2006) Docetaxel-Associated Epiphora. Pharmacotherapy 26:6, 853-867
CrossRef938
James MG Larkin, Stanley B Kaye. (2006) Epothilones in the treatment of cancer. Expert Opinion on Investigational Drugs 15:6, 691-702
CrossRef939
NIALL M. CORCORAN, ANTHONY J. COSTELLO, CHRISTOPHER M. HOVENS. (2006) Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU International 97:6, 1149-1153
CrossRef940
G. Kesava Reddy, Preeta Tyagi, Oliver Sartor, Ronald M. Bukowski. (2006) Highlights from: The 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, GA; June 2-6, 2006. Clinical Genitourinary Cancer 5:1, 18-22
CrossRef941
KAZUKI YAMANAKA, PALMA ROCCHI, HIDEAKI MIYAKE, LADAN FAZLI, ALAN SO, UWE ZANGEMEISTER-WITTKE, MARTIN E. GLEAVE. (2006) Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU International 97:6, 1300-1308
CrossRef942
P. Paula Hruska, Joel Picus. (2006) The role of primary chemotherapy for prostate cancer: Has the time come?. Current Urology Reports 7:3, 233-238
CrossRef943
John Eklund, Mark Kozloff, Joy Vlamakis, Alexander Starr, Margaret Mariott, Lilia Gallot, Borko Jovanovic, Lawrence Schilder, Erwin Robin, Michael Pins, Raymond C. Bergan. (2006) Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Cancer 106:11, 2459-2465
CrossRef944
Alan Rodney, Pauline Dieringer, Paul Mathew, Eric Jonasch, Nizar Tannir, Lance C. Pagliaro. (2006) Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer 106:10, 2143-2147
CrossRef945
G Kramer, S Schwarz, M Hägg, A Mandic Havelka, S Linder. (2006) Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. British Journal of Cancer
CrossRef946
Hideaki Miyake, Isao Hara, Masato Fujisawa, Martin E Gleave. (2006) The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opinion on Investigational Drugs 15:5, 507-517
CrossRef947
Charles J. Ryan, Amy M. Lin, Eric J. Small. (2006) Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale. Urologic Oncology: Seminars and Original Investigations 24:3, 250-253
CrossRef948
Andrew J. Armstrong, Michael A. Carducci. (2006) New drugs in prostate cancer. Current Opinion in Urology 16:3, 138-145
CrossRef949
K. Miller, C. Börgermann, J. Thüroff, P. Albers, M. Wirth. (2006) Therapieoptionen beim hormonrefraktären Prostatakarzinom. Der Urologe 45:5, 580-585
CrossRef950
M.-O. Grimm, F. H. Hartmann, R. Ackermann. (2006) Zukunft der Chemotherapie. Der Urologe 45:5, 567-571
CrossRef951
Ingrid Herr, Jesco Pfitzenmaier. (2006) Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. The Lancet Oncology 7:5, 425-430
CrossRef952
David Cella, Daniel P. Petrylak, Mayer Fishman, Chris Teigland, Jay Young, Parvez Mulani. (2006) Role of Quality of Life in Men with Metastatic Hormone-Refractory Prostate Cancer: How Does Atrasentan Influence Quality of Life?. European Urology 49:5, 781-789
CrossRef953
Michael C. Cox, William L. Dahut, William D. Figg. (2006) The use of thalidomide in androgen-independent prostate cancer. Urologic Oncology: Seminars and Original Investigations 24:3, 246-249
CrossRef954
Susan F. Slovin. (2006) Immunologic targeting: how to channel a minimal response for maximal outcome. Current Opinion in Urology 16:3, 179-185
CrossRef955
Mark Garzotto, Anne Myrthue, Celestia S. Higano, Tomasz M. Beer. (2006) Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urologic Oncology: Seminars and Original Investigations 24:3, 254-259
CrossRef956
George Wilding, Patrick Soulie, Donald Trump, Ashis Das-Gupta, Eric Small. (2006) Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer 106:9, 1917-1924
CrossRef957
Shomik Sengupta, Michael L. Blute, Stephanie M. Bagniewski, Robert P. Myers, Eric J. Bergstralh, Bradley C. Leibovich, Horst Zincke. (2006) Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival. The Journal of Urology 175:5, 1684-1690
CrossRef958
Jyoti Shah, Sara Jane Khaksar, Prasanna Sooriakumaran. (2006) Management of prostate cancer. Part 3: metastatic disease. Expert Review of Anticancer Therapy 6:5, 813-821
CrossRef959
Earle F. Burgess, Bruce J. Roth. (2006) Changing Perspectives of the Role of Chemotherapy in Advanced Prostate Cancer. Urologic Clinics of North America 33:2, 227-236
CrossRef960
Kathleen W. Beekman, Maha Hussain. (2006) Targeted approaches for the management of metastatic prostate cancer. Current Oncology Reports 8:3, 206-212
CrossRef961
D. P. Petrylak, D. P. Ankerst, C. S. Jiang, C. M. Tangen, M. H. A. Hussain, P. N. Lara, J. A. Jones, M. E. Taplin, P. A. Burch, M. Kohli, M. C. Benson, E. J. Small, D. Raghavan, E. D. Crawford. (2006) Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16. JNCI Journal of the National Cancer Institute 98:8, 516-521
CrossRef962
Manish S. Bhandari, Kenneth J. Pienta, Judith Fardig, Karin Olson, David C. Smith. (2006) Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. Cancer 106:8, 1715-1721
CrossRef963
MARI NAKABAYASHI, WILLIAM K. OH. (2006) Chemotherapy for high-risk localized prostate cancer. BJU International 97:4, 679-683
CrossRef964
Guru Sonpavde, Thomas E. Hutson, William R. Berry. (2006) Hormone refractory prostate cancer: Management and advances. Cancer Treatment Reviews 32:2, 90-100
CrossRef965
Fred Saad. (2006) Introduction. European Urology Supplements 5:7, 537-538
CrossRef966
PETER PIETRZAK, MANIT ARYA, HITENDRA R.H. PATEL. (2006) Anti-emetic therapy: updating urological cancer-care providers. BJU International 97:4, 673-675
CrossRef967
Guru Sonpavde, Thomas E. Hutson. (2006) New Approaches in Hormone Refractory Prostate Cancer. American Journal of Clinical Oncology 29:2, 196-201
CrossRef968
Fred Saad. (2006) The Treatment Continuum in the Management of Prostate Cancer Patients: What's New?. European Urology Supplements 5:7, 539-542
CrossRef969
Aurélie Cabrespine, Laurent Guy, Françoise Gachon, Hervé Curé, Philippe Chollet, Jacques-Olivier Bay. (2006) Circulating Chromogranin A and Hormone Refractory Prostate Cancer Chemotherapy. The Journal of Urology 175:4, 1347-1352
CrossRef970
R L Vinall, C G Tepper, X-B Shi, L A Xue, R Gandour-Edwards, R W de Vere White. (2006) The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene 25:14, 2082-2093
CrossRef971
Jorg Michels, Trina Montemurro, Nevin Murray, Christian Kollmannsberger, Kim Nguyen Chi. (2006) First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer. Cancer 106:5, 1041-1046
CrossRef972
Nima Sharifi, William L. Farrar. (2006) Androgen Receptor as a Therapeutic Target for Androgen Independent Prostate Cancer. American Journal of Therapeutics 13:2, 166-170
CrossRef973
Sabeeha Muneer, G. Kesava Reddy, Aarati Ranganathan, Latha Shivakumar, Oliver Sartor, Vinay K. Jain. (2006) Highlights from The 2006 American Society of Clinical Oncology Prostate Cancer Symposium; San Francisco, CA; February 24-26, 2006. Clinical Genitourinary Cancer 4:4, 240-245
CrossRef974
Hironobu Minami, Kenji Kawada, Yasutsuna Sasaki, Tadahiko Igarashi, Toshiaki Saeki, Makoto Tahara, Kuniaki Itoh, Hirofumi Fujii. (2006) Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Science 97:3, 235-241
CrossRef975
K M Kalkner, S Acosta, O Thorsson, H Frederiksen, A Nilsson, B Gustavsson, M Elingsbo, M Stridsberg, P-A Abrahamsson. (2006) Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer. Prostate Cancer and Prostatic Diseases 9:1, 92-98
CrossRef976
Robert S. Svatek, Michael Shulman, Pankaj K. Choudhary, Elie Benaim. (2006) Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 106:5, 1047-1053
CrossRef977
Benjamin K. Canales, Yingming Li, Melissa G. Thompson, Joseph M. Gleason, Zhi Chen, Bahaa Malaeb, David R. Corey, Brittney-Shea Herbert, Jerry W. Shay, Kenneth S. Koeneman. (2006) Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. Urologic Oncology: Seminars and Original Investigations 24:2, 141-151
CrossRef978
Dominik R Berthold, Ian F Tannock. (2006) Are prostate cancer clinical trial enrollment criteria and endpoints appropriate?. Nature Clinical Practice Oncology 3:2, 74-75
CrossRef979
Ray Wilkinson, Andrew J. Kassianos, Peter Swindle, Derek N.J. Hart, Kristen J. Radford. (2006) Numerical and functional assessment of blood dendritic cells in prostate cancer patients. The Prostate 66:2, 180-192
CrossRef980
Aurélie Cabrespine, Laurent Guy, Elhani Khenifar, Hervé Curé, Joël Fleury, Frédérique Penault-Llorca, Fabrice Kwiatkowski, Chantal Barthomeuf, Philippe Chollet, Jacques-Olivier Bay. (2006) Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology 67:2, 354-359
CrossRef981
Jonathan E. Rosenberg, Matthew D. Galsky, Nicholas C. Rohs, Vivian K. Weinberg, William K. Oh, W. Kevin Kelly, Eric J. Small. (2006) A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma. Cancer 106:1, 58-62
CrossRef982
Rosendo So-Rosillo, Eric J Small. (2006) Immunotherapy for Prostate Cancer. American Journal of Cancer 5:5, 331-339
CrossRef983
Sharyn D Baker, Alex Sparreboom, Jaap Verweij. (2006) Clinical Pharmacokinetics of Docetaxel. Clinical Pharmacokinetics 45:3, 235-252
CrossRef984
Flora Rozhansky, Ming-Hui Chen, Michael C. Cox, William Dahut, William D. Figg, Anthony V. D'Amico. (2006) Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 106:1, 63-67
CrossRef985
Gianfilippo Bertelli, Abdelhamid Heouaine, Giuseppe Arena, Ambrogio Botto, Ornella Garrone, Ida Colantonio, Marcella Occelli, Elena Fea, Silvia Giubergia, Marco Merlano. (2006) Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemotherapy and Pharmacology 57:1, 46-51
CrossRef986
KEVIN M. O'CONNOR, JOHN M. FITZPATRICK. (2006) Side-effects of treatments for locally advanced prostate cancer. BJU International 97:1, 22-28
CrossRef987
Mark J McKeage, Lloyd R Kelland. (2006) 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA). American Journal of Cancer 5:3, 155-162
CrossRef988
John S. Lam, John T. Leppert, Sreenivas N. Vemulapalli, Oleg Shvarts, Arie S. Belldegrun. (2006) Secondary Hormonal Therapy for Advanced Prostate Cancer. The Journal of Urology 175:1, 27-34
CrossRef989
Gerhardt Attard, Arie S. Belldegrun, Johann S. de Bono. (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU International 96:9, 1241-1246
CrossRef990
FRANS M.J. DEBRUYNE. (2005) Design of clinical trials in advanced prostate cancer: avoiding the dead ends. BJU International 96:s2, 47-53
CrossRef991
W Scott Webster, Bradley C Leibovich. (2005) Exisulind in the treatment of prostate cancer. Expert Review of Anticancer Therapy 5:6, 957-962
CrossRef992
J Spicer, T Plunkett, N Somaiah, S Chan, A Kendall, N Bolunwu, H Pandha. (2005) Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. Prostate Cancer and Prostatic Diseases 8:4, 364-368
CrossRef993
DANIEL PETRYLAK. (2005) Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU International 96:s2, 41-46
CrossRef994
Sergio Bracarda, Ottavio de Cobelli, Carlo Greco, Tommaso Prayer-Galetti, Riccardo Valdagni, Gemma Gatta, Filippo de Braud, Georg Bartsch. (2005) Cancer of the prostate. Critical Reviews in Oncology/Hematology 56:3, 379-396
CrossRef995
Pierre L. Triozzi, Graeme B. Bolger, Jeffrey Neidhart, John J. Rinehart, Mansoor Saleh, Karen O. Allen, Sandra Sellers, Mary J. Waddell. (2005) Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer. The Prostate 65:4, 316-321
CrossRef996
S. Rizzo, G. Attard, D. L. Hudson. (2005) Prostate epithelial stem cells. Cell Proliferation 38:6, 363-374
CrossRef997
Edith D. Canby-Hagino, Gregory P. Swanson, E. David Crawford, Joseph W. Basler, Javier Hernandez, Ian M. Thompson. (2005) Local and systemic therapy for patients with metastatic prostate cancer: Should the primary tumor be treated?. Current Prostate Reports 3:4, 153-159
CrossRef998
Nima Sharifi, William L. Dahut, Seth M. Steinberg, William D. Figg, Christopher Tarassoff, Philip Arlen, James L. Gulley. (2005) A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU International 96:7, 985-989
CrossRef999
JONATHAN L WRIGHT, DANIEL W LIN, PUNEET DEWAN, R BRUCE MONTGOMERY. (2005) Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. International Journal of Urology 12:11, 1012-1013
CrossRef1000
Ignacio Gil-Bazo, Juan Ignacio Martínez-Salamanca, Fernando J. Bianco. (2005) Actualización del tratamiento del cáncer de próstata avanzado y de sus complicaciones. Medicina Clínica 125:17, 671-677
CrossRef1001
Takehiko Segawa, Toshiyuki Kamoto, Hidefumi Kinoshita, Yasuharu Kunishima, Koji Yoshimura, Akihiro Ito, Takeshi Takahashi, Shin Higashi, Eijiro Nakamura, Hirofumi Nishiyama, Noriyuki Ito, Shingo Yamamoto, Tomonori Habuchi, Osamu Ogawa. (2005) Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. International Journal of Clinical Oncology 10:5, 333-337
CrossRef1002
Robert D. Loberg, Bishoy A. Gayed, Karin B. Olson, Kenneth J. Pienta. (2005) A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. Journal of Cellular Biochemistry 96:3, 439-446
CrossRef1003
James L Gulley, Philip M Arlen. (2005) Docetaxel-based therapy for prostate cancer. Aging Health 1:2, 231-240
CrossRef1004
S.R. Olsen. (2005) Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice. Biomedicine & Pharmacotherapy 59, S306-S310
CrossRef1005
Thomas H. Totterman, Angelica Loskog, Magnus Essand. (2005) The immunotherapy of prostate and bladder cancer. BJU International 96:5, 728-735
CrossRef1006
JOON-HA OK, FREDERICK J. MEYERS, CHRISTOPHER P. EVANS. (2005) MEDICAL AND SURGICAL PALLIATIVE CARE OF PATIENTS WITH UROLOGICAL MALIGNANCIES. The Journal of Urology 174:4, 1177-1182
CrossRef1007
J. Graham. (2005) Chemotherapy for Metastatic Disease: Current Status. Clinical Oncology 17:7, 572-578
CrossRef1008
R. Bruce Montgomery, Michael Bonham, Peter S. Nelson, Jonathan Grim, Ekram Makary, Robert Vessella, William L. Stahl. (2005) Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. The Prostate 65:2, 141-150
CrossRef1009
Hideaki Miyake, Isao Hara, Hiroshi Eto. (2005) Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU International 96:6, 791-795
CrossRef1010
Nancy B. Davis, Christopher W. Ryan, Walter M. Stadler, Nicholas J. Vogelzang. (2005) A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU International 96:6, 787-790
CrossRef1011
Bertrand Tombal, Afshin Rezazadeh, Patrick Therasse, Paul J. Van Cangh, Bruno Vande Berg, Frédéric E. Lecouvet. (2005) Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. The Prostate 65:2, 178-187
CrossRef1012
A Berruti, M Tucci, A Mosca, R Tarabuzzi, G Gorzegno, C Terrone, F Vana, G Lamanna, M Tampellini, F Porpiglia, A Angeli, R M Scarpa, L Dogliotti. (2005) Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. British Journal of Cancer 93:6, 633-638
CrossRef1013
J. Brantley Thrasher. (2005) What’s New in Urology. Journal of the American College of Surgeons 201:3, 438-448
CrossRef1014
HIDEAKI MIYAKE, ISAO HARA, MARTIN E GLEAVE. (2005) Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. International Journal of Urology 12:9, 785-794
CrossRef1015
Roger Kirby. (2005) Case study: management of advanced prostate cancer with soft tissue metastases. Prostate Cancer and Prostatic Diseases 8:3, 290-292
CrossRef1016
NATASHA M. TIFFANY, CHRISTOPHER W. RYAN, MARK GARZOTTO, EMILY M. WERSINGER, TOMASZ M. BEER. (2005) HIGH DOSE PULSE CALCITRIOL, DOCETAXEL AND ESTRAMUSTINE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: A PHASE I/II STUDY. The Journal of Urology 174:3, 888-892
CrossRef1017
ARUN S. SINGH, WILLIAM D. FIGG. (2005) IN VIVO MODELS OF PROSTATE CANCER METASTASIS TO BONE. The Journal of Urology 174:3, 820-826
CrossRef1018
Siegfried Seeber, Ada H Braun. (2005) Phase III trials in oncology: setting standards of care?. Nature Clinical Practice Oncology 2:9, 426-427
CrossRef1019
Niall M. Corcoran, Anthony J. Costello. (2005) Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer. BJU International 96:4, 640-646
CrossRef1020
Tomasz M. Beer. (2005) ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU International 96:4, 508-513
CrossRef1021
Charles J Ryan, Eric J Small. (2005) Progress in detection and treatment of prostate cancer. Current Opinion in Internal Medicine 4:4, 416-419
CrossRef1022
A. M. Joshua, I. Nordman, R. Venkataswaran, S. Clarke, M. R. Stockler, M. J. Boyer. (2005) Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal Medicine Journal 35:8, 468-472
CrossRef1023
Manish S. Bhandari, Maha Hussain. (2005) Epothilones and the next generation of phase III trials for prostate cancer. BJU International 96:3, 296-302
CrossRef1024
I. Olver, D. Keefe, M. Myers. (2005) Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer. Internal Medicine Journal 35:7, 405-408
CrossRef1025
Chris Parker, Mark Emberton. (2005) Prolonging survival in prostate cancer: chemotherapy will have an important role. BJU International 96:1, 2-3
CrossRef1026
Yasuhide Miyoshi, Hiroji Uemura, Masafumi Nakamura, Hisashi Hasumi, Shinpei Sugiura, Kazuhide Makiyama, Noboru Nakaigawa, Takeshi Kishida, Takehiko Ogawa, Masahiro Yao, Yoshinobu Kubota. (2005) Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. International Journal of Clinical Oncology 10:3, 182-186
CrossRef1027
Kathleen M. Donohue, Daniel P. Petrylak. (2005) Chemotherapy agents and timing of chemotherapy in prostate cancer management. Current Urology Reports 6:3, 224-227
CrossRef1028
D C Gilbert, Dr C Parker. (2005) Docetaxel for the treatment of prostate cancer. Future Oncology 1:3, 307-314
CrossRef1029
Frans M.J. Debruyne. (2005) Introduction. Urology 65:6, 1
CrossRef1030
Charles J. Ryan, Eric J. Small. (2005) Secondary hormonal manipulations in prostate cancer. Current Oncology Reports 7:3, 228-233
CrossRef1031
Susan F Slovin. (2005) Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opinion on Therapeutic Targets 9:3, 561-570
CrossRef1032
Daniel P. Petrylak. (2005) Future directions in the treatment of androgen-independent prostate cancer. Urology 65:6, 8-12
CrossRef1033
William R. Berry. (2005) The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. Urology 65:6, 2-7
CrossRef1034
Adam S. Kibel. (2005) An interdisciplinary approach to treating prostate cancer. Urology 65:6, 13-18
CrossRef1035
Kathleen M. Donohue, Daniel P. Petrylak. (2005) Chemotherapy agents and timing of chemotherapy in prostate cancer management. Current Prostate Reports 3:2, 58-61
CrossRef1036
Antonio Jimeno, Michael Carducci. (2005) Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Review of Anticancer Therapy 5:3, 419-427
CrossRef1037
Edith D. Canby-Hagino, Gregory P. Swanson, E. David Crawford, Joseph W. Basler, Javier Hernandez, Ian M. Thompson. (2005) Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?. Current Urology Reports 6:3, 183-189
CrossRef1038
Peter J Hoskin. (2005) Radioisotopes for metastatic bone pain. The Lancet Oncology 6:6, 353-354
CrossRef1039
Andrew J. Armstrong, Michael A. Carducci. (2005) Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies. Current Oncology Reports 7:3, 220-227
CrossRef1040
Robert S. Dipaola, Ian M. Thompson. (2005) National cooperative group trials. Urology 65:5, 23-29
CrossRef1041
Daniel P. Petrylak. (2005) The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 65:5, 3-7
CrossRef1042
Kathleen Beekman, Michael Morris, Susan Slovin, Glenn Heller, Andrew Wilton, Fernando Bianco, Peter T. Scardino, Howard I. Scher. (2005) Androgen deprivation for minimal metastatic disease: Threshold for achieving undetectable prostate-specific antigen. Urology 65:5, 947-952
CrossRef1043
Michael A. Carducci, Peter R. Carroll. (2005) Multidisciplinary management of advanced prostate cancer: Changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials. Urology 65:5, 18-22
CrossRef1044
Cassandra N Moore, Daniel J George. (2005) Update in the management of patients with hormone-refractory prostate cancer. Current Opinion in Urology 15:3, 157-162
CrossRef1045
Christopher W. Ryan, Walter M. Stadler, Nicholas J. Vogelzang. (2005) A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. BJU International 95:7, 963-968
CrossRef1046
Michael A. Carducci, Peter R. Carroll, Robert S. Dipaola, Joel B. Nelson, Daniel P. Petrylak, Mathew R. Smith, Ian M. Thompson. (2005) Hormone-refractory prostate cancer: Issues, approaches, and recommendations. Urology 65:5, 1-2
CrossRef1047
Aur??lie Cabrespine, Jacques-Olivier Bay, Chantal Barthomeuf, Herv?? Cur??, Philippe Chollet, Eric Debiton. (2005) In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment. Anti-Cancer Drugs 16:4, 417-422
CrossRef1048
Sheila A Doggrell. (2005) Which drug combination for hormone-refractory prostate cancer?. Expert Opinion on Pharmacotherapy 6:4, 667-670
CrossRef1049
Mario Falsaperla, Giuseppe Morgia, Alfredo Tartarone, Raffaele Ardito, Giampiero Romano. (2005) Support Ellagic Acid Therapy in Patients with Hormone Refractory Prostate Cancer (HRPC) on Standard Chemotherapy Using Vinorelbine and Estramustine Phosphate. European Urology 47:4, 449-455
CrossRef1050
Sarah P Blagden, Stan B Kaye. (2005) Docetaxel in the management of ovarian cancer. Expert Review of Anticancer Therapy 5:2, 203-214
CrossRef1051
J. Cassinello Espinosa, A. Arcediano del Amo, I. Fernández-Rañada Shaw, I. García Castro. (2005) Cáncer de próstata avanzado. Medicine - Programa de Formación Médica Continuada Acreditado 9:27, 1772-1780
CrossRef1052
Hans-Peter Lipp, Carsten Bokemeyer. (2005) Wirksamkeit und Toxizit
t der Taxane: Therapie solider Tumoren. Pharmazie in unserer Zeit 34:2, 128-137
CrossRef1053
Andrew Protheroe. (2005) Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nature Clinical Practice Oncology 2:2, 68-69
CrossRef1054
Niklas J Mackler, Kenneth J Pienta. (2005) Drug Insight: use of docetaxel in prostate and urothelial cancers. Nature Clinical Practice Urology 2:2, 92-100
CrossRef1055
Philip M Arlen, James L Gulley. (2005) Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. Future Oncology 1:1, 19-22
CrossRef1056
Daniel P. Petrylak. (2005) Chemotherapy for androgen-independent prostate cancer. World Journal of Urology 23:1, 10-13
CrossRef1057
Kim N. Chi. (2005) Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World Journal of Urology 23:1, 33-37
CrossRef1058
Stefan Sleijfer, Gerrit Stoter. (2005) Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?. Nature Clinical Practice Oncology 2:2, 70-71
CrossRef1059
Martin Gleave, Hideaki Miyake. (2005) Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World Journal of Urology 23:1, 38-46
CrossRef1060
(2005) Chemotherapy for Advanced Prostate Cancer. New England Journal of Medicine 352:2, 200-201
Full Text1061
Magnus Essand. (2005) Gene therapy and immunotherapy of prostate cancer: Adenoviral-based strategies. Acta Oncologica 44:6, 610-627
CrossRef1062
Thomas Nelius, Frank Reiher, Tobias Lindenmeir, Tobias Klatte, Olrik Rau, Jens Burandt, Stephanie Filleur, Ernst Peter Allhoff. (2005) Characterization of Prognostic Factors and Efficacy in a Phase-II Study with Docetaxel and Estramustine for Advanced Hormone Refractory Prostate Cancer. Onkologie 28:11, 573-578
CrossRef1063
Seymour Levitt. (2005) Second Acta Oncologia Symposium on Prostate Cancer Controversies. Acta Oncologica 44:6, 526-528
CrossRef1064
Cora N Sternberg. (2005) Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nature Clinical Practice Urology 2:1, 20-21
CrossRef1065
Avishay Sella. (2005) Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?. Nature Clinical Practice Urology 2:1, 18-19
CrossRef1066
Eckart Gronau, Marcus Goppelt, Rolf Harzmann, Dorothea Weckermann. (2005) Prostate Cancer Relapse after Therapy with Curative Intention: A Diagnostic and Therapeutic Dilemma. Onkologie 28:6-7, 361-366
CrossRef1067
Teodoro Sava, Umberto Basso, Antonio Porcaro, Gian Luigi Cetto. (2005) New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Expert Review of Anticancer Therapy 5:1, 53-62
CrossRef1068
(2004) Docetaxel in advanced prostate cancer. Nature Clinical Practice Urology 1:2, 62-62
CrossRef1069
Antonio Jimeno, Michael Carducci. (2004) Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opinion on Investigational Drugs 13:12, 1631-1640
CrossRef1070
Petrylak, Daniel P., Tangen, Catherine M., Hussain, Maha H.A., Lara, Primo N. Jr., Jones, Jeffrey A., Taplin, Mary Ellen, Burch, Patrick A., Berry, Donna, Moinpour, Carol, Kohli, Manish, Benson, Mitchell C., Small, Eric J., Raghavan, Derek, Crawford, E. David, . (2004) Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. New England Journal of Medicine 351:15, 1513-1520
Full Text1071
Debes, Jose D., Tindall, Donald J., . (2004) Mechanisms of Androgen-Refractory Prostate Cancer. New England Journal of Medicine 351:15, 1488-1490
Full Text
